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Abstract 
Head and neck cancer is the 7th most common cancer worldwide and the 7th 
leading cause of cancer-related death. The vast majority of head and neck 
cancers are diagnosed at advanced stage, which is characterised by large 
volume disease and locoregional metastases. The overall 5-year survival rate 
of head and neck cancer is 50%, although most patients with advanced stage 
cancers die within few years from diagnosis because of relapsing incurable 
disease.  
Head and neck cancer patients are often managed with radiotherapy, either 
as main treatment modality or in association with chemotherapy and surgery. 
Radiotherapy can cause acute and long-term complication, of which chronic 
xerostomia is one of the most debilitating. 
Current treatment of radiotherapy-associated xerostomia encompasses 
systemic and local therapeutic strategies. None of them, however, represent 
the ideal treatment in terms of efficacy and safety.  
Neuro-stimulation of salivary glands via electrical stimulation was initially 
introduced 30 years ago. It is suggested to provide the benefit of increasing 
natural salivation with no relevant adverse side effects. 
Studies using the first generation of electrostimulating devices suggested 
clinical significant benefit in a small cohort of individuals with radiotherapy-
associated xerostomia. More recently, the use of a second-generation intra-
oral device, as well as facial transcutaneous nerve stimulation, has been 
associated with an increase in saliva production and reduction in xerostomia 
symptoms. 
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Although promising, current data do not provide robust evidence and 
highlight the need of further and better designed clinical trials in order to 
investigate the real benefit of salivary electrostimulation in the post-
radiotherapy setting. 
We have performed a double-blind randomised clinical trial (The LEONIDAS-
2 study) to assess the long-term efficacy of the second generation intraoral 
electrostimulating device in lessening xerostomia symptoms, increasing 
salivary gland function and improving quality of life in individuals with 
radiotherapy-associated xerostomia. The clinical trial took place between 
January 2012 and January 2015 at the University College London Hospital 
and Bradford Royal Infirmary (UK). Eighty-four participants were randomised 
to use an active electrostimulating device (providing mechanical and 
electrical stimulation) or a sham device (providing mechanical but not 
electrical stimulation) for 12 months. Randomisation was by computer-
generation and analyses were performed on an intention-to-treat basis. Sixty-
eight participants completed the trial. At 12 months an improvement in 
xerostomia symptoms (VAS) compared to baseline was observed, with no 
significant difference in means between the active and sham group. Salivary 
flow rate, measured through sialometry, was higher in the active group but 
the difference between the two groups was not statistically significant. At 12 
months there was an improvement in quality of life, with no significant 
difference between the active and the control groups.  
The LEONIDAS-2 clinical trial showed that salivary electrostimulation through 
the second generation intra-oral electrostimulating device is safe but not 
more effective than mechanical stimulation in relieving dry mouth symptoms, 
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increasing salivary function or improving quality of life in patients with 
radiotherapy-associated xerostomia.  
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1 Introduction: Xerostomia in head and neck cancer 
survivors  
1.1 Head and Neck Cancer  
1.1.1 Definition and Epidemiology 
The term head and neck cancer (HNC) defines the group of malignancy that 
can arise in the oral cavity, pharynx and larynx (including the paranasal 
sinuses and the salivary glands) (Mehanna et al., 2010). 
The overwhelming majority of malignant tumours arising from the mucosal 
surfaces of the upper aerodigestive tract are squamous cell carcinomas in 
nature (HNSCC) (Cooper et al., 2009).  
Worldwide HNC is the seventh most common cancer with more than half 
million cases occurring per year. These figures encompass 300,373 cases of 
lip and oral cavity cancers, 229,078 pharyngeal and 156,877 laryngeal 
cancers (Ferlay et al., 2012). Head and neck cancer is also the 7th leading 
cause of cancer-related death with global deaths projected to rise from 
375,000 in 2013 to 575,000 in 2030 (Ferlay et al., 2012).  
Figure 1-1 shows the distribution of HNC by site in England and Wales as 
reported by the National Head and Neck Cancer Audit (DAHNO, 2014). The 
audit included in the analysis 8,429 patients, a number which is close to the 
9696 estimated new cancers in UK (Ferlay et al., 2012). In the graph, only 
malignant tumours arising in the salivary glands have been included. 
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Figure 1-1 Estimated head and neck cancer incidence by site (Data from the 
National Head and Neck Cancer Audit 2014) 
There remains a wide geographic variation in the epidemiology of HNC, 
incidence being more than twice in developing countries in comparison with 
more developed regions. This probably reflects differences in exposure to 
risk factors such as the use of smokeless tobacco products (betel quid) and 
areca nut (Joshi et al., 2014). The area characterised by high incidence rate 
is represented by Asia (57.6%), followed by Europe (20.3%) (Ferlay et al., 
2012). In Europe age-standardised rates are higher in Central and Eastern 
Europe, followed by Western Europe and the Southern part of the continent 
(Stewart BW, 2014). High-risk regions for lip and oral cavity cancers include 
India and Pakistan, where the prevalence of areca nut chewing nationwide 
can be estimated to be around 30% (IARC, 2004) (Figure 1-2). 
28.3%	
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Figure 1-2 Global distribution of estimated age-standardized incidence rates 
(ASR) per 100 000, for lip and oral cavity cancer in both sexes (Reproduced 
from Globocan 2012) 
 
Figure 1-3 Global distribution of estimated age-standardized incidence rates 
(ASR) per 100 000, for nasopharyngeal cancer in both sexes (Reproduced 
from Globocan 2012) 
Pharyngeal cancer is more prevalent in China and India than other countries 
such as United Kingdom and Italy (Ferlay et al., 2010) (Figure 1-3). The high 
prevalence of nasopharyngeal carcinoma in China may be due to a diet rich 
in salt-cured foods but there could also be a genetic predisposition, with first-
degree relative of patients with nasopharyngeal carcinoma having an 
increased risk of developing the same disease by 7.6-fold (Cao et al., 2011).  
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For laryngeal cancer, central and eastern Europe, South America, and 
western Asia stand out (Figure 1-4).  
 
Figure 1-4 Global distribution of estimated age-standardized incidence rates 
(ASR) per 100 000, for laryngeal cancer in both sexes (Reproduced from 
Globocan 2012) 
Overall, head and neck cancer remains a disease that typically affects the 
elderly, with 98% of patients aged over 40 and 50% aged over 60 in Europe 
(Mehanna et al., 2010). An increased incidence of oral and oropharyngeal 
squamous cell carcinoma among young individuals (18 to 44 years), 
however, has been reported in the last decade (Deschler et al., 2014). This 
trend change is likely linked to the increasing incidence of human 
papillomavirus (HPV)-related cancers. 
The risk of developing HNC varies considerably with gender, with a male to 
female ratio of approximately 3:1 (Ferlay et al., 2012). 
1.1.2 Risk Factors 
The INHANCE consortium, established in 2004 to address epidemiological 
research questions, has confirmed that both tobacco smoking and alcohol 
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intake are established causes of oral, pharyngeal, and laryngeal cancer 
(Winn et al., 2015). Tobacco consumption is correlated with exposure to 
chemical carcinogens. The International Agency for Research on Cancer 
estimates that is sufficient evidence for carcinogenicity in either laboratory 
animals or humans for over 60 carcinogens contained in cigarettes (Alavanja 
et al., 2004). With regards to alcohol, research has focused on acetaldehyde, 
an intermediate metabolite of ethanol and a known carcinogen, which could 
stimulate carcinogenesis though inhibition of DNA methylation and interaction 
with retinoid metabolism (Seitz and Stickel, 2007). Although it has been 
proved difficult to obtain precise estimates of the risk because of the high 
correlation between smoking and drinking, it has been suggested that 
cigarette smoking in never drinkers of alcohol is strongly associated with an 
increased risk of head and neck cancer (OR=2.13, 95% 1.53-2.98), whereas 
the risk is doubled (OR=2.04, 95% CI 1.29-3.21) in people who never used 
tobacco but are alcohol heavy users (three or more drinks per day) (Winn et 
al., 2015). There is evidence that quitting smoking decreases the risk of head 
and neck cancer as soon as 1-4 years after stopping, whereas it takes 20 
years to see the benefit of quitting alcohol drinking (Marron et al., 2010). 
The link between viral infection and HNC has been firstly recognised in 1966, 
when the sera of patients with Burkitt's lymphoma and carcinoma of 
postnasal space were found to manifest precipitating antibodies against cells 
infected with the Epstein-Barr virus (EBV) (Old et al., 1966). EBV has been 
strongly implicated in the development of undifferentiated nasopharyngeal 
carcinoma, whereas its implication in keratinizing and non-keratinizing 
squamous cell carcinoma is controversial (Thompson and Kurzrock, 2004). 
Furthermore, it is now clear that HPV can induce carcinogenesis in the 
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oropharynx. The prevalence of HPV-related HNC is between 20-26%, with an 
higher prevalence of HPV-related tumours in the oropharynx (41%) 
compared to oral cavity (26%) and pharyngeal cancer (15%) (Abogunrin et 
al., 2014). HPV types 16, 18, 33 and 52 are associated with HPV-HNSCC, 
with HPV16 accounting for nearly 90% HPV-positive carcinomas of the 
oropharynx (Michaud et al., 2014, Syrjänen, 2010). The HPV-positive HNC 
patient seems to differ from the traditional patients, being younger and having 
no or relatively minimal exposures to traditional risk factors such as tobacco 
and alcohol. The risk of developing oropharyngeal carcinoma is, however, 
associated with a history of six or more lifetime sexual partners (OR 1.25), 
four or more lifetime oral sex partners (OR 3.36), and, for men, an earlier age 
at first sexual intercourse (OR 2.36) (Heck et al., 2010). 
The strong association between HPV and head and neck cancer has 
received extraordinary attention because of the superior prognosis of HPV-
driven cancers, which will be discussed in section 1.1.4. 
Low education and income are also implicated in HNC development, with an 
almost 2-fold increased risk compared to intermediate and high education 
level (OR 1.61, 95%CI 1.13-2.31), the risk remaining elevated even after 
adjusting for recognized lifestyle behavioural risk factors (Conway et al., 
2015). 
Many studies have observed a protective effect of fruits (OR=0.52, 95% CI 
0.43-0.62) and vegetables (OR=0.66, 95% CI 0.49-0.90) against developing 
head and neck cancer, which could be due to the presence of carotenoids 
and flavonoids with their anticarcinogenetic properties. The opposite seems 
true for higher intake of processed meat and notably for red meat (OR=1.40, 
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95%CI 1.13-1.74) (Chuang et al., 2012), due to iron over-storage and 
oxidative stress resulting from free radicals (Wiseman, 2008). 
Family history of HNC is associated with an increased risk of developing 
cancer and a clear link can be seen in patients with Fanconi anaemia, an 
autosomal recessive genomic-instability syndrome associated with bone 
marrow failure, leukaemia, and congenital defects. In non-syndromic families, 
initial case–control studies have demonstrated a genetic predisposition, with 
first-degree relatives having a 1.7 fold increased risk of developing HNSCC 
(Negri et al., 2009). 
1.1.3 Pathogenesis and Clinical Features  
The initiation of head and neck cancer is a complex multistep process that 
entails a progressive acquisition of genetic and epigenetic alterations, leading 
to the inactivation of tumour-suppressor genes and/or activation of proto-
oncogenes. Two independent research groups sequenced the whole-exome 
of approximately 100 HNC specimens (Stransky et al., 2011, Agrawal et al., 
2011) and reported that tumour-suppressor activity is significantly more 
common than the activation of oncogenes. 
Mutations were confirmed in genes that had been previously known to play a 
role in HNSCC, such as TP53, CDKN2A, EGFR, PIK3CA, PTEN, HRAS. 
Furthermore a novel mutation in NOTCH1 gene was reported in 10% to 15% 
of the HNSCC tumours. 
TP53 gene, a tumour suppressor gene playing a key role in the response to 
DNA damage and oncogenic stress, is mutated in 47-60% (Agrawal et al., 
2011, Pickering et al., 2013) cases of HNC. Mutations in TP53 are acquired 
early in the pathogenesis of HNC and can be observed also in pre-malignant 
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lesions, but it is still unclear whether alterations in TP53 are prognostic for 
overall survival (Riaz et al., 2014). 
Inactivation of p53 can also occur as a result of inactivation of the tumour-
suppressive CDKN2A (Cyclin-Dependent Kinase Inhibitor 2A) gene, seen in 
30% of HNSCC, with the gene being mutated in another 10% of samples 
(Riaz et al., 2014). Among other proteins, CDKN2A gene provides instruction 
for p16 and p14 proteins, tumour-suppressor proteins involved in the 
regulation of cell growth and division. 
The next most commonly altered gene in HNSCC is the gene encoding for 
protein cyclin D1 (CCND1), essential for the facilitation of cell cycle 
progression. The CCND1 gene is amplified in over 20% of tumours (Cerami 
et al., 2012). 
The epidermal growth factor receptor (EGFR) is a member of the HER/erbB 
family of receptors and its activation through binding of its ligand leads to a 
downstream signalling cascade. EGFR is expressed in 90% or more of cases 
of HNSCC, with gene amplification observed in 10-30% of them (Suh et al., 
2014).  
The phosphoinositide 3-kinases (PI3Ks) family plays a pivotal role in cellular 
regulatory mechanisms. Genetic mutations of the PI3K pathway, notably in 
the PIK3CA gene, have been reported in 6% to 11% head and neck tumours 
(Agrawal et al., 2011, Pickering et al., 2013). Additionally in 3% of HNSCC 
has been observed a loss of the tumour suppressor PTEN (phosphatase and 
tensin homolog), which regulates the cellular level of activated kinases, key 
messengers in the regulation of cellular processes. Loss of PTEN results in 
unrestrained signalling by the PI3K pathway. 
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Ras proteins are ubiquitously expressed in all cell lineages and are involved 
in transmitting signals within cells (cellular signal transduction). Mutations in 
the Ras proto-oncogenes, a binding protein localised on the plasma 
membrane have been found in 4–5% of HNSCC cases (Suh et al., 2014). 
A promising new therapeutic approach is represented by the recent discovery 
of mutations in NOTCH1 gene, encoding for a transmembrane receptor that 
plays a role in cell differentiation and embryonic development, seen in 18% of 
HNSCC cases (Sun et al., 2014). 
Very recently The Cancer Genome Atlas Research Network has uncovered a 
different mutational profile of HPV-positive cancers which are characterised 
by a better prognosis with respect to their HPV-negative counterparts 
(Lawrence et al., 2015). Many patients with HPV-positive cancers have 
specific alterations of the gene FGFR3 and mutations in the PIK3CA gene, 
whereas the EGFR and p53 are rarely altered in HPV-positive malignancies. 
This study has potentially important clinical implications, offering novel 
diagnostic and treatment directions.  
Histopathologically head and neck cancer development comprises 
progressive stage of hyperplasia, dysplasia, carcinoma in situ and invasive 
carcinoma, with progressive loss of maturation, architectural disorganization, 
increasing pleomorphism and cell size (Argiris et al., 2008). 
Clinical features and symptoms of HNC can vary greatly depending on 
affected anatomical site. Early oral cancer might present as a white 
hyperkeratotic plaque (leukoplakia), a mucosal red lesion (erythroplakia), 
mixed red and white lesion (erythroleukoplakia), as well as an indurated lump 
or ulceration with fissuring or raised exophytic margins. Advanced oral 
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squamous carcinomas are associated with a wide range of extra-oral and 
intra-oral signs and symptoms, including large ulcerated mass, bleeding, 
pain, earache, dysphagia, ankyloglossia, trismus and paraesthesia (Scully 
and Bagan, 2009).  
In Europe and USA, the tongue is the most common intra-oral site, 
accounting for 40% of oral cancers, whereas cancers arising in the buccal 
mucosa are common among Asian populations due to betel quid/tobacco 
chewing habits. Other sites for oral cavity cancer include floor of mouth, 
gingivae and palate. The lip is involved more frequently in Canada and 
Australia, with a strong link to chronic exposure to sunlight (Warnakulasuriya, 
2009).  
Oral cancer can arise from clinically evident mucosal lesions (potentially 
malignant disorders) via progressive degrees of pre-malignant epithelial 
changes (Warnakulasuriya et al., 2007). The annual rate transformation of 
premalignant lesions ranges from approximately 1-4% for oral leukoplakia 
(Warnakulasuriya and Ariyawardana, 2015), to a higher risk for erythroplakia, 
for which is not possible to calculate a reliable annual malignant 
transformation due to the rarity of the disorder (estimated prevalence 0.02-
0.83%) (van der Waal, 2009). Oral lichen planus, a chronic inflammatory 
disease of unknown aetiology, is an oral disease associated with a 2% 
increased risk of developing malignancy (Landini et al., 2014). 
Early diagnosis in oropharyngeal and pharyngeal cancer is rare, with most 
patients presenting with loco-regionally advanced disease and cervical 
metastases (Wee, 2015).  
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Patients with oropharyngeal cancer may experience a foreign body 
sensation, soreness, and discomfort in the throat or altered voice. More 
advanced lesions can lead to earache, throat pain, ankyloglossia, dysarthria 
and dysphagia (Cohan et al., 2009).  
Laryngeal cancer can manifest with hoarseness, sore throat, dysphagia, 
odynophagia, earache, haemoptysis and dyspnoea due to the vocal cord 
fixation (Marioni et al., 2006). 
1.1.4 Staging and Prognosis 
Therapy for head and neck cancers has evolved over the past decade and a 
significant improvement in 5-year disease-specific survival from 55% in 1992-
1996 to 66% in 2002-2006 has been observed, although the change in 
survival does not seem to include laryngeal cancer (Howlader N, 2015). The 
most important prognostic factors of HNC include staging, site, local invasion, 
angioinvasion, and HPV status.  
The Classification of Malignant Tumours (TNM) is a cancer staging notation 
system used to indicate the tumour stage (T), nodal status of the neck (N), 
and the presence of metastases (M), representing strong prognostic factors 
in head and neck tumours. The Table 1-1, adapted from the English cancer 
networks DAHNO (Data for Head and Neck Oncology) clearly shows how 
survival rates are significantly better for patients diagnosed with early stage 
cancer at both one year and three years after the diagnosis (Watters, 2011). 
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Table 1-1 Comparison of survival rates for head and neck cancers diagnosed 
in 2004-2006 (adapted from DAHNO report 2011) 
Site Cases One year relative 
survival rates in 
% 
Three years 
relative survival 
rates % 
Oral Cavity 
 Early 
 Late 
 Not Known 
1592 
574 
616 
402 
79.9 
93.8 
68.9 
76.2 
61.4 
80.5 
45.4 
58.2 
Oropharynx 
 Early 
 Late 
 Not Known 
519 
68 
307 
144 
80.9 
85.4 
82.1 
76.2 
62.5 
71.8 
68.0 
59.0 
Hypopharynx 150 62.7 32.7 
Nasopharynx 47 93.4 60.6 
Larynx 
 Early 
 Late 
 Not Known 
1552 
587 
439 
526 
88.9 
97 
75.9 
88.9 
74.1 
89 
50.5 
74.1 
Tumour site is a strong prognosticator of survival, regardless of treatment 
modality (Ries LAG, 2007). 
The prognosis of patients with HPV-positive HNSCC is widely discussed in 
the literature. The RTOG 0129 trial has offered a significant insight in the 
prognostic value of HPV infection, retrospectively analysing a randomised 
clinical trial (RCT) where patients with stage III-IV oropharyngeal carcinoma 
were randomised to accelerated-fractionation or standard fractionation 
radiotherapy. The study revealed that patients with HPV-positive tumour had 
a 25% improvement in 3-years survival rate compared with HPV-negative 
tumour (82.4% vs. 57.1%) (Ang et al., 2010). Two years later a meta-analysis 
confirmed a 54% improvement in overall survival rate for HPV-positive 
HNSCC compared with HPV-negative HNSCC (O'Rorke et al., 2012). The 
characteristics of population affected from HPV-HNSCC, with fewer 
comorbidities, younger age and limited exposure to risk factors cannot 
entirely explain their prognostic advantage, since after adjustment of these 
confounders there was a persistent difference in survival among patients with 
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HPV-positive and HPV-negative tumours. Indeed HPV-positive tumours tend 
to respond better than HPV-negative tumours to platinum-based induction 
chemotherapy regimens and radiation therapy independently from the 
radiation regimen, the addition of radiation sensitizers, or the addition of 
chemotherapy (Benson et al., 2014). 
Patients’ general health status, including comorbidities and age, can also 
influence the prognosis, as these factors affect treatment delivery. The 
impact of comorbidity on prognosis has been confirmed in a systematic 
review including 31 studies. A quantitative analysis of 10 of these studies 
showed a significant difference in mortality in patients with comorbidities 
(mainly liver diseases and diabetes in the young group and cerebrovascular 
and cardiovascular in the older group) compared to otherwise healthy 
patients (HR 1.38; 95% CI: 1.32–1.43) (Boje, 2014). However it could be 
argued that clinical trials often tend to exclude patients with comorbidities to 
avoid the confounding influence on the outcome whereas it would be 
sensible indeed to include these patients to truly evaluate their prognosis. 
1.1.5 Quality of Life in head and neck cancer survivors 
The World Health Organization defines the Quality of Life (QoL) as “an 
individual’s perception of their position in life, in the context of the culture and 
value system in their life, and in relation to their goals, expectations, 
standards and concerns” (Kuyken, 1995). 
A diagnosis of head and neck cancer can have a negative impact on quality 
of life caused by the fear of altered appearance, changes in the ability to 
speak, swallow and breath, and high levels of symptomatology (pain, 
xerostomia, shoulder dysfunction) (Semple et al., 2013). The reported 
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prevalence of psychological distress amongst head and neck cancer patients 
varies from 12% to 45%, depending on the criteria and diagnostic tool used 
for the assessment (Haman, 2008). Patients with HNC experience 
deterioration in global QoL scores immediately after treatment, with a gradual 
return to a baseline level for the majority of distresses within one year after 
treatment completion. However, at 12 months xerostomia and fatigue are not 
returned to normality, and can per se affect patients’ QoL, as it will be 
explained in paragraph 1.3.8 (Babin et al., 2008).  
The site of tumour is also an important determinant for QoL. Oropharyngeal 
cancer is associated with lower QoL score, likely due to advanced stage at 
presentation (Rogers et al., 2007).  
There remain conflicting data regarding the influence of gender upon QoL, 
with more pronounced fatigue, general pain and salivary impairment being 
reported in women than in man (Bjordal et al., 2001).  
A different trend in QoL has been reported in patients of different age groups, 
with poorer QoL scores and more symptoms as fatigue, social eating in older 
patients when compared to younger patients, who mainly complained of 
insomnia, nausea and financial difficulties (So et al., 2012).  
Treatment modality has a profound impact on QoL outcome: combined 
chemoradiotherapy leads to a worse QoL compared with radiotherapy (RT) 
alone, whereas intensity modulated radiotherapy (IMRT) yields better QoL 
compared with conventional or three-dimensional conformal radiotherapy 
(Klein et al., 2014).  
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1.1.6 The curative treatment for head and neck cancer  
Head and neck cancer treatment is determined in a multidisciplinary setting. 
Early-stage diseases can be treated with either surgery or radiotherapy 
depending on the primary tumour site, with cure rates of 70–90%. 
Radiotherapy is the treatment of choice when function preservation is of 
paramount importance, such as carcinoma of the larynx and tongue base 
(Argiris et al., 2008).  
Unfortunately the majority of patients present with locally advanced stage 
disease which requires a multimodality therapy (Suh et al., 2014).  
1.1.6.1 Surgery 
The aim of HNC surgery is the complete surgical resection with microscopic 
clearance of the tumour. The surgical procedure has the advantage of 
providing tumour histology and achieving effective local tumour control. Over 
the past three decades there has been a change in the treatment of HNC, 
with the use of modern surgical technique and a trend toward an increased 
use of non-surgical treatment modalities in order to achieve organ 
preservation and optimise patients’ quality of life (Hartl et al., 2013).  
For early stage (I-II) HNC local excision of the tumour and a clinical margin of 
one centimetre of healthy surrounding tissue is usually recommended. Early 
HNC have an excellent prognosis, with cure rate of 80% for stage I disease 
and 65% for stage II (Kalavrezos and Bhandari, 2010).  
For advanced HNC, a combination of surgery and radiotherapy or the use of 
chemoradiotherapy (CRT) offers the highest chance of achieving cure 
(Roland, 2011). 
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The presence of cervical lymph node metastases is a key prognostic factor in 
patients with HNC and neck dissection is usually performed with a tendency 
to preserve non-lymphatic structures. The recognition that shoulder and neck 
dysfunction after neck surgery is an important contributor to quality of life 
after treatment has led to a progression from radical to selective neck 
dissection, where one or more of the lymphatic groups normally removed in 
the radical neck dissection is preserved (Medina and Krempl, 2012). 
Several techniques are being tested to improve functional outcomes, such as 
the Transoral Robotic Surgery. While there is no doubt on the advantages of 
transoral techniques over open techniques, it is still controversial whether the 
oncologic outcomes are equivalent or superior to results of other surgical and 
nonsurgical treatments (Moore et al., 2012). 
1.1.6.2 Chemotherapy 
As recently as the late 1980s, the role of chemotherapy in head and neck 
cancer was predominantly limited to palliation of recurrent or distant 
metastatic disease. Since then, chemotherapy has demonstrated to play a 
key role in the management of local or regionally advanced head and neck 
cancers. Furthermore, following a growing understanding of head and neck 
cancer molecular biology, new anticancer agents have been approved by the 
U.S. Food and Drug Administration (FDA). Cetuximab, a monoclonal 
antibody targeting the EGFR, has been approved for use in locoregionally 
advanced and recurrent disease. Docetaxel, an anti-mitotic chemotherapy 
agent, can be given along with cisplatin and 5-fluorouracil, agents which have 
been available for the treatment of cancer for more than 2 decades. 
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For many years, chemotherapy has been administered in the neoadjuvant 
setting (before radiotherapy) or adjuvant setting (after radiotherapy) and, 
more recently, concurrently with radiotherapy.  
One of the first studies on chemotherapy, the Veterans Administration Larynx 
Preservation Study, showed in a prospective randomized study that over 300 
patients with laryngeal squamous cell carcinoma (Stage III-IV) treated with 
induction chemotherapy followed by definitive radiation therapy had similar 
survival outcome to those who had conventional laryngectomy and 
postoperative radiation. It is important to highlight, however, that 36% of the 
patients in the chemotherapy group required total laryngectomy to a later 
stage (Wolf et al., 1991).  
Since this pioneering work, several studies have confirmed the additional 
benefit of chemoradiotherapy with regards to HNC local control and survival 
rates with the greatest survival benefit seen with the concurrent 
administration of chemotherapy and radiotherapy. The results of 87 
randomised trial have been combined in a meta-analysis (Blanchard et al., 
2011), which showed a significant overall survival benefit for concomitant 
chemotherapy at five years of 8.9%, 8.1%, 5.4%, and 4.0% for oral cavity, 
oropharynx, larynx and hypopharynx tumours respectively in comparison to 
loco-regional treatment alone. Of note, the benefit was largely confined to 
concomitant chemotherapy with no clear evidence of a benefit for induction 
and adjuvant chemotherapy. The original meta-analysis excluded 
nasopharyngeal cancers, but a significant overall benefit in survival of 6.3% 
at 5 years when compared to radiotherapy alone has been showed in their 
recent updated version (Blanchard et al., 2015).  
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Promising new molecular targeted therapies in head and neck oncology 
include EGFR monoclonal antibodies.  
Cetuximab, the most studied antibody has shown encouraging results in a 
phase II study on advanced head and neck cancer (3-year overall survival of 
76%), although an unexpected rate of death and adverse events led to early 
closure of the study (Pfister et al., 2006). In a landmark study by Bonner et 
al., cetuximab improved local control and survival (49.0 vs. 29.3 months) in 
424 patients with locoregionally advanced head and neck cancer randomly 
assigned to treatment with cetuximab and radiotherapy or radiotherapy alone 
(Bonner et al., 2006). The results of this study should be interpreted with 
caution, as the control group did not receive the standard of care 
(chemoradiotherapy) but only radiotherapy. Several clinical trials have 
addressed this issue comparing cetuximab to standard chemoradiotherapy 
regimen. The phase III study RTOG 0522 randomized patients to platinum 
based chemoradiation with or without cetuximab (Ang et al., 2014), failing to 
show any difference in progression-free survival between arms. Additional 
studies comparing chemoradiation to cetuximab with radiation are on-going 
(Cuneo et al., 2015). 
In addition to cetuximab, researchers have also focused their attention on the 
fully humanized monoclonal anti-EGFR antibody panitumumab. In the phase 
II study CONCERT-1 patients with locally advanced HNSCC were 
randomized to chemoradiation therapy with or without panitumumab (Mesía 
et al., 2015). The study showed a worse locoregional control rate (61% vs. 
68%) and a higher toxicity when panitumumab was added to the treatment 
(43% vs. 32%). In 2015 Giralt et al published the results of CONCERT-2, an 
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open-label, randomised trial comparing the treatment with panitumumab plus 
radiotherapy with platinum-based chemoradiotherapy in 152 participants over 
22 sites. The results of the study clearly showed the superiority of cisplatin 
therapy over panitumumab for unresected stage III-IVb squamous cell 
carcinoma of the head and neck in terms of loco-regional control at 2 years 
(61% vs. 51%) and adverse events (Giralt et al., 2015).  
1.1.6.3 Radiotherapy 
Radiotherapy is a highly effective treatment modality for HNC, either as 
single or combined treatment. 
Radiotherapy has been dramatically revolutionised by the introduction of 
IMRT, where radiotherapy beam’s intensity can be optimised to deliver a high 
dose of radiation to specified volumes, reducing the incidence and severity of 
radiation-associated side effects.  
Particle therapy such as protons therapy may allow additional advantages to 
patients with tumours close to particularly radiosensitive organs (brain, spinal 
cord), but these treatment modalities need to be validated in prospective 
clinical trials. 
1.2 Radiotherapy for Head and Neck Cancer  
1.2.1 The 4 R’s of radiobiology 
The relationship between the dose delivered to the tumour and the probability 
of tumour control is sigmoidal: below a threshold dose there is no evidence of 
tumour control whereas beyond this limit the higher the radiation dose 
delivered to the tumour the higher the tumour control (El Naqa et al., 2006). 
Increasing the dose, however, would also increase the probability of normal 
tissue complication. 
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.  
Radiotherapy has been used in the treatment of cancer for its ability to 
damage the DNA of cells leading to cell death. The damage to DNA can be 
direct, when the incident photon displaces an electron from the target 
molecule, or it can be the result of indirect ionization, if another molecule, 
such as water, is ionized and damages the DNA.  
Indirect ionization produces unstable components known as free radicals, 
able to interact with DNA resulting in either single-stranded or, most 
frequently, in double-stranded DNA breaks. Free radicals are in part 
inactivated through scavenging reactions (Caudell, 2012). 
Radiotherapy dose is prescribed in units of Gray (Gy), a measure of the 
amount of energy deposited in the tissue. For one Gy of absorbed radiation 
dose, there are in excess of 105 ionizations within the volume of every cell 
and more than 1000 damages to DNA bases (Bradly et al., 2009). 
The radiation dosage can be delivered in fractionated small daily portion to 
take advantage of the cell kill process of radiation treatment, originally 
described by Withers with the 4 R’s of radiobiology: repair of sublethal DNA 
damage, cell repopulation, redistribution of cells in the cell cycle, and 
reoxygenation of previously hypoxic tumour areas (Withers, 1999). Later, the 
principle of radiosensitivity was introduced (Steel et al., 1989). 
By fractionating radiation treatment over 5 to 7 weeks, normal cells are able 
to repair sublethal damage and repopulate, limiting the damage to the normal 
tissue. Conversely, malignant cells have often suppressed repair pathways, 
often through mutation or inhibition of TP53, preventing them from 
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undergoing efficient repair. Repopulation of tumour cells may be an important 
cause of treatment failure. Fractionation regimen allows eradication of the 
original tumour cells and also of any formed in the interval between fractions. 
Additionally fractionation overcomes the different tumour sensitivity to 
radiation, which varies during the cell cycle (redistribution of cell along the 
cell cycle), and kills the radiosensitive well-oxygenated cells, exposing the 
relative hypoxic-radioresistant cells (reoxygenation) (Marcu, 2010). 
1.2.2 Radiotherapy regimens for head and neck cancer 
Traditional RT regimen in head and neck oncology consists of a daily fraction 
dose of 1.8-2 Gy, five fractions per week, for seven weeks (conventional 
fractionation). Total dose can vary from 60 to 70 Gy (Fletcher, 1988).  
Over the past few decades new radiotherapy regimens have been designed 
and tested in order to improve tumour control and limit toxicity. The most 
commonly used altered fractionation schedules are hyperfractionated, 
accelerated and hybrid accelerated-hyperfractionated radiotherapy.  
Hyperfractionation involves multiple daily fractions (2 or 3) of small doses 
(under 1.8 Gy) with an interval between daily fractions of at least 6 hours to 
allow normal tissue repair. The aim of the hyperfractionation approach is to 
deliver a higher total dose of radiation, but in smaller doses, thus minimising 
the late side effects of the treatment. With accelerated fractionation, the total 
number of fractions is delivered over a shorter number of elapsed days, in 
order to counteract the rapid repopulation of tumour cells during the course of 
radiotherapy and improve locoregional control (Bernier and Bernier, 2011). 
Several trials have studied the role of unconventional fractionated 
radiotherapy in head and neck squamous cell carcinoma. The European 
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Organization for Research and Treatment of Cancer (EORTC) 22791 trial 
compared a radiotherapy regimen of 1.8- to 2.0-Gy fractions (total dose 70 
Gy) delivered once daily to a total dose of 80 Gy with 1.15-Gy fractions 
delivered twice daily for the treatment of T2–T3 oropharyngeal carcinomas, 
excluding base of the tongue. The authors observed a higher number of 
disease-free people at 5 years in the hyperfractionated arm (59%) compared 
the conventional arm (40%) (Horiot et al., 1992), although the benefit was not 
observed in T2 patients. The RTOG 9003 trial tested conventional 
fractionation, hyperfractionation (total dose 81.6 Gy), and two regimens of 
accelerated fractionation (67.2 Gy in 1.6 Gy fractions twice a day or 72 Gy in 
1.7 Gy fractions). The recently published final report showed an improved 
overall survival (HR 0.81) only for the hyperfractionation regimen, without 
increase of late toxicity (Beitler et al., 2014). Positive results for the 
hyperfractionation regimen were also reported in Brazil in a clinical trial 
randomly assigning 112 patients with stage III or IV oropharyngeal cancer to 
hyperfractionation (70.4 Gy in 1.1 Gy twice a day) or conventional 
radiotherapy (66Gy in 2.0 Gy daily). The overall survival rate at 42 months 
was 27% for the hyperfractionation arm and 8% for the conventional 
radiotherapy (Pinto et al., 1991). 
Accelerated fractionation in head and neck malignancies also has been 
tested in several clinical trials. The largest randomised study of accelerated 
fractionation is the Danish Head and Neck Cancer Study Group (DAHANCA) 
where almost 1500 patients received conventional fractionation or 
accelerated fractionation (six fractions per week) with the same number of 
fraction and dose per day (1 fraction of 2 Gy) and total dosage (66 Gy) 
between groups. Overall 5-year local-regional control (LRC) rates were 70% 
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and 60% for the accelerated and conventional groups respectively, with no 
difference in survival but significantly worse acute morbidity in the 
experimental group (Overgaard et al., 2003). The same study design was 
applied by the same research team few years later in developing countries 
(the IAEA-ACC study) and similar results were obtained (5- year LRC of 42% 
versus 30% in the conventional group) (Overgaard et al., 2010).  
Hybrid accelerated-hyperfractionated radiotherapy was developed to 
combine the two altered radiotherapy regimens. Although local control was 
improved in the GORTEC regimen, accelerated radiotherapy with a further 
dose reduction did not show a similar benefit in the CHART trials. The phase 
III clinical trial CHART (Continuous Hyperfractionated Accelerated 
Radiotherapy) observed similar tumour control rate in 918 patients 
randomized to 54Gy in 36 fractions of 1.5Gy (over 12 days) or to 
conventional radiotherapy (Dische et al., 1997). An improvement in local 
tumour control rate but at a prize of an increased incidence of acute 
mucositis was reported in the GORTEC study, where 268 patients were 
randomised to hybrid accelerated fractionation radiotherapy (62-64 Gy in 31-
32 fraction over 3 weeks) or conventional radiotherapy. This study reported a 
difference of 24% in the LRC in the experimental arm compared to the 
control arm. Severe toxicity, however, was observed in the accelerated 
group, with most of the patients having difficulties in swallowing liquid, and 
requiring a feeding tube (Bourhis et al., 2004).  
A meta-analysis of 6,515 patients across 15 trials assessed survival and local 
control rate between hyperfractionated, accelerated, hybrid accelerated with 
total dose reduction and conventional radiotherapy (Baujat et al., 2010). The 
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meta-analysis showed a significant survival benefit with altered fractionated 
radiotherapy, corresponding to an absolute benefit of 8% at 5 years for 
hyperfractionated radiotherapy, 2% with accelerated radiotherapy without 
total dose reduction and 1.7% with total dose reduction. 
A second meta-analysis described the potential benefit of altered 
fractionation in the treatment of unresected locally advanced HNSCC 
(Budach et al., 2006). This study confirmed a significant improvement in 
overall survival with hyperfractionated radiotherapy (14.2 months) compared 
to conventionally fractionated radiotherapy, but not with accelerated regimen. 
Conformal 3D radiotherapy and IMRT 
The close proximity of HNC to tissue at risk of severe damage (spinal cord, 
brainstem, parotid glands, lacrimal glands, eyes and optic tract) led to the 
development of new RT technologies delivering a radiation dose that 
conforms to the target volume and decreases exposure of other structures, 
the three-dimensional conformal radiotherapy (3D-CRT). The ability of 3D-
CRT in sparing salivary glands tissue and therefore limiting the incidence and 
severity of radiation-associated xerostomia has been confirmed in clinical 
trials (Portaluri et al., 2006, Wiggenraad et al., 2005).  
An advanced approach to three-dimensional treatment planning is the IMRT, 
which uses non-uniform radiation beam intensities to increase the delivery of 
radiation to the tumour while minimizing the dose to adjacent normal tissues.  
IMRT 
IMRT allows simultaneous delivery of individualized dose levels to the targets 
and elective nodal areas by modulating the intensity of the radiation beam. 
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IMRT has been used since 1996 to limit the radiation dose to critical organs 
in head and neck cancer patients. With IMRT the radiation dose to salivary 
glands is reduced, with the contralateral parotid gland receiving on average 
20 Gy (Bhide et al., 2012). This dosage well correlates with the observation 
that minimal gland function reduction occurs when the mean dose is less 
than 15 Gy, with gland function gradually reducing at radiation doses of 20–
40 Gy, and strongly reducing (usually by >75%) at >40 Gy (Deasy et al., 
2010). 
A systematic review of five randomised trials (871 patients) showed that 
IMRT can significantly provide better tumour target coverage than two- 
dimensional conventional radiotherapy (2D-CRT) and 3D-CRT (HR of 0.76; 
CI 0.66-0.87) (Marta et al., 2014).  
More than 20 clinical studies have been published in the literature reporting 
the clinical effect of IMRT on xerostomia or salivary function, but less than a 
quarter of them were randomised clinical trials. The pioneer was Pow in 2006 
who compared the treatment with IMRT and conventional radiotherapy in 51 
patients with nasopharyngeal carcinoma (Pow et al., 2006). IMRT proved to 
be better than RT in terms of parotid gland sparing, with 50% of IMRT 
patients recovering at least 25% of baseline salivary flow compared to 5% in 
the control arm. No specific outcome measure for the assessment of 
xerostomia was used in this study. He was followed by Kam et al in 2007 
who randomly assigned 56 patients with nasopharyngeal carcinoma to either 
IMRT or 2D-RT. He observed a lower incidence of severe clinician-rated 
xerostomia (RTOG) in the IMRT arm 1 year after treatment completion 
(39.3% vs. 82.1%) (Kam et al., 2007). No significant difference in the 
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reduction of patient-rated xerostomia has been observed between the two 
arms at any time point.  
Comparative studies have also confirmed that IMRT can significantly reduce 
the severity and prevalence of xerostomia in head and neck cancer survivors. 
Lee et al. (Lee et al., 2006) in a prospective non -randomised study and 
Lambrecht et al (Lambrecht et al., 2013) in a retrospective study, observed a 
similar reduced incidence of xerostomia ≥ grade 2 for IMRT vs. accelerated 
concomitant boost radiotherapy at 20 months and vs. 3D-CRT at 6 months 
(12% versus 67% and 23% versus 68% respectively). Undoubtedly the 
landmark clinical trial providing the strongest evidence regarding the benefit 
of IMRT in reducing salivary gland damage has been performed by Nutting 
and published in Lancet in 2011 (Nutting et al., 2011). In this study 94 
patients with pharyngeal carcinoma were randomly assigned either to IMRT 
or conventional RT among six UK radiotherapy centres. Clinician-rated 
xerostomia (LENT-SOMA) 12 months after treatment completion was 
observed in 38% of patients treated with IMRT versus 74% in the control 
group. Significant differences were also noted in unstimulated and stimulated 
parotid gland sialometry. No statistically significant difference between 
groups has been noted with regards to subjective xerostomia symptoms and 
quality of life. 
Although the consistent benefit offered by IMRT in achieving salivary glands 
sparing, this did not necessarily translate into significantly better QOL 
outcomes. The largest cross-sectional study evaluating post-radiotherapy 
QoL in 640 head–neck cancer survivors undergoing conventional, 3D-RT and 
IMRT, showed a benefit in global QoL and physical functioning when 
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comparing IMRT and conventional radiotherapy, however the benefit was not 
confirmed when IMRT was compared to conformal 3D-CRT (Wan Leung et 
al., 2011). 
Despite several studies focusing their attention on parotid-sparing technique, 
which is now the standard radiotherapy technique for HNSCC patients, there 
are no randomized trials evaluating the clinical outcomes of sparing the 
submandibular glands (SMGs), which contribute for 65-90% to the 
unstimulated salivary flow (Gensheimer et al., 2014).  
Very limited evidence from two small reports suggested that SMG-sparing 
IMRT could reduce long-term xerostomia compared with non-SMG sparing 
IMRT (Saarilahti et al., 2006, Wang et al., 2011). Saarilahti et al treated 36 
patients with either parotid-sparing IMRT or parotid-sparing and SMG-sparing 
IMRT observing that at 12 months there were fewer patients reporting grade 
2 or worse xerostomia (4 vs. 11) and they had better salivary gland function 
(60% vs. 25% of the baseline value) in the combined RT group. Their results 
were partly confirmed by Wang et al in a longitudinal study on 52 patients 
treated with or without contralateral submandibular gland sparing. Mean 
salivary flow at 2, 6, 12, and 18 months after RT and clinician rated 
xerostomia (RTOG) at 2 and 6 months were better in the group who had the 
submandibular salivary gland spared. However the results were not stratified 
for grades of xerostomia severity, which makes unclear the real benefit of this 
approach. 
Future approach 
There has been considerable interest in the use of radiotherapy based on 
protons, charges particles with unique physical properties, in order to further 
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reduce the toxicity of head and neck radiotherapy (Lukens et al., 2015). Initial 
dosimetric studies have suggested that proton radiotherapy could allow dose 
escalation without exceeding the tolerance of critical structures (Cozzi et al., 
2001) and the lower radiation doses delivered to the parotid glands could 
lead to complete recovery for both parotid glands (Widesott et al., 2008). 
Although randomised clinical trials are needed to understand whether the 
dosimetric advantage of proton therapy can translate into clinical benefit, 
preclinical models suggested that the reduced dose to the muscles involved 
in swallowing mechanisms and to the posterior fossa could lead to a 
reduction of the incidence of grade 2 or worse dysphagia (8%) (van der Laan 
et al., 2013) and fatigue (Gulliford et al., 2012). Of note, fatigue was the only 
adverse event more prevalent in the IMRT group compared to conventional 
radiotherapy (74% vs. 41%) in the cited study performed by Nutting (Nutting 
et al., 2011).  
1.2.3 Oral adverse side effects of radiotherapy to the head and 
neck  
Head and neck cancers can require high doses of radiotherapy on large 
areas including the oral cavity, maxilla, mandible and salivary glands and are 
therefore associated with several adverse reactions (Jham and Freire, 2006). 
Oral adverse side effects of radiotherapy to the head and neck will depend 
on the volume and area being irradiated, on the total dose of radiation. 
Functionally, tissue organization has been divided into parallel or serial 
structure, which has an effect on the radiation effects (Hodapp, 2012). A 
parallel organ, such as the parotid gland, can lose its functionality only if all 
the subvolumes of the organs are damages, whereas a serial organ can be 
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damaged even if only one of its subvolumes is damaged. As a consequence 
it is important to preserve all the functional units of serial organs (e.g. spinal 
cord) in order to guarantee the functionality of the tissue. This concept of 
tissue organization is of paramount importance during treatment planning.  
Normal tissues exhibit acute toxicity (during or right after treatment) and late 
toxicity (months or years) after cancer treatment. Acute toxicity typically 
reflect cell killing of rapid renewal systems such as skin, mucosa, or bone 
marrow and they are normally reversible. Conversely late toxicities are more 
complex, typically involving slow renewal systems, potentially causing 
significant tissue damage depending on the organ involved. Late 
complications are normally irreversible, leading to permanent incapability and 
to a worsening of quality of life.  
Oral adverse side effects of radiotherapy to the head and neck include oral 
mucositis, osteoradionecrosis, trismus and xerostomia. 
Oral mucositis 
Oral mucositis is the most common acute side effect resulting from exposure 
to chemotherapeutic agents and ionizing radiation. Severe oral mucositis 
occurs in 29-66% of all patients receiving radiation therapy for HNC 
(Satheesh Kumar et al., 2009).  
Oral mucositis is defined as an inflammation of oral mucosa manifesting with 
erythematous and ulcerative lesions (Raber-Durlacher et al., 2010). The 
lower lip, tongue, floor of the mouth, and soft palate are affected areas. The 
ulcers can be multiple and extended and, by offering a ready portal of entry 
for microorganisms, can increase the risk of systemic infection.  
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Radiation-associated mucositis typically begins from the second week of 
radiotherapy through cumulative doses of around 15 Gy, with ulcerative 
mucositis noted at doses of 30 Gy.  
The severity and the clinical manifestations of oral mucositis can vary 
depending on the dose of radiation, the association of radiotherapy with 
chemotherapy and the chemotherapeutic agent used. The risk of developing 
severe oral mucositis for cancers to the oropharynx, hypopharynx and larynx 
is approximately 34%, 57% and 43% respectively (Trotti et al., 2003). It is 
unclear whether IMRT technique can achieve a reduction in the incidence of 
acute mucositis, with a study reporting a reduction of 32% (Kouloulias et al., 
2013), and other studies showing comparable rates to patients receiving 
2/3D-RT (Kruser et al., 2013). 
Mucositis has been described as a complex biological process consisting of 
five sequential phases (Sonis, 2011).  
In the first phase (initiation) the direct wound to the DNA of the basal layer 
cells in the epithelium takes place with the appearance of reactive oxygen 
species. In the second phase (signalization) reactive oxygen species-
activated enzymes induce apoptosis, with an increased production of the 
proinflammatory cytokines. The third phase (amplication) is characterized by 
the loss of mucosa integrity, leading to the ulceration (fourth phase). Finally a 
signal from submucosal tissue allows renewed cellular proliferation and 
healing. 
The Multinational Association of Supportive Care in Cancer reviewed the 
evidence available in literature and developed guidelines for the 
management of oral mucositis. Interventions with high level of scientific 
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evidence than can be recommended are benzydamine mouthwash, 
cryotherapy, recombinant human keratinocyte growth factor and low-level 
laser therapy (Lalla et al., 2014).  
Osteoradionecrosis 
Osteoradionecrosis (ORN) is a severe and debilitating complication following 
head and neck radiotherapy. ORN is defined as an area of exposed 
irradiated bone that fails to heal over a period of 3-6 months in the absence 
of local neoplastic disease (Marx, 1983). 
The incidence of ORN following head and neck radiotherapy ranges from 
4.74%- 37.5% (Nabil and Samman, 2012), although it is significantly declined 
after the introduction of dental assessment before undergoing radiotherapy 
and advances in RT technique. Grade 3 ORN (the grade defines the need of 
mandibular resection) has been shown to be substantially reduced (to <1%) 
by the use of intensity-modulated radiation therapy (IMRT) techniques 
(Studer et al., 2006); whereas grade 1–2 ORN was reported to be <10% in 
patients at risk (radiation therapy with doses of ~70–72 Gy for tumour close 
to the mandible) (Studer et al., 2015). 
Mandibular ORN is more prevalent when compared to the maxilla due to the 
relatively poor vascularisation and to the dense structure of mandibular bone 
(Thorn et al., 2000). ORN can occur spontaneously or after trauma induced 
by dentures or dental surgery (Jiang et al., 2014). 
Pathogenesis of ORN remains unclear; the most accredited theory suggests 
that the necrosis is triggered by vascular insufficiency, radiation-associated 
fibrosis and acute inflammation (Lyons and Ghazali, 2008). Three phases 
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have been described: a pre-fibrotic phase characterised by chronic 
inflammation inducing fibroblastic activation, a constitutive organised phase 
with disorganisation of the extracellular matrix and a late fibroatrophic phase, 
featuring fragile and poorly vascularized tissue (Delanian and Lefaix, 2004).  
Controversy exists over the management of ORN with conservative 
measures (antibiotics, analgesics, oral hygiene) suggested for early or low 
grade ORN, and surgical management for advanced or refractory case (Rice 
et al., 2015).  
Trismus 
Trismus is defined as reduced mandible mobility leading to a maximal 
interincisal opening of 35 mm or less (Dijkstra et al., 2006). The limited mouth 
opening has a negative impact on quality of life as it can cause difficulties in 
chewing, speaking, delivering of proper dental care and cancer surveillance 
(Lee et al., 2015). Trismus in head and neck oncology is related to fibrotic 
damage to the muscle of mastication, mainly the pterygoid and the masseter 
muscle, and the temporomandibular joint (Dijkstra et al., 2004).  
The incidence of trismus is declined from 25.4% to 5% following the 
introduction of IMRT regimen, whereas it does not seem to be affected by 
altered-fractionated radiotherapy (Bensadoun et al., 2010). 
Indeed a recent multicentre randomised study (ARTSCAN) comparing 
conventional versus accelerated RT in 124 patients with HNC failed to find 
any significant difference in patient-reported trismus or maximal interincisal 
distance between the two trial arms (Lindblom et al., 2014).  
  47 
Different treatment modalities have been suggested. Physiotherapy using 
various external opening devices is generally considered the standard choice 
of treatment for trismus, although evidence of its effectiveness is not 
convincing (Scherpenhuizen et al., 2015). 
Radiotherapy-associated xerostomia 
Radiotherapy-associated xerostomia, the most common debilitating 
consequence of the radiation therapy for HNC, will be discussed in the next 
section (1.3). 
1.3 Radiotherapy-associated xerostomia  
1.3.1 Salivary gland anatomy  
The human salivary gland system includes major and minor salivary glands. 
The paired parotid, submandibular, and sublingual are major salivary glands. 
Additionally, the mucosa of the upper aerodigestive tract is lined by hundreds 
of minor salivary glands.  
The parotid glands are the largest of the major salivary glands and they are 
located in the preauricular region and along the posterior surface of the 
mandible. Each parotid gland is divided by the facial nerve into a superficial 
lobe and a deep lobe. The parotid duct, also known as Stensen’s duct, 
secretes serous saliva into the vestibule of the oral cavity. The 
submandibular gland is the second largest major salivary gland and is 
located between the inferior edge of the mandible and the digastric muscle. 
The submandibular gland, as the sublingual gland, has both mucous and 
serous cells that empty into ductules, which in turn empty into the Wharton’s 
duct. The smallest of the major salivary glands is the sublingual gland, which 
lies within the anterior floor of the mouth, superior to the mylohyoid muscle 
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and deep to the sublingual folds opposite the lingual frenulum. Several ducts 
(of Rivinus) from the superior portion of the sublingual gland secrete directly 
into the floor of mouth (Holsinger and Bui, 2007).  
About 600 to 1,000 minor salivary glands, ranging in size from 1 to 5 mm, line 
the oral cavity and oropharynx producing a mucous secretion. The greatest 
number of these glands are in the lips, tongue, buccal mucosa, and palate, 
although they can also be found along the tonsils, supraglottis, and 
paranasal sinuses (Holsinger and Bui, 2007).  
1.3.2 Salivary glands physiology 
Salivary fluid is composed of more than 99% water and a variety of 
electrolytes (sodium, potassium, calcium, chloride, magnesium, bicarbonate, 
phosphate) and proteins (enzymes, immunoglobulins, antimicrobial factors, 
mucosal glycoproteins) (De Almeida et al., 2008). 
Saliva has the important function of lubricating and protecting the oral cavity 
and upper pharynx, modulating the microbial population and providing 
stabilisation and remineralisation of teeth.  
The salivary gland product plays a key role in the initial phase of the 
digestion of carbohydrates and fats through two main enzymes: ptyalin, an α-
amylase able to cleave the internal α-1,4-glycosidic bonds of starches to 
yield maltose, maltotriose, and lingual lipase, a α-limit dextrin produced by 
lingual salivary glands to break down triglycerides (Pedersen et al., 2002).  
Importantly the salivary fluid is involved in taste sensitivity, transporting the 
taste substances to the taste receptors (Motsuo, 2000).  
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Saliva aids speech by facilitating movements of the lips and tongue. 
Furthermore its mucous composition aids the lubrication of food particles 
during the act of chewing, which serves to mix the food with saliva. 
Lubrication eases the processes of swallowing and the progression of the 
bolus down to the oesophagus (Holsinger and Bui, 2007).  
Saliva exerts several important actions in the maintenance of tooth and 
mucosal integrity. The antibacterial properties of saliva, mainly due to the 
presence of immunoglobulin A, lysozyme and lactoferrin allow inhibition of 
bacterial growth. Saliva also serves as a protective buffer for the teeth, 
reducing the rate of tooth demineralization due to the content of bicarbonate, 
phosphate and proteins (Pedersen et al., 2002). 
A healthy adult produces at least 500 mL of saliva in 24 h (Porter et al., 
2004).  
The secretory unit of the salivary gland is composed of acinar cells, 
myoepithelial cells, intercalated duct, striated duct and excretory duct. Saliva 
produced from the acini is relatively isotonic to plasma but as the saliva is 
transported in the oral cavity through the ductal system, it becomes hypotonic 
to plasma, with high concentration of potassium and bicarbonate and low of 
sodium and chloride (Turner and Sugiya, 2002). 
Saliva secretion is stimulated by both branches of the autonomic nervous 
system. Parasympathetic innervation of the major salivary glands leads to 
glandular vasodilation as well as myoepithelial cell contraction. The 
sympathetic innervation results in myoepithelial cell and changes in blood 
flow manifesting as vasoconstriction and vasodilation (Proctor and Carpenter, 
2007). 
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The amounts of saliva supplied by the salivary glands changes from resting 
condition to stimulation. During unstimulated salivation, the majority of the 
saliva is produced by the submandibular glands, only 20% by the parotid, 
and approximately 5% by the sublingual glands, whereas during stimulation 
two thirds of secretion is from the parotid gland (Pedersen et al., 2002) 
(Figure 1-5).  
 
Figure 1-5 Secretory contributions of the salivary glands for resting salivary 
flow (Leo M. Sreebny, 2010) 
1.3.3 Definition 
Salivary gland hypofunction can be defined as an unstimulated whole saliva 
flow rate <0.1ml/min or stimulated whole saliva flow rate <0.7 ml/min 
(Streebny and Valdini, 1988, Ericsson and Hardwick, 1978). A reduction of 
salivary secretion can be associated with a subjective perception of oral 
dryness (xerostomia), which is estimated to occur when unstimulated flow 
rate is reduced by 45–50% (Dawes, 1987).  
65%	
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8%	
7%	
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1.3.4 Prevalence of Radiotherapy-associated xerostomia 
Xerostomia is the most common late side effect of RT to the head and neck 
region as the major salivary glands are usually within the field of treatment 
(Bjordal et al., 1994b, Harrison et al., 1997). The prevalence of RT-
associated xerostomia varies with respect to RT field, dose, regimen, and 
technique (Table 1-2). Overall 63% to 93% of individuals exposed to head 
and neck RT develop xerostomia (Jensen et al., 2010b, Wijers et al., 2002). 
Table 1-2 Prevalence of xerostomia by post-treatment phase and type of 
radiation therapy, adapted from Jensen et al. (2010b) 
Type of 
Cancer 
Therapy 
Baseline During 
RT 
1-3 
months 
post RT  
3-6 
months 
post RT 
6-12 
months 
post RT 
1-2 
years 
post 
RT 
>2 
years 
post 
RT 
2D-RT 10.4% 81.4% 70.9% 83.2% 71.5% 83.8% 90.9% 
3D-RT  0% NR 46.7% 74.5% 90.3% 75.4% 69.4% 
IMRT 11.8% 100% 89.4% 72.7% 90.1% 66 % 68.1% 
As already mentioned the introduction of new radiotherapy modalities has 
allowed a selective sparing of parotid gland tissue and a reduced prevalence, 
as well of severity, of xerostomia. Patients undergoing IMRT have a 24% risk 
reduction of developing clinician-rated xerostomia (RTOG) (HR 0.76; CI 0.66-
0.87) compared to those treated with 2D-RT or 3D-RT. This benefit was 
statistically significant from 6 months to 5 years after completing the cancer 
treatment (Marta et al., 2014).  
1.3.5 Pathophysiology  
The mechanism of RT-associated salivary damage is not fully understood 
and the apparent radiosensitivity of the salivary glands is still an enigma. 
Their nature of highly differentiated cells with slow turnover would exclude 
their radiosensitivity. On the contrary, changes in quantity and composition of 
saliva occur also immediately after RT, indicating that the salivary glands are 
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highly sensitive to radiation (Burlage et al., 2001). Radiation induces a 
decline in amylase activity, bicarbonate and pH level, and a significant 
increase in osmolarity and viscosity. Furthermore alterations in the 
concentration of sodium, chloride and calcium, mucin 5b and mucin C7 have 
been observed (Randall et al., 2013). 
Radiation-associated xerostomia and hyposalivation typically start early 
during cancer treatment: during the first week of radiotherapy a 50–60% 
decrease in salivary flow can be observed; after 7 weeks of conventional 
radiotherapy salivary flow can diminish to approximately 20% of the baseline 
value (Dirix et al., 2006).  
Several studies have assessed the dose-response relationship between 
cumulative radiation dose and salivary gland damage. As previously 
mentioned following a cumulative exposure of >40 Gy, severe salivary gland 
damage (>75% of the baseline value) can be expected (Deasy et al., 2010). 
Based on animal experiments, salivary glands damage induced by 
radiotherapy can be divided in three main phases (Konings et al., 2005).  
In the first phase (0-10 days) water excretion is impaired with no cell loss; 
amylase and other protein secretions are unaffected. Clinically saliva 
becomes more dense and viscous. The second phase (10-120 days) is 
characterised by structural damage to the plasma membrane of the acinar 
cells with reduction in amylase secretion. The third phase (120-240 days) 
represents the late radiation damage, with loss of functional acinar cells as 
well as progenitor and stem cells. Histological observations suggest that 
some regeneration of acinar cells does take place after irradiation, yet the 
newly formed cells are functionally impaired due to the presence of radiation-
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induced damage to ducts, blood vessels and nerves, as well as replacement 
of parenchyma with fibrotic tissue (Figure 1-6). 
 
Figure 1-6 Illustration of the phases of salivary glands damage associated by 
radiotherapy 
Two separate mechanisms seem to cause damage to salivary glands: the 
first mechanism involves selective membrane damage resulting in altered 
intracellular signal transduction and defects in cellular functioning. The 
second mechanism includes the loss of secretory cells as a result of 
progenitor cell death (Konings et al., 2005).  
Eisbruch et al (2001) demonstrated the development of cellular degranulation 
and degeneration as soon as one hour after delivery of a single radiation 
dose of 2.5 Gy, whereas at 6 hours there was evidence of serous cell 
necrosis. Exposure to higher radiation dose was associated with 
degenerative changes progressing over time, atrophy and fibrosis. In addition 
to the necrosis, ionizing radiation can also activate apoptosis. Apoptosis 
culminates in the rapid clearance of cells by phagocytosis without 
inflammation and could be theoretically prevented by pre-treating the parotid 
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acinar cells with an agent capable of inhibiting radiation-associated apoptosis 
(Guchelaar et al., 1997). The relevance of radiation-induced apoptosis to the 
overall physiological function of the salivary gland, however, has not yet been 
elucidated, with some studies in rats showing how apoptosis could not 
explain the significant loss of gland function (Paardekooper et al., 1998). In 
contrast, studies in mice showed that radiation-induced apoptosis is dose 
dependent in parotid glands (Humphries et al., 2006).  
Salivary gland dysfunction in irradiated patients is considered irreversible 
although a partial recovery of salivary function 12-to-18 months after 
treatment completion can take place (de la Cal et al., 2012). Little is known 
about the changes of salivary gland function with time, as the majority of the 
studies had a maximal follow-up of 2 years. 
1.3.6 Symptoms and clinical manifestation  
The insufficient wetting and lubrication of the oral mucosa observed in 
individuals with RT-associated salivary gland hypofunction can cause 
significant difficulties with speaking (dysarthria), taste (dysgeusia), 
swallowing (dysphagia), and mastication. The inhibition of taste sensation 
and the impairment of chewing and swallowing can affect patients’ nutritional 
status. Patients can also experience intra-oral burning sensation and high 
sensitivity to salty and spicy foods. Wearing dentures may be extremely 
uncomfortable due to the reduced surface tension between the dry mucosa 
and the prosthesis (Hammerlid and Taft, 2001). Symptoms and signs of 
radiotherapy-induced xerostomia are summarised in Table 1-3 and Table 1-
4. 
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Table 1-3 Symptoms of radiotherapy-associated xerostomia 
General problems Oral discomfort 
Lip discomfort 
Cracking of lips 
Eating-related problems Taste disturbance 
Difficulty chewing 
Difficulty swallowing 
Speech-related problems Difficulty speaking 
Oral hygiene Halitosis 
Dental problems Poorly fitting dentures leading to trauma of oral mucosa 
Psychosocial problems Embarrassment 
Anxiety 
Depression 
Social isolation 
Miscellaneous problems Sleep disturbance 
On examination the lips of individuals with xerostomia can appear 
desquamated and fissured, and the oral mucosa atrophic, pale, and 
hyperaemic. Patients with xerostomia have an increased risk of oral 
infections, including candidal infection and sialadenitis (Abendstein et al., 
2005, Jensen et al., 2010b, Wijers et al., 2002). Dental caries are common 
and can be severe and difficult to manage.  
Table 1-4 Signs of radiotherapy-associated xerostomia 
Angular cheilitis Thick saliva 
Salivary gland enlargement Glazed, dry mucosa that tend to form 
wrinkles 
Lobulated partial/complete depapillated 
tongue 
Candida infection 
Gross accumulation of plaque Dental caries, including cervical caries 
1.3.7 Diagnosis and Assessment of xerostomia 
Diagnosis of xerostomia and salivary gland hypofunction relies on a detailed 
history and clinical examination. A number of patient-reported and clinician-
rated outcome measures have been introduced to assess the severity of this 
condition.  
Three patient-reported outcome measures have been used in clinical trials 
focusing on radiotherapy-associated xerostomia: the Visual Analogue Scale, 
the University of Michigan Xerostomia Questionnaire and the Xerostomia 
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Inventory. The Visual Analogue Scale (VAS) is the most used patient-
reported outcome measured, being brief and freely available. Originally 
designed to assess pain, it is a self-assessment tool consisting of a 10-cm 
horizontal scale to indicate the severity of oral dryness (Pai et al., 2001). The 
University of Michigan Xerostomia Questionnaire was developed and 
validated by Eisbruch in 2001 (Eisbruch et al., 2001). The questionnaire 
consists of 8 questions addressing problems in communicating, eating, and 
sleeping functions. All questions are rated on a Likert scale to produce a final 
summary score between 0 and 100. A Xerostomia Questionnaire scores ≤ 30 
corresponds to mild to no symptoms of xerostomia, with higher scores 
representing more severe xerostomia symptoms. The Xerostomia Inventory, 
has been developed and validated in 1999 by Thomson et al. (Thomson et 
al., 1999). The XI consists of 11-item summated rating scale with response 
options being “Never” (scoring 1); “Hardly ever” (2); “Occasionally” (3); “Fairly 
often” (4); or “Very often” (5). Each individual's responses are scored and 
summed to give a single XI score, which has a theoretical range from 11 to 
55, with higher scores representing worse symptoms and a score of 14.5 or 
lower considered normal. 
A total of five clinician-rated outcome measures have been used in clinical 
trials on radiotherapy-associated hypofunction, the most used being the 
quantitative measurement of salivary output (sialometry). 
The RTOG scoring criteria defines acute radiation effects to salivary glands 
(within 3 months of the commencement of therapy) and chronic radiation 
effects, with scores ranging from 0 to 5 (0 = none; 1 = slight dryness of the 
mouth, good response on stimulation; 2 = moderate dryness, poor response 
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on stimulation; and 3 = complete dryness, no response on stimulation; 4= 
fibrosis; 5= death) (Cox et al., 1995). The two large organisations that 
initiated several multicentre clinical trials in Europe and North America, the 
EORTC and the RTOG, formed a working group to update and improve the 
system for recording late injuries to normal tissues. The Late Effects of 
Normal Tissues (LENT)–Subjective, Objective, Management, and Analytic 
(SOMA) is the resulting system and has been in use since 1995 (Pavy et al., 
1995). The LENT-SOMA scoring system of xerostomia includes subjective 
grading consisting of an evaluation of dryness and objective findings of 
mucosal moisture. In 2003 the National Cancer Institute published the 
Common Terminology Criteria for Adverse Events (CTCAE) which 
incorporated the LENT SOMA items with early and late effects contained in 
one system, and it is now widely accepted throughout the oncology 
community as the standard severity grading scale for adverse events in 
cancer therapy clinical trials (Baldwin, 2003). 
Three clinical trials have used a Modified Schirmer’s Test, adapted from the 
test used routinely by ophthalmologists to measure the tear film wetness 
(Kohler and Winter, 1985, Davis and Marks, 1986, López-Jornet et al., 1996). 
One clinical trial used the Oral Assessment Guide (Andersson, 1999), 
consisting of eight categories: voice, swallow, lips, tongue, saliva, mucous 
membranes, gingival and teeth or dentures. Each category is rated by a 
scale of 1, 2 and 3, from normal findings (1) to severe (3). A sum score from 
the eight categories is calculated giving a range between 8, normal findings, 
and 24, severe alterations. 
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The vast majority of clinical trials used the salivary gland function output 
measurement (sialometry), which is also used in clinical setting as objective 
measure of hyposalivation (Dutta et al., 1973). Salivary gland function is 
assessed at rest and upon stimulation by measuring the whole-mouth saliva, 
or by selective suction from the glands’ canals orifices. The methods involve 
the collection of saliva over a period of time (usually for at least 5 min), the 
collected saliva is weighed, the volume determined assuming a specific 
gravity of 1.0, and the flow rate (mL/min) is reported. Stimulation is typically 
done by application to the dorsum of the tongue of a chemical (e.g. 2% citric 
acid) or mechanical (e.g. chewing) stimulation. Several methods have been 
traditionally used to collect and measure whole mouth saliva. Saliva is either 
allowed to drain into a receptacle for weight or volume determinations 
(draining method), or is collected in the oral cavity and then voided into a 
receptacle (spitting method). A suction tube can be used to draw saliva from 
the floor of the mouth into a vessel (suction method), or pre-weighted cotton 
swabs are inserted to absorb saliva collecting on the floor of the mouth (swab 
method). Navazesh et al. (Navazesh and Christensen, 1982) compared the 
four assessment methods among 17 subjects. The draining method was 
recognized as cumbersome, procedurally distasteful, and prohibitively time-
consuming for use in large epidemiologic studies. The study also found the 
swab method to be unreliable, whereas the suction method had the highest 
test/ retest reliability, but consistently yielded more saliva volume than the 
spit or draining methods. The authors thus concluded that the spitting method 
was preferable in terms of reliability and simplicity. There is no satisfactory 
method for selective measurement of the minor salivary glands function after 
radiation. No thorough comparison has been made of the reliability, validity, 
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and inter-correlation among the various salivary collection procedures, nor 
there has been a comprehensive comparison between resting and stimulated 
patterns of flow rate. 
Sialometry has been used in nearly twenty clinical trials but significant 
discrepancies in the methods of performing sialometry can be observed, with 
time of collection ranging from 1 minute to 10 minutes and a number of 
different techniques used to assess the salivary flow rate. The most common 
technique is to assess the whole unstimulated and stimulated flow rate by 
spitting methods, although used techniques included unstimulated and 
stimulated parotid salivary flow, only unstimulated salivary flow and 
unstimulated and stimulated sublingual/submandibular salivary flow.  
As mentioned in the definition of xerostomia, salivary hypofunction is 
commonly defined as unstimulated whole saliva flow rates of <0.1 mL/min or 
stimulated whole saliva flow rate of <0.7 mL/min (Streebny and Valdini, 1988, 
Ericsson and Hardwick, 1978). The correlation between salivary flow rate and 
subjective oral dryness sensation, however, is weak (Diogo Löfgren et al., 
2012).  
Imaging techniques such as magnetic resonance imaging (MRI), 
ultrasonography, and computed tomography can identify post-radiotherapy 
morphological changes as indirect evidence of salivary gland hypofunction. 
Magnetic resonance can show RT-changes in the internal architecture, with 
hyperintense signals due the oedema related to the damage of blood and 
lymph vessels. However this technique was found not suitable for the chronic 
observation of gland hypofunction as it cannot predict the severity of 
radiation-associated xerostomia (Wada et al., 2009). Ultrasonography can 
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show hyperechoic areas in the parotid glands indicating patches of 
inflammatory infiltrate (Ying et al., 2007). 
Functional changes can also be assessed and measured via scintigraphy 
with technetium-sodium pertechnetate, as damaged salivary glands fail to 
excrete the marker in the saliva, leading to its accumulation within the gland. 
This technique is minimally invasive and well tolerated by patients although it 
is not specific enough to distinguish between Sjogren’s syndrome and 
radiation damage (Hermann et al., 1999). 
Computer tomography has been widely used in head and neck cancer 
imaging but the information regarding its application in the post-radiotherapy 
salivary gland evaluation are very limited to justify its use (Cheng et al., 
2011).  
1.3.8 Impact of xerostomia on Quality of Life 
Despite the psychological and social impact of xerostomia, few studies have 
focused their attention on the extent of its influence on quality of life. 
Pow et al in a study from 2006 already described in the previous section, 
revealed a significant correlation between stimulated whole salivary flow and 
global health status and emotional function assessed through the EORTC 
QLQ-C30 questionnaire (Pow et al., 2006). Significant correlations were 
found between role function and stimulated parotid saliva flow. For the 
H&N35 measure, significant negative correlations were found between 
speech problem, xerostomia, sticky saliva, and stimulated parotid saliva flow 
rate. 
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A well-designed longitudinal study conducted by Jellema in 2007 indicated 
that xerostomia (assessed though RTOG) has a significant effect on different 
dimensions of QoL (EORTC QLC-C30), notably on overall QoL outcome and 
all functioning scale but emotional functioning (Jellema et al., 2007).  
A longitudinal prospective study assessed the severity of xerostomia in 
relation to the QoL in 63 head and neck cancer patients (Kakoei et al., 2012). 
Although the follow-up of this study was limited at 6 weeks after radiotherapy 
and the study is biased by the choice of improperly validated outcome 
measures, it is interesting to note that, according to regression analyses, with 
each millilitre decrease in saliva secretion, the QoL score decreased of 
2.25%. Conversely with a 1-point increase in the xerostomia score, there was 
a 1.65% decrease in the mean QoL score (Kakoei et al., 2012), with no 
significant changes to salivary flow rate.  
A prospective clinical study, confirming the hypothesis that sparing the 
parotid glands would result in significant objective and subjective 
improvement of xerostomia in patients with HNC, also observed that QOL 
questions on eating/speaking function were significantly correlated with 
stimulated and unstimulated saliva flow at 6 months. Unfortunately it is 
unclear which QoL outcome measures was used in the study and so the 
generalizability of the study remains unclear (Chao et al., 2001). 
Results were in agreement with the study performed by Lin et al in 36 head-
and-neck cancer patients receiving IMRT. The relationship between the XQ 
(University of Michigan Xerostomia Questionnaire) and QoL questionnaire 
(previously validated) scores revealed no statistically significant correlation 
before RT, with a significant linear correlation at each of the post-RT 
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endpoint (3, 6 and 12 months) between xerostomia and the eating, emotional 
and pain domain of the QoL questionnaire (Lin et al., 2003). 
1.3.9 Preventive strategies  
There is controversial evidence regarding the protection of salivary glands 
parenchyma from radiation damage.  
Pilocarpine  
Pilocarpine is a cholinergic agonist that can stimulate exocrine glands by 
acting as a muscarinic agonist. Pilocarpine eye drops have been used for 
many years to treat glaucoma. In 1994, an oral formulation of pilocarpine was 
approved by the FDA for the treatment of radiotherapy-associated 
xerostomia, but one year before the approval, its use concurrent with 
radiation had been tested. The mechanism of action of concomitant 
pilocarpine is not fully understood. Animal studies have suggested that the 
protective effect of pilocarpine on salivary glands is due to the depletion of 
secretory granules in serous cells. It has been speculated that by depleting 
heavy metals such as Zn, Mn, and Fe found in secretory granules, 
pilocarpine can decrease radiation-associated lipid peroxidation of lysosomal 
membranes and subsequent serous cell autolysis (Atri et al., 2014). 
There remain doubts on the mechanisms of action and no evidence to 
suggest efficacy of pilocarpine in preventing xerostomia and hyposalivation 
associated with RT.  
Seven studies have investigated the protective effect of pilocarpine. 
Zimmerman et al in a retrospective study suggested that the use of 
pilocarpine per day (5 mg 4 times a day) during radiation treatment and for 3 
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months after treatment completion can reduce damage to salivary gland 
(Zimmerman et al., 1997). Although the authors’ conclusion is that the 
seventeen patients using pilocarpine had significant less xerostomia 
symptoms than the eighteen who did not use the medication, no clear data 
are presented in the paper and limited evidence of pilocarpine efficacy in 
preventing radiotherapy-associated salivary gland damage is provided by this 
study. A small double-blind randomised trial of nine patients has been 
performed by Valdez (Valdez et al., 1993). In the study the subjective 
outcome measure to assess xerostomia symptoms is unclear, as well as the 
results, however patients taking pilocarpine had smaller losses in stimulated 
functions compared to the placebo group, with no difference in unstimulated 
salivary flow. Early concomitant pilocarpine use during RT has been also 
evaluated by Nyarady (2006) in a prospective unblinded randomised study in 
which 66 head and neck cancer patients were randomised to receive 5 mg 
pilocarpine three times a day from the beginning of RT for 12 weeks or to 
receive the same dosage of pilocarpine at the end of RT for 6 weeks. At the 
end of the study xerostomia symptoms of patients taking pilocarpine during 
RT returned closer to baseline compared with the control group, and the first 
group had also an improved salivary flow. However, three double-blind 
randomised clinical trials, where 58, 170 and 130 patients were assigned to 
treatment with pilocarpine 5 mg five, four and three times daily for five, two 
and 4 weeks respectively, failed to replicate positive outcomes of 
prophylactic pilocarpine (Gornitsky et al., 2004, Burlage et al., 2008, Warde 
et al., 2002). Finally the last study is burdened by the high dropout rate (35%) 
(Haddad and Karimi, 2002). 
Amifostine  
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Amifostine is a radioprotective agent currently approved for the prevention of 
radiation-associated xerostomia. Amifostine is dephosphorylated by alkaline 
phosphatase to the active cytoprotective thiol metabolite, WR-1065, which 
can act as a scavenger reducing the free radicals generated by radiation. It 
binds highly reactive nucleophiles preventing their reaction with DNA and 
relevant DNA damage. A study suggested that amifostine could also inhibit 
the apoptotic process, reducing radiation-associated cell death (Saavedra et 
al., 2010).  
Several studies have investigated the efficacy of amifostine in preserving 
salivary glands function and reducing radiation-associated xerostomia, 
clarifying its potential adverse side effects. Intravenous amifostine can cause 
adverse side effects such as hypotension (62% of patients) and nausea, 
which seem to occur less frequently when amifostine is administered 
subcutaneously (Bardet et al., 2011). There is no evidence to suggest that 
amifostine may have a tumour-protective activity and reduce efficacy of anti-
cancer therapy (Bourhis et al., 2011, Sasse et al., 2006). 
The effectiveness of amifostine in preventing RT-associated salivary gland 
damage and xerostomia has been investigated in six randomised clinical 
trials, which have been pooled together in a recent systematic review and 
meta-analysis (Gu et al., 2014). This meta-analysis clearly highlighted the 
efficacy of amifostine in reducing the risk of developing acute and late 
xerostomia by 40% respect to placebo or controls (observation), without 
tumour protection. According to this study, however, patients receiving 
concomitant chemoradiation did not benefit from the risk reduction. The 
reduction of radiotherapy-associated toxicities showed in clinical trials, which 
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also include dysphagia and mucositis, should be weighed against the toxicity 
associated to the amifostine itself. The other aspects to consider are the 
costs of the therapy and logistic problems, as there is the need to administer 
the drug immediately prior to each RT session. Subcutaneous amifostine 
administration was not found to be superior to intravenous administration in 
terms of patient compliance or efficacy (Kałuzny et al., 2014). 
Submandibular glands transfer 
In an effort to prevent radiation-associated xerostomia Jha and Seiklay firstly 
reported on a surgical procedure to transfer the submandibular gland out of 
the main RT field (to the submental space). This approach can be performed 
during cancer resective surgery, with an impact of additional 45 minutes to 
the duration of surgery. Jha et al (2003) yielded encouraging results with this 
technique in a prospective phase II trial: 81% of the 43 patients who had 
salivary gland transfer reported to have none or minimal xerostomia at the 
end of RT and 19% reported moderate to severe xerostomia. Two 
randomised trial have been conducted to investigate the clinical efficacy of 
this techniques to prevent xerostomia after radiotherapy. Zhang randomised 
65 patients with nasopharyngeal carcinoma to either unilateral 
submandibular gland transfer before RT or no intervention. The study 
reported a higher salivary flow rate up to 60 months after radiotherapy 
completion and a significant higher proportion of patients experiencing none 
or mild clinician-rated xerostomia (RTOG) in the experimental group (Zhang 
et al., 2014).  
Submandibular salivary gland transfer has also been compared to treatment 
with pilocarpine during and 3 months after radiotherapy in a multicentre 
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phase III randomised trial recruiting 120 participants (Jha et al., 2009). At 6 
months patients in the gland transfer arm showed improvement in salivary 
flow and in the domain “amount of saliva” of the University of Washington 
Quality of Life questionnaire compared to the pilocarpine group (50% vs. 
26%). No additional subjective or objective assessments have been 
performed in the study. Surgical complication associated with this technique 
include facial oedema (13.6%), submental swelling (19%), shoulder 
weakness (4.5%) and neck numbness (6.8%) (Jha et al., 2012).  
Acupuncture 
Acupuncture has been suggested to induce physiological effect, modulate 
neurological processes within the spinal cord gating mechanisms, the 
cerebral subcortical nuclei and the hypothalamic-endocrine axis (Sagar, 
2008), as well as stimulate the autonomic nervous system, increase 
peripheral blood flow, and enhance levels of vasoactive intestinal 
polypeptide, which might in turn increase salivary flow rates (Dawidson et al., 
1999, Dawidson et al., 1998). 
A single-centre randomised feasibility trial conducted by Meng (Meng et al., 
2012) showed that forty individuals receiving acupuncture concurrently to 
radiotherapy had significantly lower scores in a xerostomia questionnaire at 6 
months and greater salivary flow rate with respect to the control group 
(observation). Further large-scale, multi-centre, placebo-controlled 
randomised trials are needed to confirm these encouraging preliminary 
findings.  
Hyperbaric oxygen therapy 
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Hyperbaric oxygen therapy (HBOT) aims to counteract by oxygenation the 
effect of radiotherapy to surrounding normal tissues, which can become 
hypocellular, hypovascular, and hypoxic. HBOT has been traditionally used in 
head and neck oncology for the treatment and prophylaxis of radionecrosis of 
bone and soft tissue. During daily treatments, patients are placed in 
chambers that are pressurized to 2 to 3 atmospheres absolute and 
encourage to breathe 100% oxygen for a total of 20 to 40 dives (Fox et al., 
2015). Two randomised clinical trials have tested the efficacy of HBOT in 
reducing radiotherapy side effects. Teguh in 2009 randomised 19 head and 
neck cancer patients to receive HBOT shortly after radiotherapy completion 
or no treatment (Teguh et al., 2009). However only 19 patients out of 132 of 
the sample size calculation were recruited due to a premature closure of the 
study. Clinician-rated outcome measure were not used in the study but 
patient-centred outcome measures showed that xerostomia was significantly 
less severe in the HBOT group 18 months after radiotherapy completion, the 
difference between group being 3 on a 0-10 VAS severity scale. 
A recent systematic review has been published by Fox in 2015 (Fox et al., 
2015) concluding that HBOT can induce long-term improvement in 
xerostomia. However the strength of these conclusions are limited by the 
number of studies included (n= 7), the design of included studies (five were 
prospective in nature but only two were randomised) and the research 
questions, with the majority of studies focusing on the treatment of 
osteonecrosis. 
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2 The management of radiotherapy- associated 
xerostomia 
2.1 Systematic review and meta-analysis of the interventions 
for the management of radiotherapy-associated 
xerostomia 
2.1.1 Introduction  
A wide range of interventions for radiotherapy-induced salivary gland 
hypofunction are available (Plemons et al., 2014). Stimulation of salivary 
gland function may be appropriate for patients with some degree of residual 
salivary gland parenchyma, and it can be attempted through sialagogue 
medications (parasympathetic agonists such as pilocarpine and cevimeline) 
(Brimhall et al., 2013) or activating the salivary reflex arch via chewing gums 
or sucking pastilles and lozenges (Furness, 2011). Topical application of 
salivary substitutes (artificial saliva) can offer some benefit by providing a 
moisture-retaining coating onto the oral mucosa (Dost and Farah, 2013). 
Other interventions, such as acupuncture, have also been used to increase 
saliva production, possibly by enhancing peripheral blood flow (Wolff et al., 
2012). However no clear guidance for clinicians is available as randomised 
trials of available treatment modalities have produced unclear results and 
there is currently little robust evidence to inform the management of 
hyposalivation and xerostomia in this population. Some of the available 
systematic reviews have not specifically focused on HNC patients but rather 
considered individuals with xerostomia due to a variety of causes (Furness, 
2011). Others presented a number of methodological weaknesses (Lovelace 
et al., 2014, Jensen et al., 2010a, Mercadante et al., 2015). Overall, the 
effectiveness of available interventions in this population remains unclear, 
and it is perhaps not surprising that the majority of the HNC survivors report 
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to rely on drinking frequent sips of water (Cassolato and Turnbull, 2003) 
which does not increase salivation and is unlikely to overcome chronic 
xerostomia or prevent its complications. We have undertaken this systematic 
review and meta-analysis in order to estimate the effectiveness of available 
treatments and contribute to the development of guidelines for the 
management of radiotherapy-associated hyposalivation and xerostomia.  
2.1.2 Methods 
Study design 
We developed a protocol that defined inclusion criteria, search strategy and 
outcomes of interest. The reporting of this systematic review and meta-
analysis adheres to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement (Moher et al., 2009). 
Literature search  
For the identification of studies to be included in this review, we developed 
detailed search strategies for each database (Medline, Embase, The 
Cochrane Central Register of Controlled Trials, Cinahl, Amed). We searched 
reference lists of retrieved reports and textbooks for additional references. 
The last literature search was performed on the 19th July 2015. Citations 
were screened and full reports of potentially relevant studies obtained. Study 
inclusion criteria were (i) design: randomized controlled trials; (ii) population: 
adults with diagnosis of xerostomia (xerostomia symptoms) following head 
and neck radiotherapy; (iii) intervention: techniques designed to stimulate 
saliva production (e.g. topical and systemic sialogogues, acupuncture, laser 
therapy, and electrostimulation) or to replace saliva (e.g. saliva substitutes); 
(iv) control group: placebo, no intervention, another active intervention or a 
combination of the aforementioned options. The interventions could be given 
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by any route, formulation, or dose. Studies had to contain sufficient clear 
information on the effect of the experimental treatment on clinical outcome to 
be included. No language restrictions were imposed. 
Outcome measures and endpoints 
The primary subjective outcome measure of this review was the mean overall 
change in xerostomia symptoms, which was assessed by change in a visual 
analogue scale (VAS). Secondary objective outcomes were changes in QoL 
and salivary flow. We looked in detail at the time endpoints used for 
collection of the outcome measures; in particular we considered whether 
measurements at endpoint were taken shortly after the intervention (e.g. few 
minutes or hours) or away from treatment completion (therefore representing 
perceived symptoms and salivary flow during resting condition).  
Selection process and quality assessment  
Titles and abstracts of the references were reviewed to exclude articles out of 
scope. Full-text articles of potentially relevant records were assessed for 
eligibility by two independent reviewers (VM, AH). Any disagreements 
between reviewers were resolved by discussion until consensus was 
reached. The methodological quality assessment of the selected trials was 
performed according to the Cochrane Collaboration tool for assessing risk of 
bias, documenting the method of sequence generation, allocation 
concealment, blinding of participants, personnel and outcome assessors, 
incomplete outcome data, selective outcome reporting, and other sources of 
bias. 
Data extraction  
The following data were extracted by VM and AH: (i) study population; (ii) 
type, dosage, frequency and duration of intervention, (iii) control group; (iv) 
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xerostomia and hyposalivation outcome measures; and (v) effects on 
psychosocial outcomes (QoL).  
Meta-analysis 
We summarized the effect size for continuous data using the mean difference 
(MD) with 95% confidence intervals (95% CI). For categorical data, reported 
xerostomia relief and salivary flow changes were dichotomised into two 
categories (improvement or no improvement), and we calculated odd ratio 
(OR) of improvement, with 95% CI. A fixed effect model was used unless 
statistical heterogeneity was significant (p<0·05), after which a random effect 
model was used. Point estimates of effect were statistically significant when 
the CI did not cross 1 for OR and 0 for MD.  
Role of the funding source 
There was no dedicated funding source for this study. 
2.1.3 Included studies 
Figure 2-1 shows the process of study selection, leading to the inclusion of 
19 studies in the systematic review, with a total of 1710 patients. Ten of 19 
included studies were designed as parallel group studies whereas nine 
studies had a crossover design with washout periods of one week on 
average. Six studies were conducted in the USA, three in the United 
Kingdom, two in Canada, one in China, Germany, Hungary, Korea, 
Netherlands, Sweden, Thailand and Brazil. Sixteen trials (84%) provided 
funding information. Eight trials were funded by the pharmaceutical industry, 
four trials received government funding, and four studies received university 
funding. Trials recruited between 12 and 286 participants. The mean age of 
study participants was 58 years (SD 7), and 495 (29%) of them were women. 
Five trials provided data for systemic parasympathetic sialogogues vs. 
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placebo (two on pilocarpine and three on cevimeline), two studies focussed 
on topical pilocarpine vs. systemic pilocarpine or salivary substitutes and 
placebo, three trials studied commercially available “mouthcare systems” 
containing a combination of artificial saliva gel and/or oral rinse and/or a 
spray and/or a toothpaste, three studies focussed on saliva substitutes vs. 
other saliva substitutes or placebo, one trial investigated hyperthermic 
humidification through a nasal cannula (Vapotherm) vs. a standard 
humidifier, three trials studied acupuncture vs. sham acupuncture or 
educational oral care sessions, one trial explored acupuncture-like 
transcutaneous nerve stimulation and one low-level laser therapy. In total 
eight trials used a placebo or sham intervention as comparator whereas in 
eleven studies controls were active interventions. The duration of the 
included trials varied from two weeks to 15 months (mean 8.9). Seventeen 
studies used changes in xerostomia symptoms as an outcome. At endpoint, 
symptoms were assessed shortly after administration of the intervention in 
four studies (Cho, 2008, Blom, 1996, Chambers et al., 2007) and after 180 
minutes in one trial (Taweechaisupapong, 2006) and therefore refer to 
symptoms perceived by participants during enhancement of salivary gland 
function. Two studies collected xerostomia symptom measurements one or 
more weeks after completion of the experimental treatment (Simcock, 2013, 
Wong et al., 2015), therefore referring to symptoms perceived by patients 
during resting salivary condition. Timing of measurement collection at 
endpoint was unclear in twelve studies (LeVeque, 1993, Johnson, 1993, 
Witsell, 2012, Criswell, 2001, Epstein, 1999, Nagy, 2007, Shahdad, 2005, 
McMillan, 2006, Jellema, 2001, Momm, 2005, Davies, 1994, Saleh et al., 
2014).  
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Twelve trials used changes in salivary function as an outcome. At endpoint, 
salivary function was assessed shortly after the intervention in four studies 
(Cho, 2008, Blom, 1996, Chambers et al., 2007) after 60 minutes in two 
studies (LeVeque, 1993, Johnson, 1993) and after 180 minutes in one study 
(Taweechaisupapong, 2006) and therefore refer to enhanced salivary gland 
flow. Two studies assessed salivary flow one or more weeks after completion 
of the experimental treatment (Simcock, 2013, Wong et al., 2015) therefore 
referring to resting salivary condition, whereas the timing of salivary flow 
collection at endpoint remained unclear in three studies (Nagy, 2007, 
Epstein, 1999, Saleh et al., 2014). 
Five studies used changes in QoL scores as an outcome. Two studies 
collected QoL measures one or more weeks after completion of the 
intervention (Simcock, 2013, Wong et al., 2015) whereas timing of outcome 
collection was unclear in three studies (Saleh et al., 2014, McMillan, 2006, 
Witsell, 2012). 
Risk of bias  
We considered nine studies (47%) to have a low overall risk of bias (Figure 
2-2). Adequate sequence generation and concealment was reported in 78% 
and 68% of studies respectively, which were therefore considered to be at 
low risk of selection bias. Blinding of participants to the allocated treatment 
by use of a placebo was done in 12 of the included studies (58%) and these 
trials were assessed as low risk of performance bias. Outcome assessors 
were blinded to treatment allocation in 13 trials (68%), which were 
considered to be at low risk of detection bias. Over 80% of the included 
studies reported complete outcome data without selective reporting. 
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2.1.4 Results of the systematic review 
Systemic pilocarpine vs. placebo.  
Two placebo-controlled trials with low risk of bias investigated the 
effectiveness of systemic pilocarpine in 146 and 134 patients respectively 
(LeVeque, 1993, Johnson, 1993). With respect to primary outcome of 
xerostomia symptoms reduction, both studies showed that 12-week use of 5 
to 10mg oral pilocarpine three times a day gave rise to a reduction in 
xerostomia symptoms in significantly more patients (44% and 46%) than 
placebo (25% and 25%) (Johnson, 1993, LeVeque, 1993). Magnitude of 
improvement was unclear as both studies only reported the number of 
patients who had an arbitrary reduction of at least 25mm in the xerostomia 
visual analogue scale (“responders”) without presenting absolute figures and 
with no indication whether this could represent minimally clinical significant 
difference. Also it remains unclear whether xerostomia symptoms at endpoint 
were assessed before or shortly after administration of pilocarpine tablets, 
and therefore whether they refer to symptoms perceived by patients when 
salivary function was in resting condition or shortly after treatment (that is 
acutely enhanced salivary flow). With respect to the secondary outcome of 
increased salivation, both studies showed that the use of a single 5mg 
pilocarpine tablet was associated with a short-term 60-minute increase in 
unstimulated whole salivary flow rate in significantly more patients (69.1% 
and 68.9%) than placebo (56.3% and 42.7%) (Johnson, 1993, LeVeque, 
1993). The magnitude of improvement was however unclear as both studies 
only reported the number of patients who had any increase of salivary flow 
(“responders”). There was no information regarding the longer-term effects 
(i.e. beyond 60 minutes) of the intervention upon salivary flow rates and 
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clinical significance of the reported improvement remains unknown. Adverse 
side effects were seen more frequently in individuals using pilocarpine than in 
the placebo group and mainly consisted of sweating, urinary frequency and 
nausea. More patients in the pilocarpine group withdrew from the study 
because of adverse effects (15% vs. 10%).  
Systemic cevimeline vs. placebo.  
Two research groups assessed the effectiveness of oral cevimeline (30 mg 
three times daily) in three studies (Witsell, 2012, Chambers et al., 2007). 
Chambers et al reported two high quality clinical trials with low risk of bias, 
which enrolled 281 and 282 patients respectively and had similar design but 
different results. With respect to the primary outcome of reduction in 
xerostomia symptoms, one trial reported that 12 weeks cevimeline therapy 
was associated with an improvement in symptoms compared to pre-therapy 
in significantly more patients than placebo (48% vs. 33%; P<0.01). However, 
magnitude of improvement was unclear as the study only reported the 
number of patients who had any perceived improvement in the sensation of 
xerostomia (“better/much better”) without presenting continuous outcome 
figures. The second trial, however, showed no significant difference. Of note, 
xerostomia symptoms were measured at endpoint shortly after administration 
of one tablet of 30mg cevimeline and therefore refer to symptoms perceived 
by patients during acute enhancement of salivary flow. With respect to the 
secondary outcome of increased salivation, both studies reported that 12-
week use of cevimeline was associated with a significant, albeit small, 
increase in unstimulated whole salivary flow with respect to placebo (mean 
change from screening 0.044±0.099 mL/min and 0.052±0.161 mL/min; 
P<0.01). It is not known whether this increase in salivary flow was meaningful 
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to patients. Of note, salivary flow at endpoint was measured shortly after 
administration of one tablet of 30mg cevimeline and therefore refers to 
acutely enhanced salivary flow. Adverse side effects were seen more 
frequently in individuals using cevimeline and mainly consisted of increased 
sweating and gastrointestinal symptoms (dyspepsia). Intensity was usually 
mild-to-moderate but more patients in the cevimeline group withdrew from 
the study due to adverse effects were uncommon (~13-14% vs. 3-5%).  
A second research group assessed the effects of 30mg cevimeline three 
times a day upon QoL, observing no significant differences between 
experimental and placebo groups after 6 weeks of treatment (Witsell, 2012). 
This study was considered at unclear risk of bias.  
Systemic pilocarpine vs. “topical” pilocarpine vs. topical placebo.  
Topical administration of pilocarpine has been attempted in order to minimize 
absorption and related toxicity. Taweechaisupapong et al reported the results 
of a cross-over placebo-controlled trial, which they claim was double-blinded, 
of 33 head and neck cancer patients who were randomly assigned to receive 
every ten days one single 5mg pilocarpine tablet (to be swallowed), or one 
pilocarpine lozenge (3 mg or 5 mg dose) or one placebo lozenge both to be 
dissolved in the mouth (Taweechaisupapong, 2006). With respect to the 
subjective outcome of reduced dryness symptoms, the study reported that 
the use of one 5mg lozenge was associated with a short-term (measured at 
180 minutes) reduction in xerostomia in significantly more patients than the 
3mg lozenge, 5mg pilocarpine tablet and placebo (69.7% vs. 63.6% vs. 
12.1% vs. 42.4% respectively; P<0.05). However, the magnitude of 
improvement was unclear as the study only reported the number of patients 
who had an arbitrary reduction of at least 20mm in the xerostomia visual 
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analogue scale (“responders”). Clinical significance of the perceived 
improvement remains unknown. With respect to salivary flow, the topical use 
of one 3mg and one 5mg pilocarpine lozenge, as well as one 5mg tablet was 
associated with a significant short-term (measured within 180min) increase in 
unstimulated salivary flow compared to placebo. Again, the magnitude of 
improvement was unclear, as salivary flow rates were not reported. Of note, it 
seems that no significant difference between the use of pilocarpine lozenges 
(topical use) and tablet (systemic use) was observed. No adverse effects 
were reported. This study was considered at high risk of bias because it was 
not entirely double-blinded: investigators knew which patients were on 
pilocarpine tablets; similarly patients knew that one treatment was different 
from the other three. Also, it is rather questionable that dissolving pilocarpine 
lozenges in the mouth without spitting the content out (therefore swallowing 
the medication) really represents topical treatment with minimal/negligible 
systemic absorption.  
Saliva substitutes vs. “topical” pilocarpine.  
One cross-over randomised trial studied the effect of 3-months use of a spray 
containing mucin-based artificial saliva (Saliva Orthana) compared to a 
mouthwash containing pilocarpine (5 mg three times a day) (Davies, 1994). 
The study failed to demonstrate statistically significant difference in 
xerostomia symptom improvement between the two groups as recorded on 
visual analogue scale. This study has been classified as being at high risk of 
bias for unclear information upon blinding of study participants and 
investigators. Also, it is rather questionable that rinsing the mouth with 
pilocarpine mouthwash without spitting the content out (therefore swallowing 
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the medication) really represents topical treatment with minimal/negligible 
systemic absorption. 
Mouthcare system vs. other mouthcare system.  
Three trials evaluated the effects of commercially available “mouthcare 
systems” containing a combination of artificial saliva gel, and/or oral rinse, 
and/or spray, and/or a toothpaste (Epstein, 1999, Nagy, 2007, Shahdad, 
2005). Epstein et reported in a high-quality cross-over trial that after 2 weeks 
of treatment patients using Biotene gel and toothpaste (enzyme and 
hydroxyethylcellulose-based artificial saliva) had a significantly reduced 
xerostomia symptom on waking (VAS change) and increased stimulated 
salivary flow compared to controls using carboxymethylcellulose gel and 
commercial toothpaste, when data were analysed for carryover effect. 
However the magnitude of the effect and timing of outcome measurements 
were unclear (Epstein, 1999). Nagy et al reported another crossover trial of 4 
weeks of treatment with Biotene gel and toothpaste vs. 
carboxymethylcellulose gel and commercial toothpaste. They observed a 
significantly higher reduction in xerostomia symptoms and increase in 
unstimulated salivary flow in participants using Biotene system with respect 
to controls (mean change in VAS score of 3 for test vs. 0.7 cm for control, 
P<0.01; mean change in unstimulated salivary flow of 0.13 mL/5min for test 
vs. 0.0 in controls; P=0.6) (Nagy, 2007). The clinical meaningfulness of the 
reported changes is unknown. Of note, this study should be considered at 
high risk of bias: although study measurements refer to the post-radiotherapy 
period, the experimental intervention and placebo treatment were 
commenced during radiotherapy and therefore baseline measurements 
(week 0) do not really represent pre-study status. Shahdad et al studied the 
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effects of 2 weeks of therapy with Oral Balance or BioXtra mouthcare 
systems (gel, mouthwash and toothpaste) in a double-blind cross-over high-
quality trial (Shahdad, 2005). Oral Balance and BioXtra are both enzyme-
based salivary substitutes but the latter has higher viscosity and contains 
additional salivary peptides and immunoglobulins when compared with the 
former. Participants using BioXtra treatment achieved a greater improvement 
in xerostomia symptoms compared to those using Oral Balance mouth care 
system (mean difference in VAS score of 28.4 vs. 17.2 mm; P<0.05). Clinical 
meaningfulness of the reported effect size is unknown. This study was 
considered to be at low risk of bias.  
Salivary substitutes vs. other salivary substitutes or placebo.  
Three randomised crossover trials compared salivary substitutes vs. other 
salivary substitutes or placebo (Jellema, 2001, Momm, 2005, McMillan, 
2006). McMillan experimented a novel intra-oral device for the slow release 
of Oral Balance gel versus an oral bolus of the same gel in a randomized 
single-blind crossover clinical trial. The use of the slow-release gel device for 
4 weeks did not lead to a significantly different effect upon xerostomia 
symptoms (Xerostomia Inventory) or salivary flow with respect to the oral 
bolus of gel (McMillan, 2006). Changes in oral health-related quality of life 
scores (GOHAI) were higher in participants using the device (mean change 
was 1.38 vs. -2.1; P=0.026). Timing of outcome collection at endpoint was 
also unclear. We considered this study as being at high risk of bias because 
of its single-blind design. 
Jellema assessed the effects of 1-week use of a xanthan gum-based salivary 
substitute (Xialine) versus placebo in double blind crossover trial of 30 
participants and found no significant difference upon xerostomia symptoms 
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(xerostomia questions of QLQ-H&N35) (Jellema, 2001). Momm tested the 
effects of 1-week use of four different salivary substitutes (aloe vera gel, 
carboxymethylcellulose spray, rape oil, mucin spray) and reported a 
significant reduction in xerostomia symptoms with respect to baseline for all 
groups but not different among the 4 arms (mean xerostomia change from 
baseline 0.7-0.8 for all saliva substitutes; P<0.05) (Momm, 2005). Effect size 
was correctly reported but its clinical significance is unknown. Also timing of 
outcome collection at endpoint was unclear. We considered the studies of 
Jellema and Momm to be at high risk of bias due to the lack of information on 
blinding of participants and investigators.  
Acupuncture vs. sham acupuncture or educational oral care sessions.  
Three randomized controlled trials investigated the therapeutic efficacy of 
acupuncture in radiation-associated xerostomia (Cho, 2008, Blom, 1996, 
Simcock, 2013). 
The single-blinded study of Cho et al reported no statistically significant 
difference in salivary flow or xerostomia symptoms changes in cases (real 
acupuncture) versus controls (sham acupuncture) after 6 weeks of twice-a-
week treatment (Cho, 2008). Simcock et al studied the effects of 8 weeks of 
once a week acupuncture versus educational oral care sessions (Simcock, 
2013). They observed that those having acupuncture were more likely to 
report any improvement in xerostomia symptoms (as per QLQ-H&N35 and 
other xerostomia questions) compared to controls (OR: 2.01; P=0.03) 
(Simcock, 2013). Magnitude of the effect was unclear, as well as clinical 
significance. There was no difference in salivary flow or quality of life score 
changes between groups. Of note, endpoint assessment was performed a 
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week after the completion of treatment and therefore refers to resting salivary 
flow. Blom et al studied the effects of 12 weeks of twice-a-week acupuncture 
versus superficial acupuncture in a randomised trial where the outcome 
assessor and the participants were blinded to the treatment. No statistically 
significant difference in salivary flow rates between the two arms was 
reported. Of note, no subjective xerostomia measures were taken (Blom, 
1996). We deemed the three studies to have high risk of bias due to the 
overall poor reporting of randomisation and blinding.  
Hyperthermic, supersaturated humidification vs. standard bedside humidifier.  
One study assessed the effectiveness of a new device delivering 
hyperthermic, supersaturated humidification through a nasal cannula 
compared to a standard bedside humidifier in a randomized, controlled, 
crossover study (Criswell, 2001). The xerostomia symptom questionnaire and 
visual analogue scores showed no significant difference between the two 
devices in lessening xerostomia symptoms after 2 weeks of use. This study 
was considered at unclear risk of sequence generation, allocation 
concealment and blinding bias. 
Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) vs. 
pilocarpine.  
One multicentre unblinded study randomised 148 patients to either 12 weeks 
of acupuncture-like transcutaneous electrical nerve stimulation (twice-weekly 
for a total of 24 sessions of 20-minutes each) or pilocarpine (5mg three times 
a day) for the equivalent 12 weeks period (Wong et al., 2015). Outcomes 
were assessed at endpoint (9 months after randomisation) and revealed no 
significant difference in Xerostomia-related Quality of Life Scale score 
(XeQOLS) and salivary flow changes between groups. Of note, endpoint 
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assessment was performed several weeks after the completion of treatment 
and therefore refers to resting salivary flow. This study was considered at 
high risk of sequence generation, allocation concealment and blinding bias. 
Low-level laser therapy vs. sham low-level laser therapy.  
One randomised trial tested the effectiveness of low-level laser therapy in 
improving xerostomia symptoms (assessed through VAS), salivary flow and 
quality of life (assessed through the Oral Health Impact Profile questionnaire) 
in 23 patients (Saleh et al., 2014). The test group underwent two weekly 
sessions of low-level laser therapy for 6 weeks whereas the control group 
underwent the same number of sessions but a plastic tip blocked the 
emission of radiation. Endpoint assessments failed to show any significant 
difference between the groups with regards to long-term changes in 
xerostomia VAS, salivary flow rates or QoL scores from baseline. Of note, 
measurements at endpoints were taken shortly after the administration of the 
intervention and therefore refer to flow rate and symptoms perceived during 
enhancement of salivary function. Additionally it is unclear whether at least 
the patients or the outcome assessor were blinded to the intervention. This 
study was considered at unclear risk of sequence generation, allocation 
concealment and blinding bias.  
2.1.5 Results of the meta-analysis 
Four trials provided sufficient data to evaluate the primary outcome of the 
mean overall change in subjective xerostomia symptoms. Six studies allowed 
statistical analysis of the objective assessment of changes in salivary flow 
rate. It was not possible to analyse the QoL outcomes due to the lack of 
homogeneity between study measures. In relation to the primary outcome of 
reduction in xerostomia symptoms two comparisons were sufficiently 
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clinically homogenous to perform statistical pooling: systemic pilocarpine vs. 
placebo and systemic cevimeline vs. placebo (Figure 2-3). Two studies, with 
a total of 280 participants showed that the patients using pilocarpine for 12 
weeks were more likely to have a 25mm or higher reduction in xerostomia 
VAS score compared to placebo (OR of 2.37, 95% CI 1.43-3.94). Two 
homogeneous studies with a pooled total of 563 participants showed that the 
patients using cevimeline for 12 weeks were more likely to report an 
improvement (better/much better) in the sensation of xerostomia compared to 
placebo (OR 1.37, 95% CI 0.98-1.91).  
In relation to the secondary outcome we were able to compare the effect of 
acupuncture vs. sham/superficial acupuncture, cevimeline vs. placebo, and 
pilocarpine vs. placebo on unstimulated salivary flow rates (Figure 2-4 and 2-
5). Two studies of acupuncture (6 and 12 weeks) versus sham/superficial 
acupuncture with a pooled total of 50 participants showed no increase (MD 
0.00; 95% CI -0.02-0.03) in unstimulated salivary flow rate on continuous 
outcome measures. Pooled analysis of two RCTs of cevimeline versus 
placebo (total number of patients = 563) showed a small (MD 0.04, 95% CI 
0.02-0.06) increase in unstimulated saliva flow rate in participants using 
cevimeline for 12 weeks with respect to controls. Two RCTs (total number of 
patients = 280) showed that the use of one tablet of pilocarpine is more likely 
to be associated with a short-term increase (60 minutes) in unstimulated 
salivary flow rate compared to one tablet of placebo (OR 2.27; 95% CI 1.37-
3.76).  
  84 
2.1.6 Discussion  
No clear evidence-based guidance for clinicians is currently available to 
inform the management of radiotherapy-associated hyposalivation and 
xerostomia in HNC survivors. Available systematic reviews and meta-
analyses on xerostomia management have not specifically focused on post-
radiotherapy HNC setting (Furness, 2011) or present a number of 
methodological weaknesses (Lovelace et al., 2014, Jensen et al., 2010a). We 
have previously commented (Mercadante et al., 2015) on the questionable 
validity of the systematic review and meta-analysis of Lovelace et al, and the 
systematic review from Jensen et al also seem to have similar weaknesses 
such as the inclusion of non-randomised studies and linguistic constraints 
(Gregoire et al., 1995, Higgins et al., 2013). We have therefore undertaken 
this systematic review and meta-analysis in order to overcome limitations of 
previous studies and estimate the effectiveness of available treatments, so to 
contribute to develop evidence-based practice guidelines for the 
management of radiotherapy-associated hyposalivation and xerostomia in 
HNC survivors. Of note, we looked at a number of details of published trials 
that were not highlighted in previous reviews but we believe are important for 
the interpretation of the efficacy of interventions and therefore for clinical 
decisions upon patient management. These include the type of outcomes 
(xerostomia symptoms, salivary function, quality of life) and the timing of 
collecting outcome measurements at endpoint (shortly after administration of 
the intervention or away from treatment completion).  
We identified 19 RCTs with a total of 1710 randomized patients, which 
qualified for inclusion. Meta-analyses were only possible for three of the 
interventions included in the systematic reviews because of the limited 
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number of studies and their heterogeneous designs including major 
differences in the comparator and outcome measures. Where data polling 
was possible, results of this review suggest that long-term use of systemic 
pilocarpine or cevimeline has a positive effect in reducing xerostomia 
sensation in HNC survivors after radiotherapy, with likelihood of improvement 
being higher for pilocarpine. However the effect size of such reduction was 
unclear for pilocarpine (at least 25mm on 0-100mm VAS) and not reported 
for cevimeline. It remains unknown whether a VAS change of at least 25mm 
is clinically relevant in this patient population, whereas the improvement in 
symptoms obtained with cevimeline do seem clinically meaningful (as 
patients reported to feel better/much better). Further, this positive effect 
seems to be limited to symptoms perceived shortly after the administration of 
the intervention, whilst no information is available with respect to xerostomia 
symptoms perceived under resting salivary conditions.  
Pilocarpine and cevimeline also seem effective in increasing salivary flow. 
Our meta-analysis shows that long-term use of cevimeline can induce an 
increase in unstimulated salivation, though the relevant effect size seems 
small (MD of 0.04 mL/min). However patients reported to feel better/much 
better and therefore a MD of 0.04mL/min can be considered clinical 
meaningful. With respect to pilocarpine, available data only provide evidence 
of an increase in salivation after short-term use (one single tablet with 
salivary flow measured after 60 minutes), whereas the effect size, clinical 
significance, as well as the effects of long-term use are unknown. Again no 
information is available with respect to salivary gland function under resting 
conditions. With respect to acupuncture, data from our meta-analysis show 
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no evidence of increased salivary flow and unknown effect upon xerostomia 
symptoms due to lack of data.  
There are practical implications of these results: clinicians managing HNC 
survivors with post-radiotherapy hyposalivation and xerostomia symptoms 
should consider prescribing long-term cevimeline therapy and expect that it 
will provide some reduction in xerostomia symptoms and a small increase in 
salivary flow which can be clinically meaningful, although likely to be short-
lived. Similarly they should expect a reduction in xerostomia symptoms with 
long-term pilocarpine use, as well an increase in salivary flow after one tablet 
of pilocarpine, although these improvements are likely to have a short 
duration, unclear effect size, and unknown clinical significance. The toxicity of 
pilocarpine and cevimeline seems similar, possibly with a tendency for 
cevimeline to be better tolerated, although evidence is not robust as no direct 
comparison is available.  
With respect to acupuncture, it seems difficult to support the clinical decisions 
of recommending this treatment modality to HNC survivors with radiotherapy-
associated xerostomia as our meta-analysis suggests that it does not 
increase salivary flow in HNC cancer survivors after radiotherapy. It was not 
possible to merge data upon changes in xerostomia symptoms.  
With regard to interventions not included in the meta-analysis, our systematic 
review of single studies suggests that there is no evidence, or very weak 
evidence, that “topical” pilocarpine, hyperthermic supersaturated 
humidification, acupuncture, ALTENS or lower-laser therapy can reduce 
xerostomia symptoms, increase salivary flow, or improve QoL in this patient 
population.  
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Salivary substitutes (gel and spray) and mouth care products (toothpaste and 
mouthwash) are widely used in the management of xerostomia (Jensen et 
al., 2010a) and accordingly our systematic review included six studies 
comparing the effects of salivary substitutes/mouth care products against 
other salivary substitutes/mouth care products or placebo. There was high 
heterogeneity among studies and therefore no data pooling was possible. 
Systematic review of single studies shows that there is no study but one 
comparing the effects of salivary substitutes vs. placebo. There is some weak 
evidence from 2 small studies, of which one is at high risk of bias, that 
enzyme-enriched mouth care products (gel and toothpaste) are superior to 
traditional carboxymethyl-cellulose gel and commercial toothpaste at 
reducing xerostomia symptoms and increase salivation. The effect size, 
where reported, seems to be moderate (23mm 0-100mm VAS) with unknown 
clinical significance. There is also some weak evidence from one small trial 
that among enzyme-enriched mouth care products, the more viscous one 
(BioXtra) can lessen xerostomia symptoms more than less viscous products 
(Oral Balance); however relevant effect size seems small (11.2mm difference 
on 0-100mmVAS) and clinical significance is unknown. With respect to the 
other 3 trials on salivary substitutes, there remains very weak evidence 
regarding the beneficial effects of an intra-oral device releasing Oral Balance 
gel, xanthan gum-based salivary substitutes, aloe vera gel, rape oil, or mucin 
spray upon xerostomia symptoms, salivary flow or QoL. 
There present study has a number of limitations. The studies included in this 
review were conducted between 1993 and 2015. During this time the patient 
population has changed, and radiotherapy modalities have also changed. 
Although we could not attempt a separate analysis of patients who 
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underwent IMRT because of the lack of data in the literature, undoubtedly 
participants of the recent studies received lower radiation dosage with 
respect to those participating in studies two decades ago. The number of 
available treatment arms was also too low to estimate the impact of 
confounders. Also only summary data rather than patient level data were 
available. Finally, meta-analysis results on cevimeline should be read with 
caution as we detected moderate heterogeneity between the studies in the 
assessment of the mean difference in xerostomia. The two studies were 
conducted by the same research group so the heterogeneity is likely not due 
to variations in doses and application procedures, but rather to the baseline 
characteristics of the patients.  
2.1.7 Conclusions 
Pilocarpine and cevimeline should represent the first line of therapy in HNC 
survivors with radiotherapy-associated xerostomia and hyposalivation. There 
is very weak evidence that salivary substitutes can provide some, if any, 
benefit of small magnitude and unclear clinical significance. The use of other 
treatment modalities cannot be supported on the basis of current evidence.  
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database searching 
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Studies included in 
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Figure 2-1 Flow Chart Systematic Review Strategy Search 
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Figure 2-2 Risk of bias summary 
 
Figure 2-3 Forest Plot Primary Outcome: Xerostomia symptoms reduction 
from RCT (categorical data) 
 
Figure 2-4 Forest Plot Secondary Outcome: Standardised mean difference in 
salivary flow rate 
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Figure 2-5 Forest Plot Secondary Outcome: Unstimulated salivary flow rate 
(categorical data)  
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2.2 Future Treatment for radiotherapy-associated xerostomia 
2.2.1 Gene transfer 
The term ‘gene transfer’ refers to the delivery of a gene to a predetermined 
target cell. Gene therapy can be applied to irradiated salivary glands to 
increase salivary secretion by enhancing the water permeability of duct cells 
thus creating an osmotic gradient. Transfer of genes into cells can be 
accomplished using viral and non-viral vectors (Samuni and Baum, 2011).  
The delivery of DNA via non-viral vectors, which would reduce the safety risk, 
have scarcely been employed in the oral cavity, although current research is 
now directed toward a nanoparticle delivery (Arany et al., 2013).  
Conversely, adenoviral-mediated aquaporin-1 cDNA (AdhAQP1) transfer has 
been studied and the results of the first open-label clinical trials were 
published in 2012. In this study the viral vector (AdhAQP1 vector) was 
administered to a single previously irradiated parotid gland in 11 subjects. 
The initial report showed that this approach is feasible and safe. A subset of 
patients (6 out of 11) showed enhanced parotid flow rates and reduction in 
xerostomia symptoms (Baum et al., 2012).  
Currently, the same research group is planning to conduct a clinical trial 
using a less immunogenic vector derived from serotype 2 adeno-associated 
viral (AAV2), instead of the serotype 5 adenoviral vector used in the Phase 
I/Phase II study (Ad5) (Baum, 2014). 
2.2.2 Stem cell therapy 
A promising therapeutic approach for the management of radiotherapy-
associated xerostomia is the stem cell therapy.  
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Theoretically, stem/progenitor cells could be harvested from salivary glands 
before radiotherapy in order to be implanted into the less damaged ductal 
complex, upon treatment completion (Vissink et al., 2015). Preclinical studies 
have shown that stem/progenitor cell transplantation can restore murine 
submandibular glands function (Lombaert et al., 2008). 
2.2.3 Electrostimulation of salivary glands 
The therapeutic potential of neurostimulation has been recognized in many 
areas of modern medicine, including the treatment of pain, deafness and 
cardiac arrhythmia.  
The consideration that salivary gland function is controlled by the autonomic 
nervous system, has led to the application of neurostimulation in the 
management of salivary gland hypofunction and xerostomia.  
Different strategies have been tested during the last three decades with 
variable outcomes. A comprehensive review of the literature on the topic is 
presented in the next section (2.3). 
2.3 Electrostimulation of the salivary glands 
2.3.1 Electrostimulation of salivary glands: rationale and 
mechanisms 
Saliva secretion is controlled by dual innervation from the autonomic nervous 
system (Proctor and Carpenter, 2007). A reflex arch, comprised of three 
components, regulates saliva secretion: afferent nerves, central salivary 
nuclei, and efferent nerves.  
Peripheral stimuli (associated by mastication, taste, smell and sight) are 
transmitted by the afferent nerve pathways from oral cavity and converge to 
the salivary nuclei in the medulla oblongata. The nuclei active an efferent 
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pathway, mediated by the parasympathetic and sympathetic components of 
the autonomic nervous system, which innervates the blood vessels and the 
acini of the glands and stimulates saliva production and excretion (Proctor 
and Carpenter, 2007). Parasympathetic and sympathetic nerves act 
separately but in coordination with each other. Parasympathetic system, 
inducing contraction of myoepithelial cells, evokes most of the salivary fluid 
secreted and it is responsible for the watery and electrolyte components of 
salivary secretion. It also causes vasodilatation, increasing glandular blood 
flow as part of the salivary reflex. The sympathetic stimulation causes 
vasoconstriction and produce a concentrated and viscous saliva rich in 
proteins (Garrett et al., 1991).  
The therapeutic potential of electro-stimulating devices has been explored 
and recognised in many areas of modern medicine. Electro-stimulating 
devices are being used in the treatment of pain, deafness, bladder 
dysfunction, cardiac arrhythmia, muscular weakness, problems of the 
respiratory system and bone healing (Lafaurie et al., 2009). 
Given the autonomic control of salivary secretion, a similar principle can be 
used in the management of salivary gland hypofunction. It is hypothesized 
that the application of electrical impulses on one of the components of the 
salivary reflex could improve salivary secretion and xerostomia symptoms.  
Animal experiments have showed that the application of an electrical current 
through the oral mucosa on afferent receptors can enhance salivary 
production (Izumi and Karita, 1995, Kyriacou et al., 1988).   
As the effects of electrostimulation were reported to sustain for as long as 6 
months beyond cessation of therapy, it has been suggested that the 
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stimulation of the autonomic nervous system may cause the release of 
specific neuropeptides with trophic effects to salivary gland parenchyma, 
leading to regeneration of functional tissue. Animal studies have indeed 
demonstrated a mitogenic response in rat parotid and submandibular glands 
following electrical stimulation of their parasympathetic nerves (Mansson et 
al., 1990, Ekström and Reinhold, 2001, Calafat et al., 2009, Konttinen et al., 
2011).  
2.3.2 First generation of salivary electrostimulating device 
The first generation of salivary electrostimulating device is represented by the 
Salitron (Biosonics, Fort Washington, Pa, USA) (Figure 8-1). The 
electrostimulating system consisted of an electronic control module and a 
hand-held stimulus probe with two stainless steel electrodes. The electrodes 
were positioned between the tongue and the palate of the mouth for a few 
minutes in order to stimulate gustatory (IV cranial nerve), and tactile 
receptors (V cranial nerve), afferent pathways of the salivary reflex. In 1986 
Weiss et al tested the first generation device in a group of patients with 
xerostomia due to different causes, including radiotherapy to the head and 
neck (Weiss Jr et al., 1986). This open-label uncontrolled study showed an 
improvement in oral wetness, measured by visual inspection, in 50% of 
patients. Looking in a more detail at the subgroup of individuals with 
radiation-associated xerostomia, the improvement was sustained for 11 out 
of 13, with all the patients reporting a subjective reduction in xerostomia 
symptoms as response to the stimulation.  
A more robust study methodology and reliable outcome measures were 
employed by Steller and collaborators, who designed a placebo-controlled 
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clinical trial and assessed device efficacy through sialometry (Steller et al., 
1988). Five out of thirteen Sjögren’s syndrome patients showed a reduction 
in xerostomia symptoms, which however was objectively demonstrated only 
in three.  
The same device was studied by Talal et al in a multicentre, double blind 
study which included 77 Sjögren’s patients (Talal et al., 1992). The 
electrostimulation group showed a difference of 116% greater than the 
placebo group between the pre and post-stimulation salivary production.  
Given the promising results of these initial studies, the device was approved 
by the US Food and Drug Administration in 1998. However cost and bulky 
dimension have limited its wider diffusion within the medical community. 
2.3.3 Second generation of salivary electrostimulating device 
To overcome the limitations of the first-generation device, a EU-funded 
Consortium developed and tested a novel second-generation 
electrostimulating device, Saliwell GenNarino (Figure 8-2, 8-3,8-4). The novel 
device is a removable intraoral thermoplastic polyurethane-made appliance 
similar to mouth-guards (splints) used by individuals with temporomandibular 
disorder. It is custom made on the individual patient by using their teeth 
pattern moulds and its size is much smaller than the Salitron.  
The electrical circuit and the battery have been miniaturized and are now 
embedded within the device, to avoid saliva contamination. Two electrodes 
protrude through the appliance to deliver the electric impulses to the 
trigeminal and lingual nerves via the oral mucosa. The device is suggested to 
stimulate the afferent and efferent neural pathways controlling 
submandibular, sublingual and parotid gland, as well as minor salivary 
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glands. An external remote control regulates device function, by means of 
infrared light transmission at a wavelength of 940nm-950nm (Fedele et al., 
2010).  
The efficacy of the novel device was initially tested in a small feasibility study 
on 23 patients with xerostomia associated with Sjogren’s syndrome, 
medications, and of idiopathic nature. This was a double-blind crossover, 
sham-controlled multicentre trial aimed at investigating safety and short-term 
effectiveness of the device (Strietzel et al., 2007). The investigated device 
was equipped with a wetness sensor, embedded within the appliance, to 
record real-time changes of wetness during stimulation. The experiment 
consisted of one active stimulation test and one sham test for 10 minutes 
each, in a random order, followed by 10-minutes measurement period. After 
the performance of 158 experiments, a significant reduction of the oral 
dryness for the active mode was objectively registered by the wetness 
sensor, as well as subjectively by patients’ judgement. The device was well 
tolerated by all participants and did not give rise to adverse side effects. The 
second-generation device was granted CE mark on the basis of the results of 
this initial pilot study. 
 A larger multicentre longer-term clinical trial was performed in 2011. Strietzel 
and al designed a randomised, multicentre crossover sham-controlled 
double-blind trial with primary endpoint being defined as a subjective 
improvement in the severity of xerostomia, assessed by visual analogue 
scale (Strietzel et al., 2011). Unstimulated and stimulated salivary flow rates 
were the second outcome measures of this study, assessed though 
sialometry. The randomised controlled trial had a 2-month duration and was 
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followed by a subsequent uncontrolled phase aimed at investigating long-
term effectiveness. In the initial randomised double-blind phase, the 
electrostimulating device was used for 10 minutes at a time, each for 1 
month, in either sham mode or active mode. The analyses on 114 patients 
completing the randomised controlled phase showed a better performance in 
terms of dryness severity (subjective symptoms) for the active intervention 
than for the sham experiments. No statistical difference, however, was found 
with respect to unstimulated and stimulated flow rates and oral discomfort. 
The subsequent second open-label phase consisted of a 3-month 
investigation of active devices in a subset of patients (n=79). Approximately 
70% of treated individuals reported improvement in dryness severity and 
63% of them showed increased unstimulated salivary flow rates at the end of 
3-month treatment period. No changes were detected regarding stimulated 
salivary flow and quality of life scores. 
Alajbeg at el reported the outcomes of extended long-term follow up (after 11 
month of device usage) confirming the previous positive outcomes (Alajbeg 
et al., 2012). In 2014 a case series has been published reporting on six 
patients with chronic-versus-host disease (cGVHD) treated for 4 weeks with 
an intra-oral electrostimulator device and then randomly crossovered to a 
sham-device or vice versa, with patients and clinicians blinded to the 
intervention. The device proved to be safe in this cohort of patient, although 
two patients did develop mild mucosal lesions in areas in contact with the 
study device. Unstimulated and stimulated salivary flow and subjective 
sensation of xerostomia improved in 4 out of the 5 patients included after the 
two interventions. The limited number of participants did not allow any 
inferential statistics (Zadik et al., 2014). 
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2.3.4 Third generation electrostimulating device 
In addition to the intra-oral removable appliance (second generation device), 
the EC-founded Consortium also developed a miniaturised device having the 
dimension and shape of a molar tooth and designated to be applied onto an 
osteointegrated implant (the Saliwell Crown) (Figure 8-5). 
It was suggested that the use of a fixed device mounted on an 
osteointegrated dental implant would overcome the need of repeated 
application associated with the removable second-generation device, 
allowing constant stimulation of salivary glands without interfering with 
regular oral function. The implantable device is also equipped with an 
embedded wetness sensor in order to release electrical stimuli according the 
degree of oral dryness/wetness. A remote control would allow patients’ 
control of electronic stimuli. The device is designed to be implanted in the 
lower third molar region, in close proximity to the lingual nerve and in order to 
avoid negative cosmetic impact.  
In a clinical case report Ami et al investigated the effectiveness of the 
implanted device in a 81-years old female patient with xerostomia not 
responding to topical treatment and unable to take pilocarpine because of the 
presence of contraindications to pharmacological cholinergic stimulation (Ami 
and Wolff, 2010). The authors reported a notable objective improvement of 
salivary flow, speech, swallowing and subjective improvement of oral dryness 
symptoms.  
2.3.5 Extra-oral electrostimulating device 
The ability of extra-oral transcutaneous electric nerve stimulation to stimulate 
salivary glands, increase salivary secretion and lessen xerostomia symptoms 
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has been investigated using transcutaneous electrical nerve stimulation (high 
frequency, low intensity stimulation) and acupuncture-like transcutaneous 
electrical nerve stimulation (low frequency, high intensity stimulation).  
The mechanism of action of extra-oral neurostimulation is not fully 
understood. It has been postulated that transcutaneous electric nerve 
stimulation (TENS) could directly stimulate the auriculotemporal nerve, which 
supplies the parotid gland, whereas it remains unclear whether there is also 
an indirect action (via afferent pathways) onto the salivary reflex arch. 
Hargitai in 2005 conducted a pilot study to assess the effectiveness of a 
TENS unit to stimulate parotid salivary flow in 22 healthy participants 
(Hargitai et al., 2005). The TENS unit used in this study was an AdvanTew 
2000 (Amrex-Zetron, Carson, Calif), with the electrode pads placed on the 
skin overlying the parotid glands. Fifteen of the 22 adults showed an increase 
in the parotid flow rate, assessed through a 5- minutes collection of parotid 
saliva with Carlson-Crittended cup before and after stimulation. Three 
patients experienced fasciculation and anaesthesia of the area of pad 
application, which ceased with the cessation of TENS application.  
A recent prospective phase II study evaluated the effectiveness of TENS 
technique in 30 patients with radiation-induced xerostomia, showing that in all 
patients but one an increased salivary flow after stimulation (Vijayan et al., 
2014). 
Acupuncture-like TENS (ALTENS) has been tested in a phase 2 study 
recently conducted by Wong in patients with radiation-associated xerostomia 
(Wong et al., 2012) and the results of this study have been described 
previously in the systematic review.  
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3 Knowledge gap  
The use of intra-oral second-generation device may represent an ideal 
therapeutic strategy for individuals with RT-associated xerostomia. The 
device sits comfortably in the patient’s mouth and can be easily applied and 
removed; it stimulates natural salivation with no notable adverse side effects. 
The potential trophic effects on glandular parenchyma have been described 
(Schneyer et al., 1993). 
The evidence supporting its efficacy is however limited. Available studies 
have included very few participants with RT-associated xerostomia. More 
importantly, the design and overall quality of published clinical trials is 
debatable.  
As a consequence it remains unclear whether the second-generation 
intraoral electrostimulating device is indeed effective in providing (i) long-term 
reduction in xerostomia symptoms and (ii) increase of salivary flow. It is also 
unknown whether it could lead to a significant improvement in quality of life.  
Finally, the magnitude of any potential benefit is also unclear. 
This PhD thesis describes the aims, design and results of a multicentre 
clinical investigation on the second-generation intraoral electrostimulating 
device in individuals with RT-associated xerostomia, the LEONIDAS-2 
clinical trial. 
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4 The LEONIDAS-2 Clinical Trial 
4.1 Aims 
LEONIDAS-2 (Long-term Evaluation of the effectiveness Of a Novel Intra-
oral electro-stimulator for the treatment of raDiotherapy-ASsociated 
xerostomia) is a study funded by the National Institute of Health and 
Research (NIHR) (ISRCTN: 24437812) aimed at testing the hypothesis that 
long-term application of the second generation electrostimulating device in 
patients with radiation-associated xerostomia will (i) reduce xerostomia 
symptoms, (ii) improve salivary function, and (iii) improve quality of life. 
4.2 Methods 
4.2.1 Trial design 
LEONIDAS-2 is a double blind multicentre controlled randomised trial of 12-
months therapy, during which patients have been randomly assigned to 
treatment with a fully functioning electrostimulating device or a sham device 
(releasing mechanical but not electrical stimulation). 
4.2.2 Participants 
Patients with radiotherapy-induced xerostomia attending the UCLH Oral 
Medicine Unit, the H&N Cancer Centre of UCL/UCLH, the Maxillofacial/H&N 
Surgery Unit at Bradford Royal Infirmary, the Head and Neck Unit of the 
Royal Marsden have been considered for recruitment.  
The study has taken place at the Eastman Clinical Investigation Centre of 
Eastman Dental Institute and Hospital (University College London and 
University College London Hospitals Trust) and Bradford Royal Infirmary. 
Participants have been recruited on the basis of inclusion and exclusion 
criteria presented in Table 4-1.  
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Table 4-1 LEONIDAS-2 Inclusion and Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
(i) Be at least 18 years old (i) Severe systemic disease (on the basis of 
the classification of the American Society of 
Anaesthesiology: ASA III and ASA IV) (Table 
4-3) 
(ii) Have received more than 40 Gy of 
external beam RT for cancer in the H&N 
region at least 4 months before entry into the 
study 
(ii) Known allergy to materials similar to 
those used in the investigational product 
(iii) Have grade 1 or 2 of RTOG/EORTC Late 
Radiation Morbidity Scoring Schema (Table 
4-2) 
(iii) Wearing of other active implants such as 
cardiac pacemaker or defibrillator, or hearing 
aids 
(iv) Have a degree of minimum degree of 
dryness of 50mm (≥50mm) on a 100mm 
VAS scale (0=no dryness; 100 =maximum 
dryness). 
(iv) An unstimulated whole salivary flow of 
0ml/5min (complete absence of unstimulated 
salivary flow as measured via sialometry for 
5 minutes). 
(v) Have demonstrable residual salivary 
gland function (increase in salivary flow on 
appropriate stimulation (e.g. chewing 
paraffin wax) 
(v) Use of pilocarpine as systemic therapy 
(vi) Have at least one parotid gland (vi) Grade 3 RTOG/EORTC or no resting 
saliva (sialometry = 0mL/1.5 min) 
Table 4-2 RTOG/EORTC Late Radiation Morbidity Scoring Schema (salivary 
glands) 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
None Slight Dryness Of 
Mouth 
Good Response On 
Stimulation 
Moderate 
Dryness Of Mouth 
Poor Response 
On Stimulation 
Complete 
Dryness Of 
Mouth 
No Response 
On Stimulation 
Fibrosis Death  
 
Table 4-3 American Society of Anaesthesiology (ASA) Physical Status 
Class 1 Class 2 Class 3 Class 4 Class 5 Class 6 
A normal 
healthy 
patient 
A patient with 
mild systemic 
disease 
A patient with 
severe 
systemic 
disease 
A patient with 
severe systemic 
disease that is 
a constant 
threat to life 
A moribund patient 
who is not expected 
to survive without the 
operation 
A declared brain-
dead patient 
whose organs 
are being 
removed for 
donor purposes. 
 
4.2.3 Primary and secondary outcomes 
The primary outcome of the study was defined as the proportion of 
participants reporting a 30% reduction of xerostomia symptoms after 12 
months of treatment, as evaluated through a 100mm VAS 
(100mm=maximum dryness) based on changes between measurements 
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recorded at admission (baseline, month 0) and the end of the trial (after 
treatment, end of month 12). 
Secondary outcomes included:  
• Xerostomia symptom VAS scores [end of month 12 and repeated 
measurements up to 12 months] 
• Salivary flow rate [end of month 12 and repeated measurements up to 12 
months] 
• EORTC QLQ-H&N35 (Head and Neck cancer QoL) questionnaire [end of 
month 12 and repeated measurements up to 12 months] 
• Oral health-related quality-of-life measure (OH-QoL16) questionnaire [end 
of month 12 and repeated measurements up to 12 months]   
• Short Form-36 (SF-36) questionnaires (QoL) [end of month 12 and 
repeated measurements up to 12 months] 
• Frequency of usage of the device (from a daily diary of device usage)  
Patient data were collected at screening and baseline (visit 2, delivery of the 
individualised device) and at follow-up appointments at the end of months 1, 
2, 4, 6, 8 and 12 after the start of treatment.  
A clinical trial of 12 months has been designed in order to provide new data 
on the effectiveness and safety of this treatment over the long-term, as 
previous clinical trials have investigated the effectiveness and safety of a 9-
month intervention. 
4.2.4 Outcome measures 
Patient-centred outcome measure  
The 100-mm long Visual Analogue Scale, previously described, has been 
chosen as the primary outcome measure in LEONIDAS-2 because it is a 
patient-centred outcome and the most frequently used self-rating instruments 
for the measurement of xerostomia.  
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There are no studies determining the levels of change on standard 
xerostomia scales that represent clinically important differences to patients.  
The cut-off of 30% has been chosen in this study because of the observed 
minimum clinically significant improvement in pain studies (33%) (Farrar et 
al., 2000), and in order to promote homogeneity across studies on 
xerostomia who used the same outcome measure (Brown et al., 2014, 
Mariette et al., 2015). A critical analysis of the literature performed during the 
study to estimate the magnitude of change of the visual analogue scale in 
head and neck settings, has showed that the magnitude of VAS change 
(effect size) following the intervention could be more informative for decision-
makers than the dichotomous presentation. We have therefore added the 
analysis of xerostomia symptom though continuous VAS scores as 
secondary outcome measure. 
Clinician-rated outcome measure  
Sialometry has been discussed in the section: “Diagnosis and Assessment of 
radiotherapy-associated xerostomia”. 
Quality of Life assessment 
EORTC QLQ-H&N35 
The European Organisation for Research and Treatment of Cancer (EORTC) 
Quality of Life Study Group has developed a measurement strategy for the 
assessment of quality of life (QOL) in clinical trials (Bjordal et al., 1994a, 
Bjordal et al., 2000). The QLQ-H&N35 includes 35 items, 7 multi-item scales, 
measuring pain in the mouth, problems with swallowing, senses, speech, 
social eating and social contact, and 11 single-item scales, assessing 
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problems with teeth, mouth opening, xerostomia, sticky saliva, coughing, 
feeling ill, as well as use of analgesics, nutritional supplements, feeding tube, 
weight gain and weight loss. The time frame of the module is ‘‘during the past 
week,’’ and items are scored either on four-point Likert-type categorical 
scales (‘‘not at all,’’ ‘‘a little,’’ ‘‘quite a bit,’’ ‘‘very much’’) or have a ‘‘no/yes’’ 
response format. The scores are transformed into 0-to-100 scales, with a 
high score implying a high level of symptoms or problems. The module has 
been translated into 60 languages and is in use worldwide as one of the 
standard instruments for measuring quality of life in head and neck cancer 
patients. The reliability coefficients for most of the QLQ-H&N35 scales 
ranged from 0.61 to 0.93, indicating satisfactory internal consistency (Singer 
et al., 2013). 
The EORTC QLQ- H&N35 module has been chosen for this study because it 
is the most common tool to gather QoL data used in RCTs, and it proved to 
be well accepted by patients, with completeness of the questionnaire varying 
from 66 % to 99 % (Singer et al., 2013).  
OH-QoL16 
The impact of oral health on participant’s quality of life has been assessed 
using the UK Oral Health-related quality-of-life measure (OHQoL-UK), which 
consists of 16 key questions on key areas of oral health related quality of life. 
Participants were asked to rate the impact of gums, mouth, and/or denture on 
their overall quality of life. The overall score scores ranging from 16 (all bad 
effects of extreme impact) to 144 (all good effects of extreme impact). This 
instrument was chosen for the good psychometric properties showed in the 
validation study (McGrath and Bedi, 2001).  
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Short Form-36 (SF-36) questionnaires 
The SF-36 questionnaire has been selected because it is a valid and reliable 
instrument to assess general health and the most widely used QoL 
instruments in clinical trials to measure physical and mental health. Its 
measures eight domains: physical and social functioning, role limitations due 
to physical health or emotional problems, fatigue, emotional well-being, pain 
and general health. A single item is also included to assess the perceived 
change in health over time (Ware, 2000). Each scale is directly transformed 
into a 0-100 scale, with an overall scores ranging from 0 (worst possible level 
of functioning) to 100 (best possible level of functioning).  
4.2.5 Intervention 
The device tested in this clinical trial is the second-generation of intra-oral 
removable devices named Saliwell GenNarino, consisting of a mouthpiece 
made to fit the mandibular dental arch and an infrared remote control to 
activate or deactivate the electrical stimulation. The device contains an 
electronic circuit with a microprocessor and a receiver of remote control 
signals, a pair of stimulating electrodes, and a 30-mA/h battery. The 
electrodes contact the oral mucosa in the mandibular third molar area, close 
to the lingual nerve; therefore no conductive gel is needed. A green light on 
the intra-oral device (either active or sham) blinks upon activation of the 
remote control to show that the device received the signal from the remote.  
The electrostimulating devices have been manufactured for each participant 
using impressions taken from the dental arches (Manufacturer: Saliwell Ltd, 
Israel). Participants have been randomly assigned to:  
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- Group A (cases): patients who receive a fully functioning electrostimulating 
device. 
- Group B (controls): patients who receive a device that does not release 
electric stimuli (but provides mechanical/tactile stimulation). 
4.2.6 Experimental Procedure 
The general structure of experimental procedures consists of: 
A: Screening/Enrolment 
B: Dental Impression  
C: Delivery of individualised device 
D: Follow-up appointments 
(A) SCREENING/ENROLMENT 
Potential participants identified during routine clinical sessions have been 
invited to attend an initial screening appointment. A careful assessment of 
the general health status, comprising of medical history and details of 
previous head and neck cancer treatment has been performed. 
A dedicated anonymized Case Report Form has been used to gather clinical 
data. The forms have been stored at the UCL Eastman Dental Institute (EDI), 
London, and Bradford Royal Infirmary in locked facilities.  
Data were collected for all screened patients to assess eligibility before 
offering randomisation. Information collected included patient date of birth, 
gender, ethnic group, pulse, blood pressure, smoking and drinking habits, 
site and stage of primary tumour, details of treatment for head and neck 
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cancer. The medical history included xerostomic medical condition and 
medication. 
As the device is designed to stimulate the salivary glands, only patients 
demonstrating residual salivary gland function were included. For this 
purpose, unstimulated whole saliva (UWS) and paraffin chewing-stimulated 
whole saliva (SWS) were collected during the screening visit. All subjects 
were instructed to refrain from smoking, eating, drinking or tooth brushing at 
least 90 minutes prior to saliva collection. UWS was collected for 5 min using 
an established spitting technique. The collection time (5 minutes) was chosen 
because it is the commonly used interval, being reliable, practical for the 
clinician, and more comfortable for the patient (Villa et al., 2014). During the 
stimulated whole saliva collection, the subjects chewed a piece of tasteless 
parafilm (5 × 5cm, 0.30g; Parafilm, Fisher Scientific, UK) at their natural 
pace. Saliva volumes were determined gravimetrically (assuming 1g = 1mL), 
using pre-weighted tubes (Sterilin, UK, catalogue n.185CM) and a precision 
balance (Scout Pro SPU123, Ohaus, NJ), with saliva flow rates expressed in 
millilitres per minute (mL/min).  
All assessments have been performed preferentially at a fixed time of the day 
to minimise fluctuations related to the circadian rhythm of salivary secretion.  
The grade of xerostomia has also been assessed using the dedicated 
RTOG/EORTC Late Radiation Morbidity Scoring Schema (Table 4-2) and 
xerostomia VAS score.  
If entry criteria were satisfied, patient were provided with the relevant Patient 
Information Sheet (Appendix 8.2) and given all the time they need to consider 
participation, ask further questions and provide written consent. 
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(B) IMPRESSION and MANUFACTURING 
A full dental impression of the lower arch has been taken by the clinical 
investigators. Impression tray of the lower arch was carefully selected 
considering the potential limitation of mouth opening due to the fibrosis 
induced by the radiotherapy and the need to extend the impression to the 
distal and lingual aspect of the third molar area (at least 1 cm away in each 
direction). To ensure stability of the impression, polyvinylsiloxane materials 
(Aquasil Ultra Medium-Heavy Body, Dentsply) have been used with a one-
stage impression technique. In case of lower removable prosthesis the 
impression was taken after removal of the prosthesis, in order to ensure 
intimate and stable contact of the electrodes with the tissue. The impression 
was rinsed thoroughly under running tap water before being soaked for 10 
minutes in a disinfecting solution (Eurosept Max Impressions Powder, Henry 
Schein). The impression was then rinsed again, air-dried and labelled with 
the randomisation code before being sent to the manufacturer.  
 (C) DELIVERY OF INDIVIDUALISED DEVICE 
During the delivery of individualised device the participants have been 
instructed and trained by the clinical investigators regarding the modality of 
use of the device during the study period. Saliwell GenNarino was disinfected 
with sterile gauze and 70% alcohol and the device gently inserted in the oral 
cavity, commencing with the side containing the electrodes and then the 
other side. If the participant reported discomfort, fine adjustments were made 
to release stressful spots inside the device by removing a thin acrylic layer 
with a handpiece. In case the patient reported a pricking sensation for the 
point of contact with the electrodes, these were slightly shortened using a 
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high-speed turbine. Careful attention was paid to not excessively trim the 
electrodes, thus annulling the stimulating effect. Saliwell GenNarino was 
activated by pressing the green button of the personal remote control, 
pointing its front to the Saliwell GenNarino detector at a distance of 2-10 cm. 
The blink of the detector light was sought in order to confirm that the device 
was working properly.  
Patients were asked to use the device with a frequency of 5 minutes/hour, as 
many times as they wanted during the day.  
Following appropriate training of the participant on the safe use of the device, 
written manufacturers' instructions were provided, and contact details of the 
investigators were given to the participants. 
Participants were asked to complete a diary of the frequency of application of 
the device per day (Appendix 8.3).  
At baseline the following data were recorded: xerostomia symptoms (VAS 
scale), sialometry, EORTC QLQ-H&N35, OH-QoL16, SF-36 questionnaires.  
(D) FOLLOW-UP  
During follow-up appointment (end of months 1, 2, 4, 6, 8 and 12 after the 
delivery of the individualised device to the patient), the presence of oral 
mucosal abnormality and salivary gland swellings were recorded, together 
with xerostomia symptoms, sialometry, EORTC QLQ-H&N35, OH-QoL16 and 
SF-36 questionnaires. Safety-related secondary outcome measures and 
changes in health condition were assessed.  
  113 
4.2.7 Samples size 
A sample size of 84 subjects has been calculated with regard to the primary 
outcome. Assuming that 20% of the patients of the control group and 60% of 
patients on the active group reported the successful outcome (30% reduction 
in symptoms on the VAS), the sample size required to detect such a 
difference in reduction of xerostomia symptoms with 90% power using a cut-
off for statistical significance of p<0.05 was 70. Considering a potential drop 
out of 20%, the total sample size reached 84 participants (42 patients in the 
study group and 42 in the control group). Drop out rate was primarily 
estimated on the basis of expected mortality/recurrence of head and neck 
cancer in the first 18 months after treatment and study duration.  
4.2.8 Randomisation 
Sequence generation 
A blocked random list, allocating the patient identification numbers to the 
specific type of stimulation, has been prepared by an independent study 
coordinator (central randomisation). The method of sequence generation was 
a random-number generator on a computer. The randomisation code has 
been disclosed only at the end of the trial. 
Allocation concealment 
Allocation concealment, aimed at keeping clinicians and participants unaware 
of upcoming assignments, was guaranteed as the computer-generated list 
was prepared and maintained by the independent study coordinator based at 
a different study centre. The independent study coordinator had no contact 
with the patients and has undertaken the randomisation, allocated the study 
devices, and held the trial codes. 
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Implementation 
The implementation process has been performed by clinical researchers at 
clinical centres, who assigned to enrolled participants the next available 
study number and had no contact with the independent study coordinator. 
4.2.9 Blinding 
The study was a double blind controlled randomised trial. Neither clinical 
investigators nor participants knew which devices were active and which 
were not. The double-blind design was feasible as the electronic stimulus 
was completely asymptomatic, thus the participant could not realise whether 
or not they were using an active or sham device.  
4.2.10 Statistical analysis 
Statistical support and supervision for this study has been provided by a 
dedicated trial statistician. All statistical tests and confidence intervals were 2 
sided and significance has been considered at the 5% level and confidence 
intervals at the 95% level. Statistical analyses have been performed using 
STATA software (version 14).  
The primary outcome of proportions of patients reporting ≥ 30% reduction 
(from baseline) in xerostomia symptoms at 12 months (using a 100mm VAS 
with 0=no dryness and 100 = maximum dryness) has been compared 
between the randomised groups using a Fisher's exact test. Logistic 
regression models has been fitted to adjust odds ratios for centre, age, 
gender and other potential prognostic factors including type of radiotherapy 
(IMRT vs. conventional), total dosage of radiotherapy to primary tumour, 
fields of radiotherapy, number of residual salivary glands, type of tumour and 
years since radiotherapy completion. 
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For secondary outcomes (continuous 12-month VAS scores, 12- months 
sialometry and quality of life questionnaires), data have been compared 
between randomised groups using appropriate regression models to adjust 
for baseline data, providing estimates of adjusted treatment effect with 95% 
confidence intervals. Models have been extended to incorporate the 
repeated measures at 1,2,4,6,8 months allowing estimation of the average 
treatment effect achieved over the 12 month follow up. Changes in the effect 
of treatment over time on the VAS scores, salivary flow and quality of life 
scores have been initially examined graphically using individual patient 
response profiles plotted against time. Secondary outcomes have been 
adjusted for the prognostic factors used for the primary analysis.  
All analyses have been carried out on an intention-to-treat basis, including all 
the participants according to their original randomised group assignment.  
The average number of device applications used by patients per day has 
been summarised graphically over time within the intervention and control 
groups. 
Information about adverse events has been summarised descriptively.  
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5 Results 
5.1 Recruitment results 
One hundred and nineteen patients with radiotherapy-associated xerostomia 
were screened between the Eastman Dental Institute (UCL) and Bradford 
Royal Infirmary. The recruitment took place between January 2012 and 
November 2013. Twenty-six participants were not eligible and were not 
allocated to the intervention (6 in UCL and 20 in Bradford Royal Infirmary). 
Seven participants were eligible but declined to participate in the study 
(Figure 5-1).  
 
Figure 5-1 LEONIDAS-2 Consort Flow Diagram 
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We randomly allocated 86 participants from the two centres to treatment with 
either sham or active intra-oral electrostimulating device (43 patients to each 
group). Two participants, however, did not receive the allocated intervention 
because, due to the presence of trismus, it was not possible to take the 
dental impression needed for manufacturing the device.  
Recruitment trend for each centre and combined is presented in figure 5-2, 5-
3 and 5-4. Sixty-six participants were recruited at UCL and twenty (but two 
did not receive the allocated intervention) at Bradford Royal Infirmary. 
 
Figure 5-2 LEONIDAS-2 Recruitment trend  (University College London) 
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Figure 5-3 LEONIDAS-2 Recruitment Trend (Bradford Hospital) 
 
Figure 5-4 LEONIDAS-2 Recruitment Trend (all sites) 
5.2 Baseline characteristics  
Table 5-1 shows baseline characteristics and treatment details for each 
group. Baseline xerostomia severity (VAS) was slightly higher in the sham 
group then in the active group (7.44 for the sham group and 6.99 for the 
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active). Age, gender, radiotherapy regimen and dosage of radiotherapy to 
primary tumour were similar between groups. 
Table 5-1 Baseline characteristics of patients randomised by treatment group.  
  Sham pacemaker 
(n=43) 
Active pacemaker 
(n=43) 
Centre UCLH 33 (77%) 33 (77%) 
 Bradford 10 (23%) 10 (23%) 
Age at baseline (years) Mean (SD) 58.2 (9.3) 58.4 (10.8) 
Gender Male 31 (72%) 35 (81%) 
 Female 12 (28%) 8 (19%) 
Smoker  Yes 4 (9%) 5 (12%) 
 No 39 (91%) 38 (88%) 
Ethnic group  Caucasian 40 (93%) 38 (88%) 
 Other  3 (7%) 5 (12%) 
Alcohol (units/week)  
(0 for non drinkers) 
Median (IQ 
range) 
1 (0 to 5) 2 (0 to 5) 
Alcohol drinker Yes 23 (53%) 24 (56%) 
 No 20 (47%) 19 (44%) 
Site of first cancer Oral cancer 7 (17%) 4 (10%) 
 Oropharyngeal 22 (53%) 24 (57%) 
 Pharynx 3 (7%) 1 (2%) 
 Hypopharynx 2 (5%) 1 (2%) 
 Larynx 1 (2%) 0  
 Salivary gland 1 (2%) 2 (5%) 
 Other 6 (14%) 10 (24%) 
Stage of Primary 
Tumour 
I 4 (11%) 4 (11%) 
 II 2 (5%) 3 (8%) 
 III 10 (28%) 5 (13%) 
 IV 20 (56%) 26 (68%) 
Type of Radiotherapy Conventional 19 (44%) 18 (42%) 
 IMRT 24 (56%) 25 (58%) 
Dosage of radiotherapy 
to primary tumour 
[Gross Tumour Volume 
- GTV] (Gray) 
Mean (SD) 
Median (IQ 
range) 
64.37 (2.81) 
65 (65 to 65) n=30 
64.00 (3.27) 
65 (65 to 65) n=31 
Number of residual 
parotid  
glands 
1 0 0 
2 43 (100%) 43 (100%) 
Number of residual  
submandibular glands 
1 5 (12%) 5 (12%) 
2 35 (88%) 38 (88%) 
Years since 
Radiotherapy 
completion 
Mean (SD) 
Median (IQ 
range) 
4.71 (2.93) 
3.5 (3 to 6) n=38 
5.14 (2.92) 
5 (3 to 6) n=43 
Xerostomic medical 
condition 
Yes 10 (23%) 6 (14%) 
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 No 33 (77%) 37 (86%) 
Xerostomic medication Yes 14 (33%) 13 (30%) 
 No 29 (67%) 30 (70%) 
Chemotherapy Yes 37 (86%) 31 (72%) 
 No 6 (14%) 12 (28%) 
Surgery to primary site Yes 25 (58%) 24 (56%) 
 No 18 (42%) 19 (44%) 
Salivary flow rate 
(ml/min) (at screening) 
Median (IQ 
range) 
0.07 (0.04 to 0.15) 0.09 (0.04 to 0.14) 
Dry mouth symptoms 
VAS (at screening) 
Mean (SD) 7.44 (1.59) 6.99 (1.47) 
EORTC QLQ-H&N35    
  Swallowing Mean (SD) 29.34 (23.94) n=41 29.56 (21.08) n=42 
  Senses Mean (SD) 37.40 (27.08) n=41 37.30 (29.40) n=42 
  Speech Mean (SD) 24.93 (23.14) n=41 23.02 (18.43) n=42 
  Social eating Mean (SD) 38.62 (28.67) n=41 39.48 (26.93) n=42 
  Dry mouth Not at all/ a little 4 (10%) 3 (7%) 
 Quite a bit/ very 
much  
37 (90%) 39 (93%) 
  Sticky saliva Not at all/ a little 18 (44%) 20 (49%) 
 Quite a bit/ very 
much  
23 (56%) 21 (51%) 
  Coughing Not at all/ a little 33 (80%) 30 (71%) 
 Quite a bit/ very 
much  
8 (20%) n=41 12 (29%) 
OH-QoL16 overall 
score 
Mean (SD) 44.09 (7.45) n=39 45.43 (10.35) n=42 
SF36    
  General health 
perception 
Mean (SD) 56.55 (21.93) n=40 56.87 (19.73) n=42 
  Physical role 
functioning 
Mean (SD) 46.79 (41.82) n=39 57.74 (40.76) n=42 
  Social role 
functioning 
Mean (SD) 73.13 (23.78) n=40 74.11 (26.39) n=42 
  Mental health Mean (SD) 72.53 (15.75) n=40 70.57 (20.22) n=42 
  Reported health 
transition 
Better than a year 
ago 
25 (63%) 27 (64%) 
 
The mean age of participants was 58.2 for the sham group and 58.4 for the 
active group (Figure 5-5). 
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Figure 5-5 Histogram of baseline age 
Fifty per cent of the participants declared to drink alcohol, with an average of 
1 unit for week for the sham group and 2 units for the active group (Figure 5-
6). 
 
Figure 5-6 Histogram of baseline alcohol units per week 
The majority of participants in both groups received IMRT (56% in the sham 
group vs. 58% in the active group), with a mean dose to the primary tumour 
of 64Gy (Figure 5-7).  
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Figure 5-7 Histogram of dosage of radiotherapy to primary tumour  
For inclusion criteria, patients having completed the radiotherapy at least 4 
months before the screening visit were eligible, with no other time restraint. In 
this trial, participants had completed the radiotherapy on average 4.71 years 
for the sham and 5.14 for the active group before starting the clinical trial 
(Figure 5-8).  
 
Figure 5-8 Histogram of years since radiotherapy completion 
During the screening visit, eligible participants had to show to have 
demonstrable residual salivary function (increase in salivary flow on 
appropriate stimulation) and an unstimulated whole salivary flow higher than 
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of 0ml/5min (complete absence of unstimulated salivary flow as measured 
via sialometry for 5 minutes). The median unstimulated salivary flow was 
0.07 ml/min for the sham device and 0.09 ml/min for the active (Figure 5-9). 
 
Figure 5-9 Histogram of baseline salivary flow rate (ml/min) 
The Figure 5-10 shows that LEONIDAS-2 participants had a degree of 
dryness higher than the inclusion criteria (minimum degree of dryness of 
50mm (≥50mm) on a 100mm VAS scale (0=no dryness; 100 =maximum 
dryness). 
 
Figure 5-10 Histogram of baseline dry mouth symptoms (VAS) 
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For the EORTC QLQ-H&N35 questionnaire four multi-item sub-scale score 
(swallowing, senses, speech, social eating) and three single item sub-scale 
scores (dry mouth, sticky saliva, coughing) were analysed. The histograms of 
the baseline mean score for the multi-item sub-scales are reported in Figure 
5-11. 
 
Figure 5-11 Histograms of baseline H&N35 swallowing, sense, speech and 
social eating scores 
The distribution of the mean OH-QoL16 total score at baseline is shown in 
Figure 5-12.  
With regards to the SF 36 questionnaires five sub-scale scores were 
analysed: general health perception, social role functioning, physical role 
functioning, mental health, reported health transition (Figure 5-13). 
 
  125 
 
Figure 5-12 Histogram of baseline OH-QoL16 overall score 
 
Figure 5-13 Histograms of baseline SF36 scores 
5.3 Outcomes analyses 
5.3.1 Primary outcome  
The primary outcome (reduction of 30% in VAS dry mouth scale from 
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to the active group (22%). Therefore the null hypothesis that there would be 
no difference of >30% in the VAS scale between test and control group could 
not be rejected (Table 5-2). 
Table 5-2 Results from analysis of primary outcome 
≥ 30% reduction in dry 
mouth symptoms? 
(n=67) 
Sham (n=36) Sham (n=36) Active (n=32) 
Yes  11 (31%) 7 (22%) 
No  25 (69%) 25 (78%) 
Logistic regression models have been fitted to adjust odds ratios for centre, 
age, gender, type of radiotherapy, years since radiotherapy completion and 
number of residual salivary glands. The results were not statistically 
significant and are represented in Table 5-3. Although the statistical analysis 
plan indicated to adjust the odds ratios also for the dosage of radiotherapy to 
primary tumour, the analysis was not performed due to the missing data in 
participants recruited in Bradford Royal Infirmary.  
Table 5-3 Logistic regression models for primary outcome 
Unadjusted 
analyses (n=68) 
 
 
Estimate 95% Confidence 
interval 
 
Unadjusted 
analyses (n=68) 
    
Difference in proportions 
  
-0.087  (-0.295 to 0.121)  
Odds ratio  0.64 (0.18 to 2.16) P-value: 0.58 
(exact) 
Adjusted analysis     
Odds ratio adjusted 
for centre (n=68) 
 0.60 (0.20 to 1.83)  P-value: 0.37 
Odds ratio adjusted 
for centre, age, 
gender (n=68) 
 0.50  (0.15 to 1.74)  P-value: 0.28  
Odds ratio adjusted for centre, 
age, gender, Type of 
radiotherapy, years since 
radiotherapy completion, 
Number of residual salivary 
glands (n=64) 
0.43 (0.11 to 1.64) P-value: 0.22 
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5.3.2 Secondary outcomes 
5.3.2.1 Continuous VAS scores 
An independent-samples t-test was conducted to compare the mean VAS 
score at 12 months in the active group and in the sham group, adjusted for 
the baseline VAS score, centre, gender, type of radiotherapy and residual 
number of major salivary glands. The histogram presented in Figure 5-14 
shows the distribution for this variable. 
 
Figure 5-14 Histogram of 12 month VAS scores 
There was a not significant difference in the VAS score at 12 months 
between the active group (M=5.93, SD=2.26) and the sham group (M=6.17, 
SD=2.03); p = 0.65 (Table 5-4).  
The Figure 5-15 summarised the change in the VAS score over 12 months. 
Improvement seems to be greater in the active group over the first 6 visits 
(except visit 3), however the treatment effect over the time was not significant 
(Table 5-5). 
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Table 5-4 Results from analysis of VAS scores 
 Mean (SD) / 
Median (IQR) 
Treatment 
effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-value 
 Active 
(n=32) 
Sham 
(n=36) 
   
VAS dry mouth 
symptoms score 
Mean (SD) 
5.93 
(2.26) 
6.17 
(2.03) 
 
-0.23  -1.28 to 0.80 0.65 
Adjusted analysis 
Adjusted for baseline VAS (n=68) -0.18 -1.23 to 0.88 0.74 
Adjusted for baseline VAS and centre 
(n=68) 
-0.14 -1.21 to 0.94 0.80 
Adjusted for baseline VAS, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of 
residual salivary glands (n=64) 
-0.05 -1.13 to 1.03 0.93 
 
 
Figure 5-15 Continuous VAS scores over time (mean + SE bars) 
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Table 5-5 Results from analysis of continuous VAS scores over time (random 
effects model) 
Mean (SD) / Median (IQR) Treatment 
effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-value 
Adjusted analysis 
Adjusted for baseline VAS and visit (n=85) -0.58  -1.18 to 0.04 0.065 
Adjusted for baseline VAS, visit and centre 
(n=85) 
-0.56 -1.17 to 0.05 0.074 
Adjusted for baseline VAS, time, centre, 
age, gender, Type of radiotherapy, years 
since radiotherapy completion, Number of 
residual salivary glands, (n=80) 
-0.52 -1.16 to 0.12 0.114 
 
5.3.2.2 Salivary flow rate  
An independent-samples t-test was conducted to compare the mean 
unstimulated whole salivary flow rate at 12 months in the active group and in 
the sham group, adjusted for the baseline unstimulated whole salivary flow 
rate, centre, gender, type of radiotherapy and residual number of major 
salivary glands. The histogram presented in Figure 5-16 shows the 
distribution for this variable. 
 
Figure 5-16 Histogram of 12 month salivary flow rate (ml/min) 
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There was a non significant difference in the whole unstimulated salivary flow 
score at 12 months between the active group (M=0.22, SD=0.17) and the 
sham group (M=0.21, SD=0.18); p = 0.78 (Table 5-6).  
Table 5-6 Results from analysis of continuous 12 month salivary flow rate  
 Mean (SD) / Median (IQR) Treatment effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-
value 
 Active (n=32) Sham (n=36)    
Salivary 
flow rate 
(ml/min) 
Mean (SD) 
median 
(IQR) 
0.22 (0.17) 
0.17 (0.07 to 
0.36) 
0.21 (0.18) 
0.15 (0.06 to 
0.33) 
0.01  -0.07 to 0.09 0.78 
Adjusted analysis 
Adjusted for baseline (n=68) -0.002 -0.08 to 0.08 0.96 
Adjusted for baseline and centre (n=68) -0.0009 -0.08 to 0.08 0.98 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=64) 
-0.012 -0.10 to 0.08 0.78 
The results for the analysis estimated using a generalised linear model 
(GLM) assuming a Gamma distribution did not differ fundamentally from the 
base-case analysis (Table 5-7, 5-8) 
Table 5-7 Sensitivity analysis – GLM with identity link and gamma distribution 
 Mean (SD) / Median (IQR) Treatment effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-
value 
 Active (n=32) Sham (n=36)    
Salivary 
flow rate 
(ml/min) 
Mean (SD) 
median 
(IQR) 
0.22 (0.17) 
0.17 (0.07 to 
0.36) 
0.21 (0.18) 
0.15 (0.06 to 
0.33) 
0.01  -0.07 to 0.09 0.78 
Adjusted analysis 
Adjusted for baseline (n=68) -0.01 -0.09 to 0.06 0.66 
Adjusted for baseline and centre (n=68) -0.02 -0.09 to 0.06 0.64 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=64) 
-0.03 -0.11 to 0.04 0.39 
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Table 5-8 Sensitivity analysis – regression using square root transformation 
 Mean (SD) 
 
Treatment effect  95% 
Confidence 
interval 
P-
value 
 (transformed scale) (transformed scale)  
 Active (n=32) Sham (n=36)    
Square root 
of Salivary 
flow rate 
(ml/min) 
Mean (SD)  
0.43 (0.19) 0.41 (0.21) 0.027  -0.07 to 0.13 0.59 
Adjusted analysis 
Adjusted for baseline (n=68) 0.0007 -0.09 to 0.09 0.99 
Adjusted for baseline and centre (n=68) 0.002 -0.09 to 0.09 0.97 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=64) 
-0.007 -0.10 to 0.09 0.88 
The Figure 5-17 summarised the change in the whole unstimulated salivary 
flow rate over 12 months. The improvement seems to be greater in the active 
group over the treatment (except visit 6), however the treatment effect was 
not significant (Table 5-9). 
 
Figure 5-17 Continuous salivary flow rate over time 
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Table 5-9 Results from analysis of salivary flow rate over time (random effects 
model) 
 Treatment 
effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-value 
Adjusted analysis 
Adjusted for baseline (n=85) -0.005 -0.053 to 
0.042 
0.83 
Adjusted for baseline and centre (n=85) -0.005 -0.053 to 
0.042 
0.83 
Adjusted for baseline, centre, age, gender, 
Type of radiotherapy, years since 
radiotherapy completion, Number of 
residual salivary glands, (n=80) 
-0.016 -0.066 to 
0.033 
0.52 
 
5.3.2.3 EORTC QLQ-H&N35   
The results of the EORTC QlQ-H&N35 questionnaires with respects to the 
multi-item subscales showed a lower score in the active group at 12 months 
for the domains swallowing, senses, speech, social contact and sexuality. In 
the social eating and pain domain the difference was in favour of the control 
group (Table 5-10). 
Table 5-10 Summary data for QLQ-H&N35 domain scores at 12 months: mean 
(SD) and median (interquartile range). 
Domain score Active (n=31) 
 
Sham (n=36) 
 
Pain 23.66 (16.96) 
25.00 (8.33 to 33.33) 
21.76 (23.93) 
12.50 (0 to 33.33) 
Swallowing  20.52 (20.57) 
16.67 (8.33 to 25) 
23.23 (22.14) 
16.67 (8.33 to 41.67) 
Senses 28.89 (28.34) 
16.67 (0 to 50) (n=30) 
32. 87 (25.35) 
33.33 (16.67 to 50.00) 
Speech  17.92 (21.02)  
11.11 (0 to 22.22) 
18.83 (21.71) 
11.11 (0 to 33.33) 
Social Eating 29.84 (26.94) 
25.00 (8.33 to 41.67) 
29.09 (27.12) 
16.67 (8.33 to 41.67) 
Social Contact 11.40 (21.85) 
0 (0 to 13.33) 
11.94 (22.67) 
0 (0 to 6.67) 
Sexuality 21.84 (32.76) 
0 (0 to 33.33) (n=29) 
23.04 (28.13) 
8.33 (0 to 33.33) (n=34) 
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The analyses of the EORTC H&N-35 single items (Table 5-11) showed that 
fewer participants in the active group had quite a bit or very much problems 
with mouth opening (5 vs. 11) and quite a bit or very much dry mouth (18 vs. 
26). The results were similar for the item sticky saliva (17), cough (6 vs. 7), 
problems with teeth, use of feeding tube (2) and weight gain (5). More 
participants in the active group have lost weight (6 vs. 3), used pain killers 
(14 vs. 13) and taken nutritional supplements (7 vs. 4) but less felt ill (2 vs. 
4).   
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Table 5-11 Summary data for QLQ-H&N35 domain scores at 12 months – those 
based on single questionnaire items 
 
  
Domain  Active 
(n=31) 
Sham 
(n=36) 
Teeth: have you had problems with your 
teeth? 
Not at all 15 (48%) 21 (58%) 
A little 9 (29%) 7 (20%) 
Quite a bit 4 (13%) 5 (14%) 
Very much 3 (10%) 3 (8%) 
Opening mouth: have you had problems 
opening your mouth wide?  
Not at all 13 (42%) 13 (36%) 
A little 13 (42%) 12 (34%) 
Quite a bit 4 (13%) 8 (22%) 
Very much 1 (3%) 3 (8%) 
Dry Mouth: Have you had a dry mouth? 
 
Not at all 1 (3%) 0  
A little 12 (39%) 10 (28%) 
Quite a bit 9 (29%) 14 (39%) 
Very much 9 (29%) 12 (33%) 
Sticky Saliva: Have you had sticky saliva?  
(n=64) 
Not at all 2 (7%) 8 (23%) 
A little 11 (37%) 10 (29%) 
Quite a bit 13 (43%) 13 (37%) 
Very much 4 (13%) 4 (11%) 
Cough: Have you coughed? (n=65) Not at all 10 (33%) 14 (39%) 
A little 14 (47%) 15 (42%) 
Quite a bit 5 (17%) 5 (14%) 
Very much 1 (3%) 2 (5%) 
Felt Ill: Have you felt ill? Not at all 23 (74%) 24 (67%) 
A little 6 (19%) 8 (22%) 
Quite a bit 2 (7%) 4 (11%) 
Very much 0 0 
Pain killers: Have you used pain killers? 
(n=65) 
No 16 (53%) 23 (64%) 
Yes  14 (47%) 13 (36%) 
Nutritional supplement: Have you taken 
nutritional supplements?  
No 24 (77%) 32 (89%) 
Yes  7 (23%) 4 (11%) 
Feeding tube: Have you used a feeding tube? No 29 (94%) 34 (94%) 
Yes  2 (6%) 2 (6%) 
Weight loss: Have you lost weight? No 24 (80%) 33 (92%) 
Yes  6 (20%) 3 (8%) 
Weight gain: Have you gained weight?  No 26 (84%) 30 (86%) 
Yes  5 (16%) 5 (14%) 
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The Figure 5-18 shows the histograms of 12-month domain score for the multi-
item scales assessed (swallowing, senses, speech and social eating). 
 
Figure 5-18: Histogram of 12 month H&35 domain scores for swallowing, 
senses, speech, social eating  
An independent-samples t-test was conducted to compare the mean score 
for the domains swallowing, sense, speech and social eating and the single 
items of the EORTC QoL-H&N35 questionnaires at 12 months in the active 
group and in the sham group, adjusted for the baseline values, centre, 
gender, type of radiotherapy and residual number of major salivary glands. 
There was a non significant difference in means with regards to the 
swallowing domain (-2.71; 95% CI -13.19 to 7.78), sense (-3.98; 95% CI -
17.19 to 9.23), speech (-0.91; 95% CI -11.38 to 9.56), social eating (0.75; 
95% CI -12.48 to 13.98) (Table 5-12).  
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Table 5-12 Comparison of swallowing, senses, speech, social eating scores 
 Treatment 
effect 
(difference in 
means) 
95% Confidence 
interval 
P-value 
Swallowing domain scores    
Unadjusted analysis (N=67) -2.71 -13.19 to 7.78 0.61 
Adjusted for baseline (n=66) -3.95 -12.83 to 4.93 0.38 
Adjusted for baseline and centre (n=65) -3.98 -12.95 to 4.99 0.38 
Adjusted for baseline, centre, age, gender, 
type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=61) 
-6.04 -14.97 to 2.89 0.18 
Senses domain scores    
Unadjusted analysis (n=66) -3.98 -17.37 to 9.43 0.55 
Adjusted for baseline (n=64) -4.27 -13.90 to 5.36 0.38 
Adjusted for baseline and centre (n=64) -4.20  -13.92 to 5.52 0.39 
Adjusted for baseline, centre, age, gender, 
type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=60) 
-4.91 -15.32 to 5.49 0.35 
Speech domain scores    
Unadjusted analysis (n=67) 0.91 -11.38 to 9.56 0.86 
Adjusted for baseline (n=66) 1.26 -6.45 to 8.96 0.75 
Adjusted for baseline and centre (n=66) 1.29 -6.49 to 9.07 0.74 
Adjusted for baseline, centre, age, gender, 
type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=61) 
-0.01 -8.02 to 7.99 0.99 
Social eating domain scores    
Unadjusted analysis (n=67) 0.75 -12.48 to 13.98 0.91 
Adjusted for baseline (n=66) 2.74 -7.31 to 12.79 0.59 
Adjusted for baseline and centre (n=66) 2.81 -7.34 to 12.96 0.58 
Adjusted for baseline, centre, age, gender, 
type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=61) 
1.69 -8.49 to 11.86 0.74 
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There was no significant difference in the treatment effects also for the single 
item of the H&N35 questionnaire dry mouth, sticky saliva and cough (Table 
5-13). 
Table 5-13 Comparison of dry mouth, sticky saliva, coughing scores between 
randomised groups at 12 months 
 Odd 
ratio 
95% 
Confidence 
interval 
P-
value 
Dry mouth score    
Unadjusted analysis (N=67) 0.65 0.27 to 1.59 0.35 
Adjusted for baseline score (n=66) 0.45 0.17 to 1.21 0.11 
Adjusted for baseline score and centre (n=66) 0.45 0.17 to 1.20 0.11 
Adjusted for baseline score, centre, age, gender, type 
of radiotherapy, years since radiotherapy completion, 
number of residual salivary glands (n=62) 
0.38 0.13 to 1.15 0.09 
Sticky saliva score    
Unadjusted analysis (n=65) 1.63 0.66 to 3.99 0.29 
Adjusted for baseline score (n=63) 1.61 0.61 to 4.20 0.33 
Adjusted for baseline score and centre (n=63) 1.60 0.61 to 4.19 0.34 
Adjusted for baseline score, centre, age, gender, type 
of radiotherapy, years since radiotherapy completion, 
number of residual salivary glands (n=60) 
1.55 0.55 to 4.39 0.40 
Cough score    
Unadjusted analysis (n=66) 1.18 0.48 to 2.92 0.72 
Adjusted for baseline score (n=65) 1.04 0.40 to 2.74 0.93 
Adjusted for baseline score and centre (n=65) 1.07 0.41 to 2.82 0.89 
Adjusted for baseline score, centre, age, gender, type 
of radiotherapy, years since radiotherapy completion, 
number of residual salivary glands (n=61)* 
1.01 0.36 to 2.83 0.99 
The Figures 5-19, 5-20, 5-21 and 5-22 summarised the change in the 
subscales swallowing, sense, speech, and social eating over the time. An 
improvement can be observed over time for all the analysed subscale, less 
pronounced for the sense subscale score and not statically significant (Table 
5-14). However, analysis of repeated measurements showed a statistically 
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significant improvement over time for the dry mouth and swallowing item of 
the EORTC-QoL-H&N35 questionnaire.  
 
Figure 5-19 H&N35 swallowing sub-scale scores over time 
 
Figure 5-20 H&N35 sense subscale scores over time 
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Figure 5-21 H&N35 speech sub-scale scores over time 
 
Figure 5-22 H&N35 social eating sub-scale scores over time 
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Table 5-14 Results from analysis of H&N scores over time (random effects 
models) 
 Treatment 
effect 
(difference in 
means) 
95% Confidence 
interval 
P-value 
Swallowing domain scores    
Adjusted for baseline score (n=83) -3.48 -8.00 to 1.05 0.13 
Adjusted for baseline score and centre 
(n=83) 
-3.46 -7.96 to 1.04 0.13 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=78) 
-4.54 -9.16 to 0.07 0.05 
Senses domain scores    
Adjusted for baseline score (n=83) -2.38 -7.66 to 2.90 0.38 
Adjusted for baseline score and centre 
(n=83) 
-2.38 -7.67 to 2.92 0.38 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=78) 
-2.25 -7.98 to 3.48 0.44 
Speech domain scores    
Adjusted for baseline score (n=83) 0.68 -4.33 to 2.97 0.72 
Adjusted for baseline score and centre 
(n=83) 
-0.68 -4.31 to 2.95 0.71 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=78) 
-1.43 -5.37 to 2.50 0.47 
Social eating domain scores    
Adjusted for baseline score (n=83) -1.94 -7.03 to 3.13 0.46 
Adjusted for baseline score and centre 
(n=83) 
-1.94 -7.06 to 3.18 0.46 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=78)* 
-3.09 -8.52 to 2.34 0.27 
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 Odd 
ratio 
95% 
Confidence 
interval 
P-
value 
Dry mouth score    
Adjusted for baseline score (n=83) 0.52 0.22 to 1.21 0.13 
Adjusted for baseline score and centre (n=83) 0.52 0.22 to 1.21 0.13 
Adjusted for baseline score, centre, age, gender, type 
of radiotherapy, years since radiotherapy completion, 
number of residual salivary glands (n=78) 
0.47 0.22 to 1.01 0.05 
Sticky saliva score    
Adjusted for baseline score (n=82) 1.39 0.72 to 2.68 0.33 
Adjusted for baseline score and centre (n=78) 1.39 0.72 to 2.68 0.33 
Adjusted for baseline score, centre, age, gender, type 
of radiotherapy, years since radiotherapy completion, 
number of residual salivary glands (n=60) 
1.27 0.64 to 2.50 0.50 
Cough score    
Adjusted for baseline score (n=83) 0.72 0.34 to 1.55 0.40 
Adjusted for baseline score and centre (n=83) 0.72 0.34 to 1.55 0.40 
Adjusted for baseline score, centre, age, gender, type 
of radiotherapy, years since radiotherapy completion, 
number of residual salivary glands (n=78) 
0.72 0.32 to 1.60 0.42 
5.3.2.4 OH-QoL16  
An independent-samples t-test was conducted to compare the mean OH-
QoL16 overall score at 12 months in the active group and in the sham group, 
adjusted for the baseline overall score, centre, gender, type of radiotherapy 
and residual number of major salivary glands. The histogram presented in 
Figure 5-23 shows the distribution for this variable.  
There was a non significant difference in the OH-QoL16 overall score at 12 
months between the active group (M=46.83 SD=10.68) and the sham group 
(M=48.75, SD=10.19); p = 0.46 (Table 5-15).  
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Figure 5-23 Histogram of 12 months OH-QoL overall score 
Table 5-15 Results from analysis of continuous 12 months OH-QoL 
questionnaire (overall score)  
 Mean (SD) / Median (IQR) Treatment effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-
value 
OH-QoL16 
(Overall 
Oral health 
score) 
46.83 (10.68) 48.75 (10.19) -1.92 -7.06 to 3.23 0.46 
Adjusted analysis 
Adjusted for baseline score and centre (n=64) -3.68 -7.58 to 0.21 0.06 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=64) 
-3.15 -7.01 to 0.72 0.11 
There was a trend toward a higher OH-QoL overall score (all good effects of 
extreme impact) over the treatment, but the difference seems greater in the 
sham group compared to the active group (Figure 5-24; Table 5-16). 
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Figure 5-24 OH-QoL16 overall score over time 
Table 5-16 Results from analysis of OH-QoL16 overall score over time 
(random effects model) 
 Treatment 
effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-value 
Adjusted analysis 
Adjusted for baseline score (n=81) -1.53 -3.49 to 0.42 0.12 
Adjusted for baseline score and centre 
(n=83) 
-1.54 -3.50 to 0.42 0.12 
Adjusted for baseline score, centre, age, 
gender, Type of radiotherapy, years since 
radiotherapy completion, Number of 
residual salivary glands, (n=76) 
-1.30 -3.38 to 0.78 0.22 
5.3.2.5 SF-36 
An independent-samples t-test was conducted to compare the mean SF-36 
subdomains of general health, physical role functioning, social role 
functioning, mental health and reported health transition. The histogram 
presented in Figure 5-25 shows the distribution for these variable. 
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Figure 5-25 Histogram of 12 month SF-36 domain scores for general health, 
physical role, social role, mental health, reported health transition.  
The subdomains were adjusted for the baseline values, centre, gender, type 
of radiotherapy, and residual number of major salivary glands. 
There was a non significant difference in the general health subdomain and 
the social role functioning score at 12 months between the active group 
(M=52.75, SD=23.74) and the sham group (M=59.11, SD=21.00) and 
(M=77.02 SD=24.17) and the sham group (M=72.57, SD=28.32); p = 0.50, 
respectively. The difference was also not significant for mental health 
subdomain for the active group (M=65.58 SD=16.77) compared to the sham 
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group (M=69.89 SD=19.82) (p = 0.35) and reported health transition (p = 
0.56). 
The difference was non significant for the physical role functioning in the 
active group (M=60.48 SD=45.08) and the sham group (M=54.63, 
SD=40.89); p = 0.58 (Table 5-17). 
Table 5-17 Comparison of general health, physical role functioning, social 
functioning, mental health and reported health transition between randomised 
groups at 12 months 
 Mean (SD) / Median (IQR) Treatment effect 
(difference in 
means) 
95% 
Confidence 
interval 
P-
value 
General Health domain scores 
 Active (n=31) Sham (n=35)    
Mean (SD) 
median 
(IQR) 
52.75 (23.74) 
52 (35 5o 72) 
59.11 (21.00) 
57 (45 to 77) 
-6.36 -17.37 to 
4.64 
0.25 
Adjusted analysis 
Adjusted for baseline and centre (n=65) -5.13 -13.51 to 
3.24) 
0.23 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=61) 
-4.48 -13.64 to 
4.68 
0.33 
Physical Role Functioning domain scores 
 Active (n=31) Sham (n=36)    
Mean (SD) 
median 
(IQR) 
60.48 (45.08) 
75 (0 to 100) 
54.63 (40.89) 
50 (12.5 to 
100) 
5.85 -15.13 to 
26.84 
0.58 
Adjusted analysis 
Adjusted for baseline and centre (n=65) 1.25 -18.01 to 
20.52 
0.90 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=61) 
2.35 -19.11 to 
23.81 
0.83 
Social functioning domain scores 
 Active (n=31) Sham (n=36)    
Mean (SD) 
median 
(IQR) 
77.02 (24.17) 
87.5 (50 to 
100) 
72.57 (28.32) 
75 (62.5 to 
100) 
4.45 -8.51 to 
17.41 
0.50 
Adjusted analysis 
Adjusted for baseline and centre (n=66) 3.43 -6.46 to 
13.32 
0.49 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=60) 
5.75 -4.95 to 
16.45 
0.29 
Mental health 
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 Active (n=31) Sham (n=36)    
Mean (SD) 
median 
(IQR) 
65.58 (16.77) 
65 (52 to 76) 
69.89 (19.82) 
72 (58 to 86) 
-4.31 -13.35 to 
4.73 
0.35 
Adjusted analysis 
Adjusted for baseline and centre (n=66) -2.90 -10.07 to 
4.27 
0.43 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=62) 
-0.75 -7.84 to 6.33 0.83 
Reported Health Transition 
 Active (n=31) Sham (n=36)    
Mean (SD) 
median 
(IQR) 
2.52 (0.73) 
3 (2 to 3) 
2.39 (0.99) 
2 (2 to 3) 
0.13 -0.30 to 0.56 0.56 
Adjusted analysis 
Adjusted for baseline and centre (n=66) 0.18 -0.26 to 0.62 0.42 
Adjusted for baseline, centre, age, gender, type 
of radiotherapy, years since radiotherapy 
completion, number of residual salivary glands 
(n=62) 
0.04 -0.42 to 0.51 0.19 
There was a trend toward a higher general health perception score, physical 
role functioning and health transition score over time in the sham group, with 
a lower mental health score and unchanged social functioning. Participants in 
the active group showed a lower general health perception and mental health 
score at 12 months compared to baseline, an unchanged physical role 
functioning and a higher score for the domains reported health transition and 
social functioning (Figures 5-26, 5-27, 5-28, 5-29, and 5-30). The difference 
in mean of the reported mental health transition between the two groups was 
statistically significant (Table 5-18). 
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Figure 5-26 SF-36 General health perception score over time 
 
Figure 5-27 SF-36 Physical role functioning score over time 
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Figure 5-28 SF-36 Social role functioning over time 
 
Figure 5-29 SF-36 Mental Health score over time 
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Figure 5-30 SF-36 Reported Health Transition score over time 
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Table 5-18 Results from analysis of SF-36 scores over time (random effects 
models) 
 Treatment 
effect 
(difference in 
means) 
95% Confidence 
interval 
P-value 
General Health perception    
Adjusted for baseline score (n=82) 0.40 -3.99 to 4.79 0.86 
Adjusted for baseline score and centre (n=82) 0.42 -4.01 to 4.84 0.85 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=7) 
-0.006 -4.82 to 4.80 0.99 
Role Physical Score    
Adjusted for baseline score (n=81) 3.30 -6.13 to 12.73 0.49 
Adjusted for baseline score and centre (n=81) 3.31 -6.20 to 12.82 0.50 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=76) 
3.34 -7.46 to 14.14 0.54 
Social functioning    
Adjusted for baseline score (n=83) 1.14 -3.60 to 5.88 0.64 
Adjusted for baseline score and centre (n=83) 1.14 -3.63 to 5.92 0.64 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=78) 
2.03 -3.12 to 7.18 0.44 
Mental Health    
Adjusted for baseline score (n=82) -1.04 -4.38 to 2.30 0.54 
Adjusted for baseline score and centre (n=82) -1.07 -4.39 to 2.25 0.53 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=77) 
0.47 -3.94 to 3.00 0.79 
Health Transition    
Adjusted for baseline score (n=82) 0.31 0.09 to 0.53 0.005 
Adjusted for baseline score and centre (n=82) 0.31 0.10 to 0.53 0.005 
Adjusted for baseline score, centre, age, 
gender, type of radiotherapy, years since 
radiotherapy completion, number of residual 
salivary glands (n=77) 
0.22 0.002 to 0.43 0.05 
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5.3.2.6 Device usage 
The average number of applications used by patients per day was 1.79 per 
day during the first month, with an average daily cumulative use of 8.9 
minutes. The number of applications declined over the study period, as it can 
be seen in the Figure 5-31. 
 
Figure 5-31 Average daily number of device application 
  
1	month	 2	months	 4	months	 6	months	 8	months	 12	months	
AcNve	Group	 1.82	 1.85	 1.7	 1.54	 1.44	 1.26	
Sham	Group	 1.76	 1.8	 1.66	 1.5	 1.42	 1.22	
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In the present study participants’ compliance with regards to appointment 
attendance was similar between the active and sham group (Figure 5-32). 
 
Figure 5-32 Attendance Rate of Participants  
The study was completed by 68 participants (58 at UCL and 10 in Bradford) 
of the 84 receiving the allocated intervention. Thirty-six participants in the 
sham group and thirty-two in the active group completed the study. The 
overall dropout rate was 19%, as expected in the sample size calculation.  
Reasons given by patients for not completing the study are displayed in 
Table 5-19. Time constraints and personal problems were an issue in 7 
participants. As expected recurrence of cancer was the reason for the 
exclusion of 3 participants from the trial (one oesophageal cancer, one lung 
cancer, one tumour to the base of the spine). Other reasons for dropout were 
being unable to use the device due to PEG tube feeding (1 participant), to 
dental pain (1 participant), to bone exposure (1 participant) and device not 
fitting properly and causing discomfort (3 participants).  
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Table 5-19 Drop-out rate and reasons 
Reasons for Drop-out  Number of patients  
Withdrawal of consent UCLH 4 
 Bradford 3  
Cancer UCLH 3  
 Bradford 0  
Unable to use the device due to PEG 
tube feeding 
UCLH 0 
 Bradford 1  
Unable to use the device due to dental 
pain 
UCLH 0 
 Bradford 1  
Unable to use the device due to bone 
exposure 
UCLH 0 
 Bradford 1  
Unable to use the device due to 
discomfort  
UCLH 0 
 Bradford 3  
We recorded six Serious Adverse Event, related to 4 admissions to the 
hospitals for reason not related to the study (continuous abdominal pain, 
hernia repair surgery, ankle surgery, swollen right arm) and one 
osteonecrosis of the jaw. One participant presented to his second review 
appointment with a broken investigational device: the two 2-mm electrodes 
were missing, likely broken during intraoral usage. It remains unclear when 
the event happened, as the patient was unaware of the episode and denied 
respiratory or gastrointestinal symptoms. 
For the theoretical potential risk of inhalation/ingestion and consequent 
damage to respiratory or GI tract, a chest plus abdominal X-ray has been 
arranged but was unable to locate the electrodes. The participant completed 
the trial with no complications. 
Due to the long duration of the study we had 36 non-serious advent events, 
the most common being cold, fungal infections, oral ulcerations and dental 
extractions (Table 5-20). 
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Table 5-20 Non-serious advent events 
Side effects   
Serious Adverse Event UCLH 4  
 Bradford 2 
 Admission to hospital 4 
 Osteonecrosis 1 
 Potential inhalation/ingestion of 
the device electrodes  
1 
Non Serious Adverse Event UCLH 33 
 Bradford 3 
 Anaemia 1 
 Broken wrist 3 
 Burning sensation 1 
 Cold 4 
 Dizziness 1 
 Dysphagia 2 
 Ear infection 3 
 Fungal infection 4 
 Gingivitis 1 
 Hernia 1 
 Hypertension 1 
 Kidney mass 1 
 Migraine 1 
 Muscle spasms 1 
 Nasal obstruction 1 
 Oral keratosis 1 
 Oral pain 1 
 Oral ulcer 5 
 Parotid gland swelling 1 
 Pigmented lesion 1 
 Root canal treatment 1 
 Swelling buccal mucosa 1 
 Throat infection 3 
 Tooth extraction 4 
 Tooth fracture 1 
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6 Discussion 
Head and neck cancers represent 7% of all cancers that are diagnosed in the 
world, with approximately 600,000 new cases per year (Ferlay et al., 2012). 
Nearly two-thirds of all HNC patients will receive radiation as part of their 
treatment. IMRT has been shown to reduce the incidence of xerostomia.  
Nevertheless at 12 months approximately forty per cent of patients would still 
report xerostomia of grade 2 or worse. Therefore, even with IMRT, nearly 
200,000 HNC cancer survivors will develop persistent xerostomia, with 
significant reduction in their quality of life due to the impact of dry mouth 
symptoms upon daily activities, speech, swallowing, sleeping, and emotional 
function (Kakoei et al., 2012). 
Our systematic review has demonstrated that pilocarpine can provide some 
benefit in patients with radiotherapy-associated xerostomia. This medication, 
however, is not well-tolerated and up to 20% of patients discontinue the 
treatment with pilocarpine because of the low benefit-to-cost ratio, both in 
terms of side effects and efficacy of the treatment (Rieke, 1995). 
Salivary electrostimulators are emerging devices that can apply electrical 
stimuli to the submucosal/subcutaneous cranial nerve that innervate the 
salivary glands, thus stimulating salivation. Among them, the remote 
controlled intraoral removable device GenNarino (Saliwell Ltd, Saarbruecken, 
Germany) has emerged for its miniaturized size and user-friendliness. 
Saliwell GenNarino has been granted approval for marketing in Europe (CE 
mark) and is sold at a price of $575 (£370/500€) per device (Sasportas et al., 
2013), thus significantly less than 12 months of pilocarpine therapy at 
maximum dosage (£1096). 
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The aim of this clinical trial was to assess the long-term potential benefit of 
the removable intra-oral electrostimulating device GenNarino in the 
management of radiotherapy-induced xerostomia.  
The results of this RCT showed a reduction in VAS dry mouth symptoms of 
1.27 for participants assigned to the non-active device providing only 
mechanical stimulation and 1.06 for participants assigned to the active 
devices providing electrical and mechanical stimulation. Statistical analyses 
showed that the difference between the two means was not significant 
(P>0.05). Therefore the main null hypothesis of this RCT could not be 
rejected. In other words the trial failed to show any significant difference in 
the VAS score (dry mouth) between cases and controls. There was a trend 
towards to an improvement in the VAS score over time but the difference 
between the two groups was not significant. 
With regards to the secondary outcomes, the mean salivary flow rate in 
patients receiving the active device was higher compared to the patients 
using the sham device but the difference between the two means was not 
statistically significant (P>0.05).  
The analyses of Quality of Life questionnaires revealed a benefit, although 
non-significant, for the domains swallowing, senses, speech and social 
eating of the EORTC H&N-35 single items in patients using the active device. 
The Oral Health Quality of life questionnaires did not reveal any benefit in the 
quality of life of participants allocated to the active group.  
The SF-36 showed higher score of physical role functioning and social 
functioning (indicating better functioning) and reported health transition in the 
active group but lower score in the general health perception and mental 
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health. The treatment effect, however, was not significant for any subscale. 
Therefore the hypothesis for the secondary outcomes also could not be 
rejected.  
The results of this clinical trial conflict with the findings of other clinical trials 
showing a preferential short-term effect for the active second-generation 
electrostimulating device compared to the sham device.  
However, our study differs significantly from previous studies. 
The only two previous placebo-controlled studies, showing an improvement 
of the salivary function following electrostimulation device, used the first 
generation device (Salitron) and did not include any patient with 
radiotherapy-induced xerostomia (Steller et al., 1988, Talal et al., 1992). One 
study testing the first generation of electrostimulator device included 
irradiated patients and the results of the studies were stratified for this 
condition, however the study design was open-label and uncontrolled.  
Quantitative comparison of LEONIDAS-2 clinical trial with other studies on 
the second generation electrostimulating device is problematic because of 
the lack of uniformity in study design and definition of endpoints. Previous 
trials excluded participants with history of radiation to the head and neck, and 
if included, they represented only a small proportion of the included 
population. Furthermore the results were never stratified for patients with 
radiotherapy-induced xerostomia and so they cannot be entirely compared to 
the results of this study.  
This is the only study limiting the recruitment to patients with radiotherapy-
associated xerostomia. One clinical trial on first generation electrostimulating 
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device have included, among other causes of xerostomia, patients with 
radiotherapy-associated xerostomia (13 out of 24) (Weiss Jr et al., 1986). 
Two clinical trials on second generation electrostimulating devices included 
14 and 9 patients respectively (12% and 7% of the total cohort) (Strietzel et 
al., 2011, Alajbeg et al., 2012). 
The first proof-of-concept clinical trials on the II generation device 
(GeNnarino) by Strietzel et al excluded patients with depression, complete 
edentulous patients and irradiated patients (Strietzel et al., 2007). Included 
patients were tested with one active stimulation and one sham stimulation of 
10 minutes in a random order with a crossover design. Objective evaluation 
included a wetness sensor whereas the subjective sensation was recorded 
asking the participants if the effect of both experiments was similar or one of 
them had a better effect. After 1 min of wearing GeNnarino, the registered 
dryness status was similar in the two groups, whereas after an application of 
3, 5 and 10 minutes a lower dryness could be observed in the active mode. 
Subjectively 24% of the patients did not perceive any differences between 
the two tests and a difference was only perceived in 33% of participants 
when the active device was used after the sham but not when used before. 
Quality of life has not been assessed in this study.  
Four years later the same author designed a clinical trial which this time 
included also patients with radiotherapy-associated xerostomia (Strietzel et 
al., 2011). Patients were excluded if they had mental disease or depression 
and were not allowed to use systemic sialogogues only during the first two 
months of the trial, which had a total duration of 11 months. In the first stage 
of the study, participants were randomised to use the active and the sham 
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device for one month each. Participants were asked to use the device for 10 
minutes each application and the average daily cumulative length of use of 
the electrostimulation device was 40 minutes. In the LEONIDAS-2 study each 
application was limited to 5 minutes and the average daily cumulative use 
was significantly lower (8 minutes). The active intervention performed better 
than sham with regards to subjective VAS xerostomia scale, with a change of 
8 mm in the VAS scale vs. 5 mm (P=0.05), but not with regards to stimulated 
or unstimulated salivary flow. Although the different study design (cross-
over), duration (2 months) and lack of stratification of the results for irradiated 
patients make comparison with our study difficult, one possible explanation of 
the different treatment effect could also be the higher length of device use.  
The study was followed by an open-label phase, during which the active 
devices were used for additional 9 months, completed only by 60% of the 
initial cohort and only 7% of them with our condition of interest (Alajbeg et al., 
2012). The average daily cumulative use of the device was 18 minutes in this 
study, with applications ranging from 1 to 10 minutes. There was no control in 
this study and a statistically significant difference in the VAS scale of 12 mm 
has been observed between month 11 and baseline. The median difference 
in unstimulated salivary flow between endpoint and baseline was 0.062 
ml/min (p<0.05). In our study the median difference after 12 months was 
similar (0.08) with no difference among the active and sham group. The 
difference in the quality of life was not statistically significant and results are 
not comparable because a different and not validated QoL questionnaire has 
been used in the study.  
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The participants in this study were recruited from three Head and Neck 
Cancer Unit in UK (University College London Hospital, The Royal Marsden 
Hospital, Bradford Royal Infirmary). Participants were also referred from the 
Guy's and St Thomas' NHS Foundation Trust. The setting is different from 
other studies on salivary gland electrostimulation, where patients were 
recruited in the Sjogren’s syndrome Clinic (Steller et al., 1988), in an Oral 
Medicine or Oral Surgery Department (Strietzel et al., 2007) or referred by 
the Rheumatologist (Strietzel et al., 2011).  
In all previous trials the vast majority of participants were women (81%-
86%)(Strietzel et al., 2011, Alajbeg et al., 2012, Strietzel et al., 2007, Talal et 
al., 1992, Steller et al., 1988), whereas in our study 80% of the participants 
were men. Men and women may differ in their response to treatment for 
several reasons, including differences in the size of salivary glands. 
Menopause and hormone replacement therapy do not seem be associated 
with salivary dysfunction of the parotid (De Almeida et al., 2008).  
The mean age of 58 years was comparable to the other studies (Strietzel et 
al., 2011, Alajbeg et al., 2012, Strietzel et al., 2007, Steller et al., 1988).  
The salivary flow and saliva composition are strictly related to the presence 
of systemic disease. Xerostomia can be due to autoimmune exocrinopathies 
(notably Sjogren’s syndrome), dehydration, cognitive alteration, oral sensory 
dysfunction and psychological disorders. Metabolic disturbances, alteration of 
the gland innervation as seen in neurological disorders can also cause 
hyposalivation and/or alter salivary composition. In this study, patients with 
Sjogren’s syndrome were excluded; however, xerostomic medical conditions 
were present in 23% of the sham and 14% of the active group. These 
  161 
included diabetes (7 participants), hypothyroidism (4), anxiety (1), and 
depression (3). 
Xerostomia is a relatively common complaint, notably in poorly controlled 
diabetics due to a decreased flow rate of both unstimulated and stimulated 
salivary. A change in salivary composition with regards to antimicrobial 
substances, protein and buffering capacity has also been observed in 
patients with diabetes (Vissink et al., 2015). 
Unstimulated and stimulated salivary flow is decreased in patients with 
hypothyroidism and autoimmune thyroiditis. In addition salivary gland 
enlargement (sialadenosis) has also been described. Furthermore anxiety 
and depression are well recognized causes of reduced salivary flow 
(Scarabelot et al., 2014). 
More than 500 medications are associated with xerostomia. The drugs most 
commonly implicated in xerostomia are tricyclic antidepressants, 
antipsychotics, benzodiazepines, atropinics, β-blockers, and antihistamines, 
due to the anticholinergic or sympathomimetic action of the cited medication. 
In our study 33% of participants in the sham group and 30% in the active 
group were taking xerostomic medications. 
In the LEONIDAS-2 study the majority of patients had oropharyngeal cancer 
(53% in the sham group vs. 57% in the active group), which is often cured 
with radiotherapy. Although parotid-sparing intensity-modulated radiation 
therapy is now a standard radiotherapy technique for patients with HNSCC, 
there are no randomised trials evaluating the submandibular-sparing 
technique. The submandibular glands contribute for 70% to the resting 
salivary flow, producing saliva rich in mucins. In oropharyngeal cancer 
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patients, it is rarely possible to spare the ipsilateral submandibular gland, due 
to the close proximity to the primary tumour. In this study submandibular 
glands received an average dose of 57 Gy and the dose was higher in the 
active group (60 Gy). Regarding the dose response, Murdoch-Kinch et al. 
reported that submandibular gland-stimulated salivary function decreased 
significantly after a mean dose of >40 Gy (Murdoch-Kinch et al., 2008). This 
threshold are compatible with a review of the literature reporting a lesser 
sensitivity of the submandibular glands compared to the parotid glands, for 
which the threshold is 26 Gy. 
Adherence to the treatment is a main factor for success in therapeutic 
approach and the lower daily cumulative use of the device in this study 
compared to the other clinical trials could also have affected the results. It is 
very important, therefore, to analyse the reasons that can have influenced 
the patient’s compliance with the device. The main reason for lack of use of 
the device was device failures, when the device could not have been 
switched on. In case of device failure, a first attempt was made to change the 
batteries on the remote control. In the event of a permanent failure, the 
manufacturer was contacted in order to request a new device. Device 
replacement was required for 10 participants. While waiting for the 
replacement, which took an average of 8 weeks, participants were asked to 
use the device as normal. 
Serious adverse events were not related to the intervention of the study, 
whereas expected non-serious adverse events were oral fungal infections, 
one episode of osteonecrosis and oral ulcers. 
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The risk of fungal infections is largely increased in patients with salivary 
gland hypofunction due to the loss of the antimicrobial actions (Porter et al., 
2004). Bone necrosis secondary to radiation damage was reported as early 
as 1926, with an identifiable trauma in 65% of the cases (Marx, 1983). The 
occurrence of oral ulcers in the study (5%) is in keeping with the prevalence 
of ulcerations in the general population, between 5% and 25% (McCullough 
et al., 2007). 
Although the study did not meet the planned main outcome of dry mouth 
symptoms reduction in the active device arm versus sham device and there 
was no evidence of significantly increased salivary function, we have 
observed a statistically significant reduction in dry mouth symptoms and 
swallowing perception over time. These results suggest that some benefits 
may be expected with the use of electrostimulation although there remains at 
the moment no convincing evidence from our trial.  
We suggest that further research is needed and that future studies should 
consider defining a better phenotyped and more homogenous study 
population and testing the revised stimulating device, which is characterised 
by easier fitting that is not operator-dependent. 
Study limitations 
LEONIDAS-2 clinical trial’s primary outcome was defined as the proportion of 
participants reporting a 30% reduction of xerostomia symptoms after 12 
months of treatment, as evaluated through a 100mm VAS. A critical analysis 
has been performed during the study to estimate the magnitude of change of 
the visual analogue scale in head and neck settings, by looking at 
randomized clinical trial that used the visual analog scale to assess 
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radiotherapy-induced xerostomia. Results showed that the average change 
scores in controlled clinical trials of treatment for radiotherapy-induced 
xerostomia was lower than the one estimated in the protocol, being between 
20% and 25%. Furthermore we have identified that the magnitude of VAS 
change (effect size) following the intervention could be more informative for 
decision-makers than the dichotomous presentation. We have therefore 
added the analysis of continuous VAS as a secondary outcome of the study. 
Participants recruited in this study were heterogeneous with respect to ethic 
group, smoking habits, site and stage of primary tumour, years since 
radiotherapy completion. Heterogeneity occurs in many clinical fields and 
may lead to imbalance of randomized groups in terms of results, even when 
with strict inclusion criteria. This imbalance, however, has been reduced 
considerably by following a proper randomization procedure. 
A multi-centre design has been chosen to provide evidence that the trial 
results were not strongly setting-dependent and they could be applied to a 
broader population of clinical sites. A pilot or feasibility study on a smaller 
number of patients has not been conducted to clarify issues such as 
participant recruitment and retention strategies, appropriate length of follow-
up and attrition likelihood. 
The clinical trial’s accrual period has been estimated considering the accrual 
rate of each clinical centre, using questionnaires to measure the total number 
of cases currently or recently seen for the targeted condition. Although the 
accrual period was 6 months longer than planned in order to enforce 
similarity of centre sample sizes, the planned samples sizes was achieved 
but the ratio within-centre was unequal, with 79% of the participants recruited 
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in one centre (University College London Hospital) and 21% in the remaining 
participating centre (Bradford Royal Infirmary).  
Furthermore, the multi-centre design has not allowed us to perform all the 
statistical analyses detailed in the statistical analysis plans. In particular 
radiation dose of primary tumour and number of remaining salivary glands 
were not available for the participants recruited at the Bradford Royal 
Infirmary.  
An important limit of our statistical analysis was that parotid mean dose was 
not available for participants recruited in both centre and we could not stratify 
participants based on the parotid mean dose. There is strong evidence that 
chronic salivary dysfunction is correlated to the mean parotid gland dose and 
severe xerostomia is usually avoided if at least one parotid gland is spared to 
a mean dose of less than ≈20 Gy or if both glands are spared to less than 
≈25 Gy. Due to the missing data we are unable to comment on whether 
participants who received a lower parotid mean dose reported better function 
or higher benefit following the experimental intervention.  
Site visits combined with scheduled meetings were arranged between the 
investigators and the clinical trial coordinator, in order to discuss the 
deviation of trial recruitment from the expected trajectory graph of 
recruitment. Problems with recruitment were attributed to strict inclusion and 
exclusion criteria, mainly in the ability of showing that salivary flow rate could 
be enhanced by stimulation. Inadequate staffing has also been an issue in 
the first phase of the trial, later solved by recruiting a new investigator. 
The dropout rate was similar to the rate estimated in the sample size. 
However, of the 70 participants required to satisfy the sample size 
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requirement, only 68 completed the trial. The attrition rate was significantly 
lower in one centre (University College London Hospital), where retention 
strategies such as letter remainders for follow-up study visits, detailed report 
of the up-to-date status of every participant and calls to reschedule missed 
study visits were put in place. University College London Hospital also offers 
the facility of a dedicated clinical research space and team, which includes a 
trial coordinator. It is possible that the retention strategies and facility played 
a role in retention. In accordance with the Code of Federal Regulations (the 
compensation is neither coercive nor at the level that would present undue 
influence), financial incentives were offered to participants as an incentive for 
trial completion, enhancing participants’ engagement with the trial. Dropout 
occurred at random and was not related to the randomization assignment.  
The large number of follow-up visits, which were eight in total over one year 
period, has probably increased the likelihood of attrition. In this study 7 
participants withdrew their consent because of the time commitment. In order 
to address this issue, an intention to treat analyses has been performed, 
including all randomised study participants in the groups to which they were 
randomised. 
Performing statistical analysis with reduced number of patients has an effect 
on the outcome. With a small number of patients there is a higher standard 
error and therefore a wider confidence interval. It is therefore more difficult to 
obtain significant results. This may explain why our results were not 
statistically significant. 
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7 Conclusions 
In conclusion, the use of a second-generation intra-oral electrostimulating 
device in this study appeared to be safe, acceptable but not superior to a 
sham device in relieving dry mouth symptoms, increasing salivary gland 
function and improving quality of life of head and neck cancer survivor.  
There was, however, a tendency of improvement of dry mouth symptoms and 
swallowing symptoms over time in individuals using the active device. 
These results suggest that some benefits may be expected with the use of 
electrostimulation although there remains at the moment no convincing 
evidence from our trial. We suggest that further research is needed which 
may also benefit from some of the information and data obtained in 
LEONIDAS-2 study in order to inform the design and better phenotyped and 
more homogenous study population. 
A new trial using the recently developed revised version of the 
electrostimulating device which is characterised by easier fitting that is not 
operator-dependent, thus overcoming some of the weaknesses of the 
previous device, can be suggested.   
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8 Appendix 
8.1 Intra-oral electrostimulating device 
 
Figure 8-1 First generation electrostimulating device, consisting of a console 
(A) and a hand-held probe (B) 
 
  
B 
A B 
Figure 8-2 Second generation electrostimulating device (Saliwell GeNarino), 
consisting of a remote control (A) and a removable intraoral device (B) 
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Figure 8-3 Second generation electrostimulating device (Saliwell GenNarino) 
 
Figure 8-4 Second generation electrostimulating device activation 
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Figure 8-5 Third generation electrostimulating device (Saliwell Crown) 
 
 
  
Micro-processor 
Diode 
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8.2 Participant Information Sheet And Consent Form 
 
STUDY ON A NOVEL MEDICAL DEVICE FOR THE TREATMENT OF 
REDUCED SALIVATION (DRY MOUTH) RESULTING FROM RADIATION 
THERAPY 
Please read this sheet carefully. Please ask if you do not understand or 
would like more information 
 
1.Invitation to participate 
We would like to invite you to take part in our research study. Before you decide we 
would like you to understand why the research is being done and what it would 
involve for you. One of our team will go through the information sheet with you and 
answer any questions you have.  
You have been selected as a potential participant because you might have the 
appropriate condition that we are studying. The following information is provided so 
that you can make an informed decision regarding your willingness to participate. 
Please discuss with family and friends and ask us if there is anything which is not 
clear or if you would like more information.  
 
2.What is the purpose of the study? 
The majority of patients with cancer of the head and neck (e.g. cancer of the mouth 
or throat) receive radiotherapy as part of their treatment. Radiotherapy to the head 
and neck often causes permanent damage to the salivary glands and consequent 
reduction in salivation – also known as dry mouth. Dry mouth can be very 
distressing and affect the way you talk and eat. Unfortunately, current therapies of 
dry mouth are often unsatisfactory, and may result in adverse side effects. 
Preliminary studies indicated that a device that releases mild and painless electric 
stimuli to skin of the mouth can increase salivation and reduce the sensation of dry 
mouth.  
The main purpose of this study is to investigate whether this device will reduce dry 
mouth symptoms in patients who had radiotherapy to the Head and Neck.  
The medical device to be investigated in this research was introduced few years 
ago, showed to be effective and safe in humans and was recently granted approval 
for commercialization in EU. 
We also aim at analysing and comparing levels of salivary components associated 
by the device as it has been suggested that electrostimulation may also alter the 
composition of saliva and the function of cells that secret saliva. 
 
3. Why have I been invited? 
You have been identified as a potential participant by doctors in your cancer or 
dental clinic because you have persistent dry mouth due to radiotherapy to the Head 
and Neck.  
 
4. Do I have to take part?  
It is up to you to decide to join the study. We will describe the study and go through 
this information sheet, and you can take as much time as you need to decide upon 
taking part in this study. If you agree to take part, we will then ask you to sign a 
Version 6; 28th November 2012 
Study Number: OM-11-03 
Subject Initials: _________ 
Screening Number: _______ 
Randomisation Number (if applicable):_____ 
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consent form. You are free to withdraw at any time, without giving a reason. This 
would not affect the standard of care you receive. Participation in this study will in no 
way affect your legal rights.  
 
5 What will happen to me if I take part? 
A total of 84 individuals with dry mouth caused by radiotherapy will participate in this 
study. If you decided to take part, an appointment will be arranged at the study 
centre to see whether you fulfil the criteria for participation. Individuals who fulfil the 
criteria will participate into the study and will be divided into 2 groups of 42 each 
(group A and group B). Participants will be allocated into these 2 groups casually (a 
process known as randomisation) and neither participants nor investigators will 
know which patients belong to group A or B (known as “double blind design”) until 
the end of the study. Participants of both groups will receive an individual 
customised device that is shaped on a cast (model) of their dentition taken with a 
routine dental impression (the same as that taken for dentures). Participants will be 
explained how to use the device and will be asked to bring it home and test it for 12 
months. Participants of Group A (cases) will receive a device that releases electric 
stimuli while those of Group B (controls) consist of participants who will receive a 
device that does not release electric stimuli.  
During this time, participants will be asked to attend 6 predefined hospital 
appointments (at month 1, 2, 4, 6, 8, 12; each appointment lasting about 30 
minutes) in order to let doctors to assess the potential benefits of the device (doctors 
will measure salivation and will ask participants to complete 3 questionnaires – they 
will also check the device and examine the mouth of study participants). After 
measurement, saliva will be stored in freezer (in anonymised containers) and 
subsequently analysed for changes in its composition pre and posttreatment with 
electrostimulation. 
After the study is completed, we may store remaining saliva samples in our Tissue 
Bank for possible use in future research upon review by ethical committee. 
Participants will also be asked to report into a home diary the frequency of device 
application per day and degree of dryness per week.  
 
6. Expenses and payments 
We will reimburse your travel expenses and will compensate you for your time you 
will spend to attend hospital appointments relevant to the study.   
 
7. What will I have to do? 
You will be asked to bring the device home and use it as directed for the duration of 
the study (12 months). A dedicated remote control will also be provided to switch the 
device on/off.  
We shall recommend keeping the device in its protective case to avoid damage 
(suck as breaks or heat deformation).  
You will not be allowed to use pilocarpine tablets (a medication which is sometimes 
prescribed for dry mouth) during the study but you can continue to use your usual 
topical treatment (e.g. spray, mouthwash) for dry mouth control.  
You will also be asked to attend pre-arranged hospital appointments for 
measurement and to fill questionnaires regarding the degree of dry mouth.  
We will provide a home diary for you to report the frequency of device application 
per day and degree of dryness per week.  
 
8. Alternatives 
Treatment of dry mouth consists of: 
(i) Salivary substitutes (mouthwash, spray, gel), which are applied into the mouth 
and typically provide only mild and transient benefit;  
(ii) Tablets of pilocarpine, a medication that can stimulate your own salivation but is 
often burdened by adverse side effects.   
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Overall treatment modalities for dry mouth are unsatisfactory and many individuals 
attempt to lessen dry mouth sensation with frequent sips of water.   
 
9. What are the possible disadvantages and risks of taking part? 
Previous studies showed that the device is safe and its use does not cause 
discomfort as it is custom-made on the shape of individual dentition. Occasionally 
the device may cause friction and irritation to the lining of the mouth – this can be 
promptly resolved by the investigators (study doctors) who can easily re-shape the 
device and remove the irritating parts. The device may affect you speech but only 
while you are wearing it. As with any form of oral appliances or dental restorations 
(e.g. dentures, fillings and orthodontic treatment), it is possible that small broken 
fragments from the device may accidentally be ingested or inhaled. A case of device 
breakage, which went unnoticed and caused no harm, has been reported. We 
recommend informing the study Investigators right away if this occurs, and they will 
assess your condition. 
 
10. What are the possible benefits of taking part? 
Study participants will benefit from using a novel medication-free therapeutic means 
that – based on previous research - is likely to lessen their dry mouth sensation. 
Also participants in the control group (those using the non-functional device) should 
benefit from increase salivation due to tactile stimulation of the device onto the 
mouth – although this is expected to be lower than that caused by the electric 
stimuli.  
 
11. What happens when the research study stops?  
On study completion, participants will be required to return the device - as it is 
designed to operate for no longer than 13 months from the manufacturing date – 
and will be offered the return to their usual NHS clinics and receive currently 
available treatment means of dry mouth. Information will also be provided regarding 
the modality of purchasing a new device from the manufacturer (should they wish 
so).  
It is anticipated that the results of the present study, if positive, will contribute 
towards device availability on NHS prescription – which means that cancer patients 
could receive it free of charge on the basis of their medical exemption (MedEx) 
certificate.  
 
12. Will my taking part in the study be kept confidential? 
The Investigator (study doctor) will make every possible effort to keep your personal 
information confidential. All the information collected will be kept by the research 
coordinator. The Chief Investigator is responsible for safety and security of the data. 
Medical records which identify you and the consent form signed by you may be 
inspected by an Institutional Review Board or Ethical Review Committee. The 
results of this research project may be presented at meetings or in publications; 
however, any research data released or published will not identify volunteers by 
name. All data and results will be completely anonymised and it will be impossible to 
identify you from them.  
 
13. What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. Contact numbers of study 
investigators are provided at the end of this document – as an alternative, you can 
also complain directly to UCLH.  
If you are harmed by taking part in this research project, there are no special 
compensation arrangements – although the normal NHS complaints mechanisms 
will still be available to you (where appropriate). If you are harmed due to someone’s 
negligence, you may have legal grounds for compensation, but you may have to pay 
for it. 
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14. Study results 
The results of this research study may be presented at meetings and may be 
published, likely at least one year after the end of the project. No patients will be 
identified in any report. If you would like to receive the results of the study, please 
contact the Chief Investigator, Prof. S. Porter, or Principal Investigator, Dr S Fedele 
by phone, letter or email. 
 
15. Who is organising and funding the research 
The study is sponsored by UCLH and funded by the National Institute for Health 
Research (NIHR)  
 
16. Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by Sheffield Research Ethics Committee 
 
13.Whom to ask questions regarding this study or to make a complaint to 
You have the right to ask questions concerning this study at any time - please 
contact Prof. Stephen Porter at 020 7916 1142 or Dr Stefano Fedele at 020 7916 
1004. 
 
Complaints 
• To Study Investigators: please contact Prof Stephen Porter or Dr Stefano 
Fedele. 
• To UCLH: please speak to the person in charge of the ward or clinic, or to our 
Patient Advice and Liaison Service (PALS) who will help with your problem 
quickly and informally. Contact PALS on 020 7380 9975.  
• You can also make formal complaint. You can do this within 12 months of the 
events concerned, or within 12 months of becoming aware of the problem. Please 
write with full details to the Complaints Manager at: Governance Department, 
UCLH, 2nd Floor West, 250 Euston Road, London, NW1 2PG (Fax: 02073809595- 
email: complaints.officer@uclh.nhs.uk).  
 
A copy of this information sheet and a signed consent form will be 
given to you. 
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Version 5, 28th November 2012 
Study Number: OM-11-03 
Patient Identification Number for this trial: 
 
Title of project:  
Study on a novel medical device for the treatment of reduced salivation (dry 
mouth) resulting from radiation therapy 
-------------------------- 
[Scientific title: Long-term Evaluation of the effectiveness Of a Novel Intra-
oral electro-stimulator for the treatment of raDiotherapy-ASsociated dry 
mouth (The LEONIDAS-2 study)]. 
 
Name of Chief Investigator: Prof. Stephen Porter  
Name of Principal Investigator: Dr. Stefano Fedele 
Please initial box 
 
1. I confirm that I have read and understood the information sheet Version 6 dated  
28th November 2012 for the above study. I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
   
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
   
3. 
 
 
 
 
4. 
 
 
5. 
 
 
6. 
I understand that sections of any of my medical notes may be looked at by the 
researchers and responsible individuals from regulatory authorities where it is 
relevant to my taking part in research. I give permission for these individuals to have 
access to my records.  
 
I agree to my General Practitioner and General Dental Practitioner being informed 
of my participation in the study. 
  
I understand that the medical device to be investigated meets the requirements of 
all relevant European Directives (CE Marking)  
 
I understand that this study will investigate whether a novel medical device will 
lessen dry mouth sensation caused by radiotherapy to the Head and Neck area 
(provided to treat head and neck cancer). I also understand that saliva sample will 
be stored in freezers during the study and analyzed for changes in composition of 
saliva. 
 
   
7. I understand that the saliva sample taken from me may be stored after the study is 
completed and use for potential future research at a later date upon review by 
ethical committee. I understand that these results will remain anonymous. 
 
 
8. 
 
I agree to take part in the above study 
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8.3 Home Diary 
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8.4 Quality of Life questionnaires 
Table 8-1 OHQoL-16 questionnaire 
What effect does your oral health (teeth, gums and 
mouth) have on your… 
Very 
Bad 
Bad None Good Very 
Good 
1 eating or enjoyment of food?      
2 appearance?      
3 speech?      
4 comfort (lack of pain and discomfort)?      
5 breath odor?      
6 general health?      
7 smiling or laughing?      
8 social life?      
9 romantic relationships?      
10 work or ability to do your usual jobs?      
11 finance?      
12 ability to relax or sleep?      
13 confidence (lack of embarrassment)?      
14 carefree manner (lack of worry)?      
15 mood or happiness?      
16 personality?      
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Table 8-2 EORTC QLQ - H&N35 questionnaire 
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Table 8-3 SF-36 questionnaire 
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